Daphnia galeata metabolite - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Daphnia galeata metabolite	go back to main search page
Accession:	CHEBI:83038	browse the term
Definition:	A Daphnia metabolite produced by the species Daphnia galeata.
Synonyms:	related_synonym:	Daphnia galeata metabolites

show annotations for term's descendants Sort by:
Rat (857) Mouse (874) Human (870) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (14) Green Monkey (0) Naked Mole-rat (0) All
Genes (870)

(22R)-22-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1 group H member 3

increases expression

22(R)-hydroxycholesterol increases expression of NR1H3 mRNA in macrophages

RGD

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

(24S)-24-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

24-hydroxycholesterol results in increased expression of ABCA1 mRNA; 24-hydroxycholesterol results in increased expression of ABCA1 protein

PMID:15148325 PMID:19126211

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily G member 1

increases expression

24-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

amyloid beta precursor protein

multiple interactions
increases metabolic processing

24-hydroxycholesterol affects the metabolism of and results in increased activity of APP protein; 24-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
24-hydroxycholesterol results in increased metabolism of APP protein

PMID:15148325 PMID:17532301 PMID:19126211

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

24-hydroxycholesterol results in increased expression of CCL2 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

CD36 molecule (CD36 blood group)

increases expression
multiple interactions

24-hydroxycholesterol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

C-X-C motif chemokine ligand 8

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CXCL8 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA]

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 27 subfamily A member 1

decreases abundance

CYP27A1 protein results in decreased abundance of 24-hydroxycholesterol

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 39 subfamily A member 1

increases metabolic processing

CYP39A1 protein results in increased metabolism of 24-hydroxycholesterol

NCBI chr 6:46,549,580...46,652,818
Ensembl chr 6:46,549,580...46,652,830

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions

[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 46 subfamily A member 1

affects abundance
increases chemical synthesis
increases metabolic processing

CYP46A1 gene SNP affects the abundance of 24-hydroxycholesterol
CYP46A1 protein results in increased chemical synthesis of 24-hydroxycholesterol
CYP46A1 protein results in increased metabolism of 24-hydroxycholesterol

PMID:14640697 PMID:19286353

NCBI chr14:99,684,298...99,727,301
Ensembl chr14:99,684,298...99,727,301

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

CYP7A1 protein results in increased metabolism of 24-hydroxycholesterol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

estrogen receptor 1

multiple interactions

24-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions

24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity

24-hydroxycholesterol results in decreased activity of HMGCR protein

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

integrin subunit beta 1

increases expression
multiple interactions

24-hydroxycholesterol results in increased expression of ITGB1 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

matrix metallopeptidase 9

multiple interactions
increases expression

Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

nuclear receptor subfamily 1 group H member 3

multiple interactions

[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

prostaglandin E synthase

increases expression
multiple interactions

24-hydroxycholesterol results in increased expression of PTGES mRNA
Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
24-hydroxycholesterol results in increased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

toll like receptor 4

increases expression
multiple interactions

24-hydroxycholesterol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

(25R)-cholest-5-ene-3beta,26-diol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein
[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA

PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 More...

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 1

increases expression

27-hydroxycholesterol results in increased expression of ABCB1 mRNA

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

increases expression

27-hydroxycholesterol results in increased expression of ABCC1 mRNA

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily G member 1

increases expression

27-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of ACTA2 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

PMID:33131013 PMID:33880675

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

apolipoprotein A1

multiple interactions

27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein E

increases expression

27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions
decreases secretion
increases expression

27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
27-hydroxycholesterol results in decreased secretion of APP protein alternative form
27-hydroxycholesterol results in increased expression of APP protein alternative form

PMID:15148325 PMID:19126211 PMID:19158428

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

activity regulated cytoskeleton associated protein

decreases expression

27-hydroxycholesterol results in decreased expression of ARC protein

NCBI chr 8:142,611,049...142,614,479
Ensembl chr 8:142,611,049...142,614,479

G

beta-secretase 1

increases expression

27-hydroxycholesterol results in increased expression of BACE1 protein

NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259

G

catalase

multiple interactions

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 3

increases expression
increases secretion

27-hydroxycholesterol results in increased expression of CCL3 mRNA
27-hydroxycholesterol results in increased secretion of CCL3 protein

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

increases expression
increases secretion

27-hydroxycholesterol results in increased expression of CCL4 mRNA
27-hydroxycholesterol results in increased secretion of CCL4 protein

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

cellular communication network factor 5

multiple interactions
increases expression

Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA]

NCBI chr20:44,714,861...44,727,811
Ensembl chr20:44,714,844...44,728,509

G

CD36 molecule (CD36 blood group)

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

cadherin 5

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]
27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein

NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784

G

cadherin 6

decreases expression

27-hydroxycholesterol results in decreased expression of CDH6 mRNA

NCBI chr 5:31,193,686...31,329,146
Ensembl chr 5:31,193,686...31,329,146

G

carboxylesterase 1

decreases activity
multiple interactions

27-hydroxycholesterol results in decreased activity of CES1 protein
27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin]

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

catenin beta 1

increases activity
multiple interactions

27-hydroxycholesterol results in increased activity of CTNNB1 protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]

NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CXCL12 mRNA
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CXCL8 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA]

PMID:19426978 PMID:24802026

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 27 subfamily A member 1

increases abundance
multiple interactions
increases chemical synthesis

CYP27A1 protein results in increased abundance of 27-hydroxycholesterol
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol

PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 More...

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases hydroxylation
increases metabolic processing
increases abundance

CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol
CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol
CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol

PMID:10588945 PMID:10748047

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

E2F transcription factor 1

increases expression

27-hydroxycholesterol results in increased expression of E2F1 mRNA

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

erb-b2 receptor tyrosine kinase 4

decreases expression

27-hydroxycholesterol results in decreased expression of ERBB4 mRNA

NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841

G

estrogen receptor 1

multiple interactions
affects response to substance
increases degradation

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein]
ESR1 protein affects the susceptibility to 27-hydroxycholesterol
ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased degradation of ESR1 protein

PMID:17872378 PMID:17873880

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions
affects response to substance

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
ESR2 protein affects the susceptibility to 27-hydroxycholesterol
ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

PMID:17872378 PMID:17873880

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

glutamate ionotropic receptor NMDA type subunit 1

decreases expression

27-hydroxycholesterol results in decreased expression of GRIN1 protein

NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases phosphorylation

27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein

NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of GSK3B protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of HIF1A protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]

PMID:27856279 PMID:33880675

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
decreases expression
multiple interactions

27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein
27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]

PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 More...

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

heme oxygenase 1

increases expression

27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heat shock protein family A (Hsp70) member 9

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of HSPA9 protein
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

NCBI chr 5:138,553,756...138,575,401
Ensembl chr 5:138,553,756...138,575,675

G

intercellular adhesion molecule 1

increases expression

27-hydroxycholesterol results in increased expression of ICAM1 mRNA

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 1 beta

multiple interactions

27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

increases secretion
increases expression
multiple interactions

27-hydroxycholesterol results in increased secretion of IL6 protein
27-hydroxycholesterol results in increased expression of IL6 mRNA
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]

PMID:11851725 PMID:28739487

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

integrin subunit beta 1

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of ITGB1 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

lecithin-cholesterol acyltransferase

increases metabolic processing

LCAT protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

low density lipoprotein receptor

decreases activity
decreases expression

27-hydroxycholesterol results in decreased activity of LDLR protein
27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein

PMID:8820113 PMID:28167099

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

lipase E, hormone sensitive type

multiple interactions

LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]

NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,514...42,427,388

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 9

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of MMP9 mRNA
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
increases expression

HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

nitric oxide synthase 2

decreases expression
multiple interactions

27-hydroxycholesterol results in decreased expression of NOS2 mRNA
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

decreases expression
multiple interactions

27-hydroxycholesterol results in decreased expression of NOS3 mRNA
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NPC intracellular cholesterol transporter 1

affects abundance

NPC1 protein affects the abundance of 27-hydroxycholesterol

NCBI chr18:23,506,184...23,586,506
Ensembl chr18:23,506,184...23,586,506

G

NAD(P)H quinone dehydrogenase 1

increases expression

27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group H member 3

increases expression

27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

nuclear receptor subfamily 5 group A member 1

increases activity
multiple interactions

27-hydroxycholesterol results in increased activity of NR5A1 protein
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

G

progesterone receptor

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]

NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813

G

peroxisome proliferator activated receptor gamma

increases expression

27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

prostaglandin E synthase

multiple interactions
increases expression

Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
27-hydroxycholesterol results in increased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

selectin E

increases expression

27-hydroxycholesterol results in increased expression of SELE mRNA

NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705

G

sphingomyelin phosphodiesterase 2

decreases activity

27-hydroxycholesterol results in decreased activity of SMPD2 protein

NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919

G

synuclein alpha

increases expression

27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein

NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases activity

27-hydroxycholesterol results in decreased activity of SRC protein

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

sterol regulatory element binding transcription factor 1

decreases expression

27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

steroidogenic acute regulatory protein

multiple interactions
increases abundance
increases expression

27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
STAR protein results in increased abundance of 27-hydroxycholesterol
27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]

PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]

PMID:27856279 PMID:28739487

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

trefoil factor 1

multiple interactions
increases expression

27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]

PMID:17872378 PMID:27856279

NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535

G

transforming growth factor beta 1

multiple interactions

[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 4

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

vascular cell adhesion molecule 1

increases expression

27-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vascular endothelial growth factor A

increases expression
multiple interactions
increases secretion

27-hydroxycholesterol results in increased expression of VEGFA mRNA
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vimentin

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]
27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta

multiple interactions

27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr22:31,944,535...31,957,603
Ensembl chr22:31,944,522...31,957,603

1,2,3-trilinoleoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

decreases expression

trilinolein results in decreased expression of ABCA1 mRNA

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily G member 5

decreases expression

trilinolein results in decreased expression of ABCG5 mRNA

NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865

G

ATP binding cassette subfamily G member 8

decreases expression

trilinolein results in decreased expression of ABCG8 mRNA

NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988

G

cytochrome P450 family 27 subfamily A member 1

decreases expression

trilinolein results in decreased expression of CYP27A1 mRNA

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

trilinolein results in increased expression of HMGCR mRNA

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

microsomal triglyceride transfer protein

increases expression

trilinolein results in increased expression of MTTP mRNA

NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

trilinolein results in decreased expression of NPC1L1 mRNA

NCBI chr 7:44,512,535...44,541,330
Ensembl chr 7:44,512,535...44,541,330

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:57,544,377...57,586,702
Ensembl chr18:57,544,377...57,586,732

1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions
decreases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

decreases abundance
multiple interactions

LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

increases hydrolysis

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

1-palmitoyl-2-oleoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

decreases abundance

LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

decreases abundance

LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

1-stearoyl-2-arachidonoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type I alpha 1 chain

multiple interactions

1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

diacylglycerol lipase alpha

increases metabolic processing

DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol

NCBI chr11:61,680,391...61,747,001
Ensembl chr11:61,680,391...61,747,001

G

diacylglycerol lipase beta

increases metabolic processing

DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol

NCBI chr 7:6,409,129...6,447,954
Ensembl chr 7:6,409,126...6,484,190

G

diacylglycerol kinase epsilon

increases phosphorylation

DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol

NCBI chr17:56,834,151...56,869,567
Ensembl chr17:56,834,107...56,869,567

G

PPARG coactivator 1 alpha

increases expression

1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

transforming growth factor beta 1

multiple interactions

1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transient receptor potential cation channel subfamily M member 6

multiple interactions

TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium]

NCBI chr 9:74,722,495...74,887,921
Ensembl chr 9:74,722,495...74,888,094

1-stearoyl-2-linoleoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

decreases abundance

LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

decreases abundance

LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

13-HPODE

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

increases expression

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolin 1

increases expression

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA

NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,524,994...116,561,179

G

C-C motif chemokine ligand 2

multiple interactions

[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

early growth response 1

multiple interactions

[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

peroxisome proliferator activated receptor alpha

increases expression

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor gamma

increases expression

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

14,15-EET

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

angiotensin converting enzyme 2

multiple interactions

14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein]

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

angiotensinogen

multiple interactions
decreases expression
increases cleavage

14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form
[14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7)

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

AKT serine/threonine kinase 1

increases phosphorylation

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

cytochrome P450 family 2 subfamily C member 8

increases chemical synthesis

CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

increases chemical synthesis
multiple interactions

CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid
Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 3 subfamily A member 4

increases chemical synthesis
multiple interactions

CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

epoxide hydrolase 2

multiple interactions
increases abundance

[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid

PMID:19896470 PMID:22680237 PMID:24472606

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

G

fibroblast growth factor 2

increases expression

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

mitogen-activated protein kinase 1

increases phosphorylation

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

increases phosphorylation

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

ribosomal protein S6 kinase B1

increases phosphorylation

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein

NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574

G

transforming growth factor beta 1

multiple interactions
decreases secretion

12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

19(S)-HETE

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily E member 1

affects metabolic processing

CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 4 subfamily A member 11

increases chemical synthesis

CYP4A11 protein results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 1:46,929,188...46,941,476
Ensembl chr 1:46,929,177...46,941,484

G

cytochrome P450 family 4 subfamily F member 2

increases chemical synthesis

CYP4F2 protein results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,878,023...15,898,074
Ensembl chr19:15,878,023...15,898,077

G

cytochrome P450 family 4 subfamily F member 3

increases chemical synthesis

CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

19-HETE

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily E member 1

affects metabolic processing

CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 4 subfamily A member 11

increases chemical synthesis

CYP4A11 protein results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 1:46,929,188...46,941,476
Ensembl chr 1:46,929,177...46,941,484

G

cytochrome P450 family 4 subfamily F member 2

increases chemical synthesis

CYP4F2 protein results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,878,023...15,898,074
Ensembl chr19:15,878,023...15,898,077

G

cytochrome P450 family 4 subfamily F member 3

increases chemical synthesis

CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

2-arachidonoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

abhydrolase domain containing 12, lysophospholipase

increases hydrolysis

ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate

NCBI chr20:25,294,743...25,390,835
Ensembl chr20:25,294,742...25,390,835

G

abhydrolase domain containing 6, acylglycerol lipase

increases hydrolysis

ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate

NCBI chr 3:58,237,792...58,294,734
Ensembl chr 3:58,237,532...58,295,693

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA
Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

apolipoprotein E

multiple interactions

[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

arrestin beta 1

multiple interactions

glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]

NCBI chr11:75,260,122...75,351,661
Ensembl chr11:75,260,122...75,351,705

G

arrestin beta 2

multiple interactions

[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]

NCBI chr17:4,710,632...4,721,497
Ensembl chr17:4,710,596...4,721,499

G

activating transcription factor 4

increases expression
multiple interactions

glyceryl 2-arachidonate results in increased expression of ATF4 mRNA
iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA]

NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683

G

BTG anti-proliferation factor 2

increases expression

glyceryl 2-arachidonate results in increased expression of BTG2 mRNA

NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602

G

C-C motif chemokine ligand 2

increases expression

glyceryl 2-arachidonate results in increased expression of CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine receptor 1

increases expression

glyceryl 2-arachidonate results in increased expression of CCR1 mRNA

NCBI chr 3:46,201,711...46,208,313
Ensembl chr 3:46,201,711...46,208,313

G

CD36 molecule (CD36 blood group)

increases expression

glyceryl 2-arachidonate results in increased expression of CD36 mRNA

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

carboxylesterase 1

increases hydrolysis
multiple interactions

CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate
[CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

carboxylesterase 2

increases hydrolysis
multiple interactions

CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate
[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096

G

cannabinoid receptor 1

multiple interactions
increases expression

[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]
glyceryl 2-arachidonate results in increased expression of CNR1 mRNA
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein]

PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 More...

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

cannabinoid receptor 2

multiple interactions
affects response to substance

[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]
CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate

PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 More...

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

cAMP responsive element binding protein 3 like 3

multiple interactions
increases expression

glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]

NCBI chr19:4,153,631...4,173,054
Ensembl chr19:4,153,631...4,173,054

G

corticotropin releasing hormone

increases abundance

CRH protein results in increased abundance of glyceryl 2-arachidonate

NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions

glyceryl 2-arachidonate analog results in increased expression of CXCL8 protein; glyceryl 2-arachidonate results in increased expression of CXCL8 protein
[SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 27 subfamily A member 1

multiple interactions
increases expression

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
increases expression

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases expression
multiple interactions

glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

cytochrome P450 family 8 subfamily B member 1

increases expression
multiple interactions

glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898

G

diacylglycerol lipase alpha

multiple interactions

1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]

NCBI chr11:61,680,391...61,747,001
Ensembl chr11:61,680,391...61,747,001

G

DNA damage inducible transcript 3

multiple interactions
increases expression

iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein]
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein

PMID:29441458 PMID:32357311

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]

NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516

G

estrogen related receptor gamma

increases abundance

ESRRG protein results in increased abundance of glyceryl 2-arachidonate

NCBI chr 1:216,503,246...217,137,702
Ensembl chr 1:216,503,246...217,137,755

G

fatty acid binding protein 1

affects abundance
multiple interactions

FABP1 protein affects the abundance of glyceryl 2-arachidonate
FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate

NCBI chr X:147,911,919...147,951,125
Ensembl chr X:147,911,919...147,951,125

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452

G

G protein-coupled receptor kinase 2

multiple interactions

[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]

NCBI chr11:67,266,473...67,286,556
Ensembl chr11:67,266,473...67,286,556

G

hypocretin neuropeptide precursor

increases chemical synthesis
multiple interactions

HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate
1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]

NCBI chr17:42,184,060...42,185,452
Ensembl chr17:42,184,060...42,185,452

G

heat shock protein family A (Hsp70) member 5

increases expression

glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

intercellular adhesion molecule 1

increases expression

glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 1 beta

decreases expression
multiple interactions

glyceryl 2-arachidonate results in decreased expression of IL1B mRNA
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]

PMID:16364651 PMID:30611738

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 2

multiple interactions

glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 6

decreases expression
multiple interactions

glyceryl 2-arachidonate results in decreased expression of IL6 mRNA
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

PMID:16364651 PMID:30611738

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

insulin

multiple interactions

INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

INS-IGF2 readthrough

multiple interactions

glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

leptin

multiple interactions

[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

mitogen-activated protein kinase kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase kinase 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122

G

mitogen-activated protein kinase 1

multiple interactions
decreases phosphorylation

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein
glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:31917333

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
decreases phosphorylation

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein
glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:31917333

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

monoglyceride lipase

multiple interactions
affects abundance
increases degradation
increases abundance
increases hydrolysis

[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate]
MGLL protein affects the abundance of glyceryl 2-arachidonate
MGLL protein results in increased degradation of glyceryl 2-arachidonate
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate
MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate

PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 More...

NCBI chr 3:127,689,066...127,823,185
Ensembl chr 3:127,689,062...128,052,190

G

myeloperoxidase

multiple interactions

glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

poly(ADP-ribose) polymerase 1

multiple interactions
increases cleavage

GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein]

PMID:29441458 PMID:32357311

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

peroxisome proliferator activated receptor alpha

affects localization
multiple interactions

glyceryl 2-arachidonate affects the localization of PPARA protein
[palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor gamma

affects binding
multiple interactions
increases expression

glyceryl 2-arachidonate metabolite binds to PPARG protein
glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]
T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA]

PMID:21511917 PMID:26209559

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate

NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703

G

prostaglandin-endoperoxide synthase 2

increases metabolic processing
multiple interactions

PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]
glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate]

PMID:18297109 PMID:21511917 PMID:26209559

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

tumor necrosis factor

decreases expression
multiple interactions

glyceryl 2-arachidonate results in decreased expression of TNF mRNA
glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein]
glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]

PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

transient receptor potential cation channel subfamily V member 1

multiple interactions
affects response to substance

glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein
TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate

PMID:18550765 PMID:21949157

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

YY1 transcription factor

increases expression

glyceryl 2-arachidonate results in increased expression of YY1 mRNA

NCBI chr14:100,239,144...100,282,788
Ensembl chr14:100,238,298...100,282,788

2-oleoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

fatty acid binding protein 1

affects abundance

FABP1 protein affects the abundance of 2-oleoylglycerol

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

monoglyceride lipase

increases degradation
multiple interactions

MGLL protein results in increased degradation of 2-oleoylglycerol
Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol]

NCBI chr 3:127,689,066...127,823,185
Ensembl chr 3:127,689,062...128,052,190

20-HETE

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

clock circadian regulator

affects abundance

CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 4:55,427,903...55,546,909
Ensembl chr 4:55,427,903...55,546,909

G

collagen type I alpha 1 chain

increases expression
multiple interactions

20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

cytochrome P450 family 4 subfamily A member 11

multiple interactions
increases chemical synthesis
increases secretion

isoliquiritigenin inhibits the reaction [CYP4A11 protein results in increased secretion of 20-hydroxy-5,8,11,14-eicosatetraenoic acid]
CYP4A11 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

PMID:23747687 PMID:30259074

NCBI chr 1:46,929,188...46,941,476
Ensembl chr 1:46,929,177...46,941,484

G

cytochrome P450 family 4 subfamily A member 22

increases chemical synthesis
multiple interactions

CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]]

PMID:11124159 PMID:12388396

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

cytochrome P450 family 4 subfamily F member 2

increases chemical synthesis

CYP4F2 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,878,023...15,898,074
Ensembl chr19:15,878,023...15,898,077

G

cytochrome P450 family 4 subfamily F member 3

increases chemical synthesis

CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

G

cytochrome P450 family 4 subfamily Z member 1

multiple interactions
increases abundance

HET0016 inhibits the reaction [CYP4Z1 protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid]

NCBI chr 1:47,055,525...47,118,318
Ensembl chr 1:47,067,231...47,118,318

G

nuclear factor of activated T cells 4

multiple interactions
increases localization

Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]

NCBI chr14:24,366,911...24,379,604
Ensembl chr14:24,365,673...24,379,604

G

proopiomelanocortin

multiple interactions
increases abundance

HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid]
POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

PMID:18067589 PMID:19458537

NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903

G

SMAD family member 3

multiple interactions
increases phosphorylation

20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]

NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173

G

transforming growth factor beta 1

increases expression
multiple interactions

20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

UDP glucuronosyltransferase family 1 member A4

increases glucuronidation

UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 2:233,718,736...233,773,300
Ensembl chr 2:233,718,736...233,773,300

G

UDP glucuronosyltransferase family 2 member B7

increases glucuronidation

UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987

20-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 11 subfamily A member 1

multiple interactions

[NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

CYP7A1 protein results in increased metabolism of 20-hydroxycholesterol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

hydroxysteroid 17-beta dehydrogenase 10

multiple interactions

[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein

NCBI chr X:53,431,258...53,434,376
Ensembl chr X:53,431,258...53,434,370

G

melanocortin 2 receptor

multiple interactions

[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]

NCBI chr18:13,882,044...13,915,707
Ensembl chr18:13,882,044...13,915,707

G

nuclear receptor subfamily 5 group A member 1

multiple interactions

[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

25-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

25-hydroxycholesterol results in increased expression of ABCA1 mRNA
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol co-treated with Alitretinoin] results in increased expression of ABCA1 protein; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]
[Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA

PMID:12595494 PMID:16023994 PMID:17526932 PMID:19260826

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily G member 1

increases expression

25-hydroxycholesterol results in increased expression of ABCG1 mRNA

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

25-hydroxycholesterol results in increased expression of ACTA2 mRNA
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

adiponectin receptor 1

multiple interactions
decreases expression

[25-hydroxycholesterol co-treated with alitretinoin] results in decreased expression of ADIPOR1 mRNA
25-hydroxycholesterol results in decreased expression of ADIPOR1 mRNA

NCBI chr 1:202,940,825...202,958,572
Ensembl chr 1:202,940,826...202,958,572

G

caspase 3

multiple interactions
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

increases activity
multiple interactions

25-hydroxycholesterol results in increased activity of CASP8 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

increases activity
multiple interactions

25-hydroxycholesterol results in increased activity of CASP9 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

cyclin dependent kinase inhibitor 1B

increases expression

25-hydroxycholesterol results in increased expression of CDKN1B mRNA

NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369

G

calponin 1

multiple interactions
increases expression

15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]

NCBI chr19:11,538,851...11,550,323
Ensembl chr19:11,538,767...11,550,323

G

C-X-C motif chemokine ligand 8

increases secretion
increases expression

25-hydroxycholesterol results in increased secretion of CXCL8 protein
25-hydroxycholesterol results in increased expression of CXCL8 mRNA

PMID:16142584 PMID:19426978

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 27 subfamily A member 1

multiple interactions
increases chemical synthesis

[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 25-hydroxycholesterol

PMID:8078928 PMID:17890683

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

CYP7A1 protein results in increased metabolism of 25-hydroxycholesterol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases metabolic processing
increases abundance

CYP7B1 protein results in increased metabolism of 25-hydroxycholesterol
CYP7B1 gene mutant form results in increased abundance of 25-hydroxycholesterol

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

estrogen receptor 1

multiple interactions

25-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions

25-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

fatty acid desaturase 1

multiple interactions
decreases expression

25-hydroxycholesterol inhibits the reaction [beta-hydroxy simvastatin acid results in increased expression of FADS1 mRNA]
25-hydroxycholesterol results in decreased expression of FADS1 mRNA

NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318

G

Fas cell surface death receptor

increases expression

25-hydroxycholesterol results in increased expression of FAS mRNA

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

four and a half LIM domains 1

multiple interactions
increases expression

15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Brefeldin A inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Dactinomycin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Genistein inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]

NCBI chr X:136,146,702...136,211,359
Ensembl chr X:136,146,702...136,211,359

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression
decreases activity

[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [25-hydroxycholesterol co-treated with Mevalonic Acid] results in increased ubiquitination of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]
25-hydroxycholesterol results in decreased expression of HMGCR protein
25-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 25-hydroxycholesterol results in decreased activity of HMGCR protein
25-hydroxycholesterol results in decreased expression of HMGCR mRNA; 25-hydroxycholesterol results in decreased expression of HMGCR protein

PMID:7749852 PMID:7751816 PMID:9059514 PMID:12477733 PMID:18024962 More...

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

interleukin 1 beta

multiple interactions
increases secretion
increases expression

25-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
25-hydroxycholesterol results in increased secretion of IL1B protein
25-hydroxycholesterol results in increased expression of IL1B mRNA

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

increases secretion
multiple interactions

25-hydroxycholesterol results in increased secretion of IL6 protein
25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
25-hydroxycholesterol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:11851725 PMID:27052460

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

inhibin subunit alpha

increases expression

25-hydroxycholesterol results in increased expression of INHA mRNA; 25-hydroxycholesterol results in increased expression of INHA protein

NCBI chr 2:219,572,310...219,575,711
Ensembl chr 2:219,569,162...219,575,711

G

inhibin subunit beta A

increases expression
decreases expression

25-hydroxycholesterol results in increased expression of INHBA mRNA
25-hydroxycholesterol results in decreased expression of INHBA protein

NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834

G

inhibin subunit beta B

increases expression

25-hydroxycholesterol results in increased expression of INHBB mRNA; 25-hydroxycholesterol results in increased expression of INHBB protein

NCBI chr 2:120,346,136...120,351,803
Ensembl chr 2:120,346,136...120,351,803

G

insulin induced gene 1

decreases expression

25-hydroxycholesterol results in decreased expression of INSIG1 mRNA

NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235

G

low density lipoprotein receptor

decreases expression
multiple interactions

25-hydroxycholesterol results in decreased expression of LDLR mRNA; 25-hydroxycholesterol results in decreased expression of LDLR protein
25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of LDLR mRNA]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]

PMID:12477733 PMID:19260826 PMID:22153697 PMID:27447558

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

lipoprotein lipase

decreases expression
decreases activity

25-hydroxycholesterol results in decreased expression of LPL mRNA
25-hydroxycholesterol results in decreased activity of LPL protein

NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259

G

membrane associated ring-CH-type finger 6

increases stability

25-hydroxycholesterol results in increased stability of MARCHF6 protein

NCBI chr 5:10,353,695...10,440,388
Ensembl chr 5:10,353,695...10,440,388

G

nitric oxide synthase 2

increases expression

25-hydroxycholesterol results in increased expression of NOS2 mRNA

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

decreases expression

25-hydroxycholesterol results in decreased expression of NOS3 mRNA

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

nuclear receptor subfamily 1 group H member 3

increases activity
multiple interactions

25-hydroxycholesterol results in increased activity of NR1H3 protein
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein]

PMID:9603267 PMID:12595494 PMID:27052460

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

nuclear receptor subfamily 5 group A member 1

increases activity
multiple interactions

25-hydroxycholesterol results in increased activity of NR5A1 protein
25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor gamma

multiple interactions

[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

RAR related orphan receptor A

affects binding

25-hydroxycholesterol binds to RORA protein

NCBI chr15:60,488,284...61,229,302
Ensembl chr15:60,488,284...61,229,302

G

RAR related orphan receptor C

multiple interactions
affects binding

bisphenol A analog inhibits the reaction [25-hydroxycholesterol binds to RORC protein]; T0901317 inhibits the reaction [25-hydroxycholesterol binds to RORC protein]

PMID:22659100 PMID:31195007

NCBI chr 1:151,806,071...151,831,802
Ensembl chr 1:151,806,071...151,831,845

G

stearoyl-CoA desaturase

decreases expression

25-hydroxycholesterol results in decreased expression of SCD protein

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions

25-hydroxycholesterol results in increased expression of SREBF1 protein
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein

PMID:19260826 PMID:27324795

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

sterol regulatory element binding transcription factor 2

decreases activity
multiple interactions

25-hydroxycholesterol results in decreased activity of SREBF2 protein
25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of SREBF2 protein modified form]; [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein]

PMID:17052361 PMID:22153697 PMID:27324795

NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306

G

steroidogenic acute regulatory protein

multiple interactions

25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

signal transducer and activator of transcription 3

multiple interactions

25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

sulfotransferase family 2B member 1

multiple interactions

SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein]
SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 25-hydroxycholesterol]

NCBI chr19:48,552,172...48,599,427
Ensembl chr19:48,552,172...48,599,425

G

TNF superfamily member 15

increases expression

25-hydroxycholesterol results in increased expression of TNFSF15 mRNA

NCBI chr 9:114,784,635...114,806,039
Ensembl chr 9:114,784,652...114,806,039

G

vascular cell adhesion molecule 1

increases expression

25-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

26-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA
27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein
Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]

PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 More...

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 1

increases expression

27-hydroxycholesterol results in increased expression of ABCB1 mRNA

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

increases expression

27-hydroxycholesterol results in increased expression of ABCC1 mRNA

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily G member 1

increases expression

27-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of ACTA2 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

PMID:33131013 PMID:33880675

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

apolipoprotein A1

multiple interactions

27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein E

increases expression

27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions
increases expression
decreases secretion

27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
27-hydroxycholesterol results in increased expression of APP protein alternative form
27-hydroxycholesterol results in decreased secretion of APP protein alternative form

PMID:15148325 PMID:19126211 PMID:19158428

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

activity regulated cytoskeleton associated protein

decreases expression

27-hydroxycholesterol results in decreased expression of ARC protein

NCBI chr 8:142,611,049...142,614,479
Ensembl chr 8:142,611,049...142,614,479

G

beta-secretase 1

increases expression

27-hydroxycholesterol results in increased expression of BACE1 protein

NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259

G

catalase

multiple interactions

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CCL2 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 3

increases expression
increases secretion

27-hydroxycholesterol results in increased expression of CCL3 mRNA
27-hydroxycholesterol results in increased secretion of CCL3 protein

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

increases expression
increases secretion

27-hydroxycholesterol results in increased expression of CCL4 mRNA
27-hydroxycholesterol results in increased secretion of CCL4 protein

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

cellular communication network factor 5

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CCN5 mRNA
Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA]

NCBI chr20:44,714,861...44,727,811
Ensembl chr20:44,714,844...44,728,509

G

CD36 molecule (CD36 blood group)

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

cadherin 5

decreases expression
multiple interactions

27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]

NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784

G

cadherin 6

decreases expression

27-hydroxycholesterol results in decreased expression of CDH6 mRNA

NCBI chr 5:31,193,686...31,329,146
Ensembl chr 5:31,193,686...31,329,146

G

carboxylesterase 1

multiple interactions
decreases activity

27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin]
27-hydroxycholesterol results in decreased activity of CES1 protein

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

catenin beta 1

increases activity
multiple interactions

27-hydroxycholesterol results in increased activity of CTNNB1 protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]

NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CXCL12 mRNA
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of CXCL8 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA]

PMID:19426978 PMID:24802026

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 27 subfamily A member 1

increases abundance
increases chemical synthesis
multiple interactions

CYP27A1 protein results in increased abundance of 27-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 More...

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases abundance
increases metabolic processing
increases hydroxylation

CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol
CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol
CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol

PMID:10588945 PMID:10748047

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

E2F transcription factor 1

increases expression

27-hydroxycholesterol results in increased expression of E2F1 mRNA

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

erb-b2 receptor tyrosine kinase 4

decreases expression

27-hydroxycholesterol results in decreased expression of ERBB4 mRNA

NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841

G

estrogen receptor 1

multiple interactions
affects response to substance
increases degradation

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein]
ESR1 protein affects the susceptibility to 27-hydroxycholesterol
ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased degradation of ESR1 protein

PMID:17872378 PMID:17873880

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions
affects response to substance

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
ESR2 protein affects the susceptibility to 27-hydroxycholesterol
ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

PMID:17872378 PMID:17873880

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

glutamate ionotropic receptor NMDA type subunit 1

decreases expression

27-hydroxycholesterol results in decreased expression of GRIN1 protein

NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases phosphorylation

27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein

NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of GSK3B protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of HIF1A protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]

PMID:27856279 PMID:33880675

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression
decreases activity

[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]
27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein
27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein

PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 More...

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

heme oxygenase 1

increases expression

27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heat shock protein family A (Hsp70) member 9

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of HSPA9 protein
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

NCBI chr 5:138,553,756...138,575,401
Ensembl chr 5:138,553,756...138,575,675

G

intercellular adhesion molecule 1

increases expression

27-hydroxycholesterol results in increased expression of ICAM1 mRNA

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 1 beta

multiple interactions

27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

increases secretion
increases expression
multiple interactions

27-hydroxycholesterol results in increased secretion of IL6 protein
27-hydroxycholesterol results in increased expression of IL6 mRNA
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]

PMID:11851725 PMID:28739487

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

integrin subunit beta 1

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

lecithin-cholesterol acyltransferase

increases metabolic processing

LCAT protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

low density lipoprotein receptor

decreases activity
decreases expression

27-hydroxycholesterol results in decreased activity of LDLR protein
27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein

PMID:8820113 PMID:28167099

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

lipase E, hormone sensitive type

multiple interactions

LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]

NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,514...42,427,388

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 9

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of MMP9 mRNA
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

MYC proto-oncogene, bHLH transcription factor

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of MYC protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

nitric oxide synthase 2

multiple interactions
decreases expression

27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

multiple interactions
decreases expression

27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NPC intracellular cholesterol transporter 1

affects abundance

NPC1 protein affects the abundance of 27-hydroxycholesterol

NCBI chr18:23,506,184...23,586,506
Ensembl chr18:23,506,184...23,586,506

G

NAD(P)H quinone dehydrogenase 1

increases expression

27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group H member 3

increases expression

27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

nuclear receptor subfamily 5 group A member 1

increases activity
multiple interactions

27-hydroxycholesterol results in increased activity of NR5A1 protein
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

G

progesterone receptor

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]

NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813

G

peroxisome proliferator activated receptor gamma

increases expression

27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

prostaglandin E synthase

multiple interactions
increases expression

Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
27-hydroxycholesterol results in increased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

selectin E

increases expression

27-hydroxycholesterol results in increased expression of SELE mRNA

NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705

G

sphingomyelin phosphodiesterase 2

decreases activity

27-hydroxycholesterol results in decreased activity of SMPD2 protein

NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919

G

synuclein alpha

increases expression

27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein

NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases activity

27-hydroxycholesterol results in decreased activity of SRC protein

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

sterol regulatory element binding transcription factor 1

decreases expression

27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

steroidogenic acute regulatory protein

increases expression
multiple interactions
increases abundance

27-hydroxycholesterol results in increased expression of STAR protein
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]
27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein
STAR protein results in increased abundance of 27-hydroxycholesterol
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]

PMID:27856279 PMID:28739487

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

trefoil factor 1

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of TFF1 mRNA
27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]

PMID:17872378 PMID:27856279

NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535

G

transforming growth factor beta 1

multiple interactions

[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 4

increases expression
multiple interactions

27-hydroxycholesterol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

vascular cell adhesion molecule 1

increases expression

27-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vascular endothelial growth factor A

multiple interactions
increases expression
increases secretion

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vimentin

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]
27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta

multiple interactions

27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr22:31,944,535...31,957,603
Ensembl chr22:31,944,522...31,957,603

3beta-hydroxycholest-5-en-26-oic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 27 subfamily A member 1

increases chemical synthesis
multiple interactions

CYP27A1 protein results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid

PMID:8078928 PMID:9215552 PMID:9660774 PMID:14622972

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

nuclear receptor coactivator 2

multiple interactions

3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]

NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808

G

nuclear receptor subfamily 1 group H member 3

multiple interactions

3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]; 3-hydroxy-5-cholestenoic acid binds to and results in increased activity of NR1H3 protein

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

4beta-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions
increases chemical synthesis

[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol
CYP3A4 protein results in increased chemical synthesis of cholest-5-ene-3,4-diol

PMID:11514559 PMID:19954708

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

5,6-EET

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions
increases chemical synthesis

Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid]

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

epoxide hydrolase 2

increases abundance

EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

5,6alpha-epoxy-5alpha-cholestan-3beta-ol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

epidermal growth factor receptor

increases phosphorylation

cholesterol alpha-oxide results in increased phosphorylation of EGFR protein

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

epoxide hydrolase 1

increases metabolic processing
multiple interactions

EPHX1 protein results in increased metabolism of cholesterol alpha-oxide
disparlure promotes the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]; Lanosterol analog inhibits the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

epoxide hydrolase 2

multiple interactions

cholesterol alpha-oxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein
RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 2

increases expression

cholesterol alpha-oxide results in increased expression of MMP2 mRNA

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 9

increases expression

cholesterol alpha-oxide results in increased expression of MMP9 mRNA

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

cholesterol alpha-oxide results in increased phosphorylation of MTOR protein
RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein]

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

7-ketocholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily D member 1

decreases expression
multiple interactions

7-ketocholesterol results in decreased expression of ABCD1 mRNA
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]

NCBI chr X:153,724,856...153,744,755
Ensembl chr X:153,724,856...153,744,755

G

ATP binding cassette subfamily D member 3

multiple interactions
decreases expression

alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]

NCBI chr 1:94,385,131...94,518,663
Ensembl chr 1:94,418,389...94,518,666

G

ATP binding cassette subfamily G member 5

multiple interactions
decreases expression

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG5 mRNA
7-ketocholesterol results in decreased expression of ABCG5 mRNA

NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865

G

ATP binding cassette subfamily G member 8

multiple interactions

[7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG8 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG8 mRNA

NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988

G

acetyl-CoA acetyltransferase 1

multiple interactions

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ACAT1 mRNA

NCBI chr11:108,116,705...108,147,603
Ensembl chr11:108,116,695...108,147,603

G

acyl-CoA oxidase 1

decreases expression

7-ketocholesterol results in decreased expression of ACOX1 mRNA

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

aryl hydrocarbon receptor

multiple interactions
affects binding

7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]
7-ketocholesterol binds to AHR protein

PMID:11042205 PMID:16480812

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

AKT serine/threonine kinase 1

multiple interactions

7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

7-ketocholesterol results in increased expression of BAX protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 11

affects localization

7-ketocholesterol affects the localization of BCL2L11 protein

NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444

G

BH3 interacting domain death agonist

decreases expression
multiple interactions

7-ketocholesterol results in decreased expression of BID protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]

NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770

G

caspase 1

affects localization
multiple interactions
increases activity

7-ketocholesterol affects the localization of CASP1 protein
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

increases activity
multiple interactions
increases cleavage

7-ketocholesterol results in increased activity of CASP3 protein
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]; argan oil inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]

PMID:12450566 PMID:16934673 PMID:24650663 PMID:25845326 PMID:29065513

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

increases activity
multiple interactions

7-ketocholesterol results in increased activity of CASP7 protein
Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP7 protein]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

caspase 8

multiple interactions
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

multiple interactions
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

7-ketocholesterol results in increased expression of CCL2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL2 protein]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL3 protein]

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

increases expression
multiple interactions

7-ketocholesterol results in increased expression of CCL4 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL4 protein]

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL5 protein]

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

CD38 molecule

multiple interactions

CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein]

NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232

G

colony stimulating factor 2

increases expression
multiple interactions

7-ketocholesterol results in increased expression of CSF2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF2 protein]

NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170

G

colony stimulating factor 3

increases expression
multiple interactions

7-ketocholesterol results in increased expression of CSF3 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF3 protein]

NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813

G

C-X-C motif chemokine ligand 10

increases expression

7-ketocholesterol results in increased expression of CXCL10 protein

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 8

increases secretion
multiple interactions
increases expression

7-ketocholesterol results in increased secretion of CXCL8 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CXCL8 protein]

PMID:23454145 PMID:24895526

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome b-245 beta chain

affects localization
multiple interactions

7-ketocholesterol affects the localization of CYBB protein
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein]

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
decreases expression

7-ketocholesterol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
7-ketocholesterol inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
7-ketocholesterol results in decreased expression of CYP1A1 protein

PMID:11042205 PMID:18708364

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 27 subfamily A member 1

increases metabolic processing

CYP27A1 protein results in increased metabolism of 7-ketocholesterol

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

decreases activity

7-ketocholesterol results in decreased activity of CYP7A1 protein

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

epidermal growth factor receptor

increases phosphorylation

7-ketocholesterol results in increased phosphorylation of EGFR protein

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
increases expression
multiple interactions

7-ketocholesterol results in decreased activity of HMGCR protein
7-ketocholesterol results in increased expression of HMGCR mRNA
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of HMGCR mRNA

PMID:7751816 PMID:23454145

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

hydroxysteroid 17-beta dehydrogenase 4

decreases expression

7-ketocholesterol results in decreased expression of HSD17B4 mRNA

NCBI chr 5:119,452,497...119,542,332
Ensembl chr 5:119,452,465...119,637,199

G

intercellular adhesion molecule 1

increases expression

7-ketocholesterol results in increased expression of ICAM1 mRNA; 7-ketocholesterol results in increased expression of ICAM1 protein

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 10

decreases expression
multiple interactions
increases expression

7-ketocholesterol results in decreased expression of IL10 mRNA
resveratrol promotes the reaction [7-ketocholesterol results in increased expression of IL10 protein]

PMID:24727230 PMID:24895526

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

multiple interactions
increases expression

Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 1 receptor antagonist

multiple interactions

[resveratrol co-treated with 7-ketocholesterol] results in increased expression of IL1RN protein

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 6

increases expression
multiple interactions

7-ketocholesterol results in increased expression of IL6 protein
7-ketocholesterol results in decreased degradation of and results in increased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]

PMID:18515973 PMID:24895526

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

kininogen 1

multiple interactions

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA

NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410

G

microtubule associated protein 1 light chain 3 beta

increases expression
multiple interactions

7-ketocholesterol results in increased expression of MAP1LC3B protein
CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein]

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]

PMID:15955068 PMID:20466046

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

7-ketocholesterol results in increased phosphorylation of MAPK3 protein
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]
U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]

PMID:15955068 PMID:20466046

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 2

increases expression
multiple interactions

7-ketocholesterol results in increased expression of MMP2 mRNA
7-ketocholesterol results in increased expression of MMP2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP2 protein]

PMID:20466046 PMID:24895526

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 9

increases expression
multiple interactions

7-ketocholesterol results in increased expression of MMP9 mRNA
7-ketocholesterol results in increased expression of MMP9 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP9 protein]

PMID:20466046 PMID:24895526

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

7-ketocholesterol results in increased phosphorylation of MTOR protein
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

7-ketocholesterol results in increased expression of NFKB1 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]

PMID:24895526 PMID:25845326

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

7-ketocholesterol results in increased phosphorylation of NFKBIA protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of NFKBIA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NLR family pyrin domain containing 3

affects localization
multiple interactions

7-ketocholesterol affects the localization of NLRP3 protein
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of NLRP3 protein]

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108

G

nitric oxide synthase 2

increases expression

7-ketocholesterol results in increased expression of NOS2 mRNA

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

7-ketocholesterol results in decreased expression of NPC1L1

NCBI chr 7:44,512,535...44,541,330
Ensembl chr 7:44,512,535...44,541,330

G

poly(ADP-ribose) polymerase 1

increases cleavage
multiple interactions

7-ketocholesterol results in increased cleavage of PARP1 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

paraoxonase 1

multiple interactions

7-ketocholesterol inhibits the reaction [Methylcholanthrene results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [Quercetin results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [Resveratrol results in increased expression of PON1 mRNA]

PMID:15169886 PMID:15458977

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

paraoxonase 2

increases activity
increases expression

7-ketocholesterol results in increased activity of PON2 protein
7-ketocholesterol results in increased expression of PON2 mRNA

NCBI chr 7:95,404,862...95,435,028
Ensembl chr 7:95,404,862...95,435,329

G

paraoxonase 3

multiple interactions

7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 7:95,359,872...95,396,375
Ensembl chr 7:95,359,872...95,396,375

G

peroxisome proliferator activated receptor alpha

decreases expression
multiple interactions

7-ketocholesterol results in decreased expression of PPARA mRNA
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

protein tyrosine kinase 2 beta

multiple interactions

7-ketocholesterol results in increased phosphorylation of and results in increased activity of PTK2B protein

NCBI chr 8:27,310,506...27,459,391
Ensembl chr 8:27,311,482...27,459,391

G

PYD and CARD domain containing

multiple interactions
affects localization

Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

RELA proto-oncogene, NF-kB subunit

increases expression
multiple interactions

7-ketocholesterol results in increased expression of RELA protein
7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of RELA protein]

PMID:24895526 PMID:25845326

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

sphingomyelin phosphodiesterase 1

multiple interactions

SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]

NCBI chr11:6,390,474...6,394,996
Ensembl chr11:6,390,440...6,394,998

G

transglutaminase 2

multiple interactions

7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TGM2 mRNA]

NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578

G

tumor necrosis factor

multiple interactions
increases expression

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

increases expression
multiple interactions

7-ketocholesterol results in increased expression of TP53 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

vascular cell adhesion molecule 1

increases expression

7-ketocholesterol results in increased expression of VCAM1 mRNA; 7-ketocholesterol results in increased expression of VCAM1 protein

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vascular endothelial growth factor A

increases expression
multiple interactions

7-ketocholesterol results in increased expression of VEGFA protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

7alpha-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 17

decreases activity

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of ADAM17 protein

NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732

G

amyloid beta precursor protein

increases chemical synthesis
decreases secretion

APP protein results in increased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol
cholest-5-en-3 beta,7 alpha-diol results in decreased secretion of APP protein

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

caspase 3

multiple interactions
increases activity

alpha-Tocopherol inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]

PMID:12450566 PMID:16934673

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL2 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL2 mRNA]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 3

increases secretion
increases expression

cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL3 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL3 mRNA

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

increases expression
increases secretion

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL4 mRNA
cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL4 protein

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

CD36 molecule (CD36 blood group)

increases expression
multiple interactions

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions
increases secretion

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CXCL8 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CXCL8 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CXCL8 mRNA]; Quercetin inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CXCL8 mRNA]
cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CXCL8 protein

PMID:16142584 PMID:24802026

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 46 subfamily A member 1

increases hydroxylation

CYP46A1 protein results in increased hydroxylation of cholest-5-en-3 beta,7 alpha-diol

NCBI chr14:99,684,298...99,727,301
Ensembl chr14:99,684,298...99,727,301

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Uranyl Nitrate results in decreased activity of CYP7A1 protein] which results in decreased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of HMGCR protein

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

hydroxysteroid 17-beta dehydrogenase 10

multiple interactions

[cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein

NCBI chr X:53,431,258...53,434,376
Ensembl chr X:53,431,258...53,434,370

G

integrin subunit beta 1

increases expression
multiple interactions

cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

lipoprotein lipase

decreases activity
decreases expression

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of LPL protein
cholest-5-en-3 beta,7 alpha-diol results in decreased expression of LPL mRNA

NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259

G

mitogen-activated protein kinase 1

increases activity

cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK1 protein

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

increases activity

cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK3 protein

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 9

multiple interactions
increases expression

Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of MMP9 mRNA]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

prostaglandin E synthase

increases expression
multiple interactions

cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA
Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA]

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

toll like receptor 4

increases expression
multiple interactions

cholest-5-en-3 beta,7 alpha-diol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

8,9-EET

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily C member 9

increases chemical synthesis
multiple interactions

CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid
Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 3 subfamily A member 4

increases chemical synthesis
multiple interactions

CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

epoxide hydrolase 1

affects hydrolysis

EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

epoxide hydrolase 2

increases abundance

EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

9,10,13-TriHOME

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

epoxide hydrolase 3

multiple interactions

[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid

NCBI chr19:15,226,919...15,237,008
Ensembl chr19:15,226,919...15,233,435

AACOCF3

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

C-X-C motif chemokine ligand 8

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL8 mRNA]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA]

PMID:18938131 PMID:19063610 PMID:19162293

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]

NCBI chr 8:119,557,086...119,673,390
Ensembl chr 8:119,557,086...119,673,453

G

interleukin 1 beta

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

insulin

increases secretion
multiple interactions

arachidonyltrifluoromethane results in increased secretion of INS protein
arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

INS-IGF2 readthrough

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

leptin

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA]

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

mitogen-activated protein kinase 1

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

neuregulin 1

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666

G

phospholipase A2 group IVA

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]

PMID:18938131 PMID:19063610 PMID:19162293

NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981

G

peroxisome proliferator activated receptor gamma

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

prostaglandin-endoperoxide synthase 2

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]]

PMID:18938131 PMID:19063610 PMID:19162293

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

S100 calcium binding protein A11

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to oxaliplatin]

NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907

G

suppressor of cytokine signaling 3

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA]

NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077

G

superoxide dismutase 2

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2]

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

tumor necrosis factor

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular endothelial growth factor A

multiple interactions

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]
arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]]

PMID:19063610 PMID:19162293

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

anandamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1

increases export

ABCB1 protein results in increased export of anandamide

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily G member 2 (JR blood group)

decreases expression
multiple interactions

anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]

PMID:30610963 PMID:34756920

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

acyl-CoA oxidase 1

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA]

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA]

NCBI chr 9:136,673,143...136,687,457
Ensembl chr 9:136,673,143...136,687,457

G

amyloid beta precursor protein

decreases response to substance
decreases metabolic processing
decreases abundance

anandamide results in decreased susceptibility to APP protein
APP protein results in decreased metabolism of anandamide
APP protein results in decreased abundance of anandamide

PMID:22233683 PMID:26976670

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

arrestin beta 2

multiple interactions

anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]

NCBI chr17:4,710,632...4,721,497
Ensembl chr17:4,710,596...4,721,499

G

bradykinin receptor B1

multiple interactions
decreases activity

AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein]

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

caspase 3

multiple interactions
increases cleavage

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

CD36 molecule (CD36 blood group)

increases expression

anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

glycoprotein hormones, alpha polypeptide

decreases expression

anandamide results in decreased expression of CGA mRNA

NCBI chr 6:87,085,498...87,095,106
Ensembl chr 6:87,085,498...87,095,106

G

cannabinoid receptor 1

affects activity
increases response to substance
decreases expression
affects binding
increases activity
multiple interactions

anandamide affects the activity of CNR1 protein
CNR1 protein results in increased susceptibility to anandamide
anandamide results in decreased expression of CNR1 protein
anandamide binds to CNR1 protein
anandamide results in increased activity of CNR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]
[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]

PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 More...

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

cannabinoid receptor 2

affects activity
affects binding
multiple interactions

anandamide affects the activity of CNR2 protein
anandamide binds to CNR2 protein
anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]

PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

cAMP responsive element binding protein 1

decreases phosphorylation
multiple interactions

anandamide results in decreased phosphorylation of CREB1 protein
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

corticotropin releasing hormone

decreases abundance

CRH protein results in decreased abundance of anandamide

NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464

G

cytochrome P450 family 2 subfamily J member 2

multiple interactions
increases metabolic processing

cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]

NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773

G

DNA damage inducible transcript 3

increases expression
multiple interactions

anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]
4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]

PMID:21949157 PMID:26513129 PMID:29441458

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516

G

endogenous retrovirus group FRD member 1, envelope

decreases expression

anandamide results in decreased expression of ERVFRD-1 mRNA

NCBI chr 6:11,102,489...11,111,725
Ensembl chr 6:11,102,489...11,111,725

G

endogenous retrovirus group W member 1, envelope

decreases expression

anandamide results in decreased expression of ERVW-1 mRNA

NCBI chr 7:92,468,380...92,477,946
Ensembl chr 7:92,468,380...92,477,986

G

coagulation factor III, tissue factor

multiple interactions
increases expression

anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
anandamide results in increased expression of F3 protein

NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759

G

fatty acid amide hydrolase

multiple interactions
increases response to substance
decreases metabolic processing
increases degradation
affects expression

[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]
FAAH gene mutant form results in decreased metabolism of anandamide
[Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide]
FAAH results in increased degradation of anandamide
anandamide affects the expression of FAAH protein

PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 More...

NCBI chr 1:46,394,317...46,413,845
Ensembl chr 1:46,394,317...46,413,848

G

fatty acid binding protein 1

affects binding
affects abundance
multiple interactions

anandamide analog binds to FABP1 protein
FABP1 protein affects the abundance of anandamide
FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein]

PMID:29414765 PMID:30232874

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein]
anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein

PMID:9748483 PMID:15601931 PMID:19515121

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

interferon gamma

multiple interactions

anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

insulin like growth factor 1

increases expression

anandamide results in increased expression of IGF1 protein

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

interleukin 12B

multiple interactions

[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

interleukin 1 beta

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]

PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions

anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

leptin

decreases abundance
multiple interactions
decreases activity
decreases transport

LEP protein results in decreased abundance of anandamide
Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide]
LEP protein results in decreased activity of anandamide
LEP protein results in decreased transport of anandamide

PMID:16154199 PMID:29967158

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

mitogen-activated protein kinase kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase kinase 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 1

increases expression

anandamide results in increased expression of MMP1 mRNA

NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160

G

matrix metallopeptidase 3

increases expression

anandamide results in increased expression of MMP3 mRNA

NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609

G

matrix metallopeptidase 9

multiple interactions
increases expression

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

nitric oxide synthase 2

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

PMID:11891798 PMID:15748152

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

poly(ADP-ribose) polymerase 1

increases cleavage

anandamide results in increased cleavage of PARP1 protein

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

peroxisome proliferator activated receptor alpha

multiple interactions

anandamide binds to and results in increased activity of PPARA protein

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing

[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide
anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein
PTGS2 results in increased metabolism of anandamide
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]

PMID:16330497 PMID:17245358 PMID:20702753

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

selectin P

multiple interactions
increases expression

anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein]
anandamide results in increased expression of SELP protein

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

anandamide results in increased expression of TIMP1 mRNA
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

tumor necrosis factor

multiple interactions
increases abundance

anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]
TNF protein results in increased abundance of anandamide
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]

PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

transient receptor potential cation channel subfamily V member 1

multiple interactions
increases response to substance
increases activity
affects response to substance
affects binding

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]
TRPV1 protein results in increased susceptibility to anandamide
anandamide results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein]
anandamide binds to TRPV1 protein

PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 More...

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

vascular endothelial growth factor A

multiple interactions

anandamide results in decreased expression of and results in decreased secretion of VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

arachidonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases degradation

Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Arachidonic Acid results in increased degradation of ABCA1 protein

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 11

multiple interactions

Arachidonic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA]

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily D member 3

decreases expression

Arachidonic Acid results in decreased expression of ABCD3 mRNA

NCBI chr 1:94,385,131...94,518,663
Ensembl chr 1:94,418,389...94,518,666

G

ATP binding cassette subfamily G member 1

decreases expression

Arachidonic Acid results in decreased expression of ABCG1 mRNA

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

adenosine deaminase RNA specific B1

decreases expression

Arachidonic Acid results in decreased expression of ADARB1 mRNA

NCBI chr21:45,074,578...45,226,563
Ensembl chr21:45,073,853...45,226,560

G

angiotensinogen

multiple interactions

Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

aryl hydrocarbon receptor

multiple interactions

AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

Arachidonic Acid results in increased phosphorylation of AKT1 protein
aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

arachidonate 12-lipoxygenase, 12S type

affects response to substance
increases metabolic processing

ALOX12 protein affects the susceptibility to Arachidonic Acid
ALOX12 protein results in increased metabolism of Arachidonic Acid

PMID:17027136 PMID:19373248

NCBI chr17:6,996,049...7,010,754
Ensembl chr17:6,996,049...7,010,754

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid

NCBI chr17:8,072,636...8,087,716
Ensembl chr17:8,072,636...8,087,716

G

arachidonate 15-lipoxygenase

affects metabolic processing
multiple interactions
increases metabolic processing

ALOX15 protein affects the metabolism of Arachidonic Acid
[ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid
ALOX15 protein results in increased metabolism of Arachidonic Acid
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA

PMID:8305483 PMID:11861792 PMID:21193584 PMID:23872364

NCBI chr17:4,630,919...4,641,678
Ensembl chr17:4,630,919...4,642,294

G

arachidonate 5-lipoxygenase

multiple interactions
increases metabolic processing

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]

PMID:7577949 PMID:7592874 PMID:9495842 PMID:10779545 PMID:11698504 More...

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

apolipoprotein A1

multiple interactions
decreases expression

Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Arachidonic Acid results in decreased expression of APOA1 mRNA

PMID:7983038 PMID:16118212

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein C1

decreases expression

Arachidonic Acid results in decreased expression of APOC1 mRNA

NCBI chr19:44,914,325...44,919,346
Ensembl chr19:44,914,247...44,919,349

G

apolipoprotein E

multiple interactions
decreases response to substance

APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]
Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

increases secretion
multiple interactions

APP protein modified form results in increased secretion of Arachidonic Acid
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

aquaporin 3 (Gill blood group)

decreases expression

Arachidonic Acid results in decreased expression of AQP3 mRNA

NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596

G

Rho GDP dissociation inhibitor alpha

increases expression

Arachidonic Acid results in increased expression of ARHGDIA mRNA

NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,721...81,871,378

G

activating transcription factor 1

multiple interactions

Arachidonic Acid inhibits the reaction [Quercetin results in increased phosphorylation of ATF1 protein]

NCBI chr12:50,763,459...50,821,162
Ensembl chr12:50,763,710...50,821,162

G

activating transcription factor 2

multiple interactions
increases phosphorylation

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein]

NCBI chr 2:175,072,259...175,168,203
Ensembl chr 2:175,072,250...175,168,382

G

activating transcription factor 3

increases expression

Arachidonic Acid results in increased expression of ATF3 mRNA

NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777

G

arginine vasopressin

increases abundance

AVP protein results in increased abundance of Arachidonic Acid

NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724

G

BCL2 associated agonist of cell death

multiple interactions

[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]

NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704

G

BARX homeobox 1

decreases expression

Arachidonic Acid results in decreased expression of BARX1 mRNA

NCBI chr 9:93,951,627...93,955,355
Ensembl chr 9:93,951,627...93,955,355

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]

PMID:19540902 PMID:19720122 PMID:30626086

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

Arachidonic Acid results in decreased expression of BCL2 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]

PMID:19540902 PMID:19620254 PMID:19720122

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 1

multiple interactions
decreases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]

PMID:19540902 PMID:19620254 PMID:19720122 PMID:27916511 PMID:30626086

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989

G

brain derived neurotrophic factor

decreases expression

Arachidonic Acid results in decreased expression of BDNF mRNA

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

BH3 interacting domain death agonist

increases cleavage
multiple interactions

Arachidonic Acid results in increased cleavage of BID protein
FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]

NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770

G

caspase 3

increases activity
multiple interactions
increases degradation

Arachidonic Acid results in increased activity of CASP3 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]

PMID:16704987 PMID:19540902 PMID:19620254 PMID:19720122 PMID:23266427 More...

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

multiple interactions
increases activity

FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

increases activity

Arachidonic Acid results in increased activity of CASP9 protein

PMID:19540902 PMID:19720122

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catalase

increases activity

Arachidonic Acid results in increased activity of CAT protein

PMID:7548195 PMID:16982041

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

CD40 molecule

multiple interactions

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]

NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863

G

carboxylesterase 1

decreases activity
multiple interactions

Arachidonic Acid results in decreased activity of CES1 protein
[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]

PMID:19761868 PMID:21049984 PMID:37353134

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

carboxylesterase 2

multiple interactions

[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096

G

cannabinoid receptor 2

multiple interactions

CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein]

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

collagen type XVIII alpha 1 chain

decreases expression

Arachidonic Acid results in decreased expression of COL18A1 mRNA

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

carnitine palmitoyltransferase 1A

increases expression

Arachidonic Acid results in increased expression of CPT1A mRNA

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

cAMP responsive element binding protein 1

increases phosphorylation
multiple interactions

Arachidonic Acid results in increased phosphorylation of CREB1 protein
Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein]

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

C-terminal Src kinase

increases activity
affects localization

Arachidonic Acid results in increased activity of CSK protein
Arachidonic Acid affects the localization of CSK protein

NCBI chr15:74,782,080...74,803,197
Ensembl chr15:74,782,080...74,803,197

G

CTD small phosphatase like

decreases expression

Arachidonic Acid results in decreased expression of CTDSPL mRNA

NCBI chr 3:37,861,880...37,984,469
Ensembl chr 3:37,861,880...37,984,469

G

C-X-C motif chemokine ligand 8

multiple interactions
increases secretion

Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA]
CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein]
Arachidonic Acid results in increased secretion of CXCL8 protein

PMID:15115777 PMID:19063610 PMID:21457203

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome c, somatic

affects localization

Arachidonic Acid affects the localization of CYCS protein

NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260

G

cytoglobin

multiple interactions

CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]

NCBI chr17:76,527,356...76,551,193
Ensembl chr17:76,527,356...76,551,175

G

cytochrome P450 family 1 subfamily A member 1

affects metabolic processing
multiple interactions

CYP1A1 protein affects the metabolism of Arachidonic Acid
Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

PMID:15258110 PMID:19063610

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

increases metabolic processing
decreases activity

CYP1A2 protein results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP1A2 protein

PMID:12675279 PMID:16978661

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 1 subfamily B member 1

affects metabolic processing

CYP1B1 protein affects the metabolism of Arachidonic Acid

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 24 subfamily A member 1

decreases expression

Arachidonic Acid results in decreased expression of CYP24A1 mRNA

NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986

G

cytochrome P450 family 2 subfamily B member 6

increases metabolic processing

CYP2B6 protein results in increased metabolism of Arachidonic Acid

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

decreases activity
increases metabolic processing
multiple interactions

Arachidonic Acid results in decreased activity of CYP2C19 protein
CYP2C19 protein results in increased metabolism of Arachidonic Acid
CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]

PMID:12675279 PMID:16978661 PMID:18004210

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 23, pseudogene

multiple interactions

CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein]

NCBI chr10:100,105,754...100,140,151
Ensembl chr10:100,105,754...100,140,151

G

cytochrome P450 family 2 subfamily C member 8

increases metabolic processing

CYP2C8 protein results in increased metabolism of Arachidonic Acid

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

increases metabolic processing
decreases activity
multiple interactions

CYP2C9 protein results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP2C9 protein
CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Arachidonic Acid]

PMID:12675279 PMID:16978661

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily D member 6

increases metabolic processing

CYP2D6 protein results in increased metabolism of Arachidonic Acid

NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions
affects hydroxylation
increases response to substance
decreases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid]
CYP2E1 protein affects the hydroxylation of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP2E1 protein

PMID:12086689 PMID:12566070 PMID:15205388 PMID:16978661 PMID:17034788 More...

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 2 subfamily J member 2

multiple interactions

Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole]

NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773

G

cytochrome P450 family 3 subfamily A member 4

increases metabolic processing
decreases activity
multiple interactions

CYP3A4 protein results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP3A4 protein
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid]

PMID:12675279 PMID:16978661

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 4 subfamily A member 11

increases hydroxylation

CYP4A11 protein results in increased hydroxylation of Arachidonic Acid

NCBI chr 1:46,929,188...46,941,476
Ensembl chr 1:46,929,177...46,941,484

G

cytochrome P450 family 4 subfamily F member 2

multiple interactions
increases hydroxylation

rubiarbonone C inhibits the reaction [CYP4F2 protein results in increased hydroxylation of Arachidonic Acid]

NCBI chr19:15,878,023...15,898,074
Ensembl chr19:15,878,023...15,898,077

G

cytochrome P450 family 4 subfamily F member 3

increases hydroxylation
multiple interactions

CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid
rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

G

dopachrome tautomerase

decreases expression

Arachidonic Acid results in decreased expression of DCT mRNA

NCBI chr13:94,436,811...94,549,406
Ensembl chr13:94,436,811...94,479,682

G

DNA damage inducible transcript 4

increases expression

Arachidonic Acid results in increased expression of DDIT4 mRNA

NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036

G

DEAD-box helicase 24

decreases expression

Arachidonic Acid results in decreased expression of DDX24 mRNA

NCBI chr14:94,048,287...94,081,202
Ensembl chr14:94,048,287...94,081,202

G

desmin

increases expression

Arachidonic Acid results in increased expression of DES mRNA

NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735

G

7-dehydrocholesterol reductase

decreases expression

Arachidonic Acid results in decreased expression of DHCR7 mRNA

NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868

G

EBP cholestenol delta-isomerase

decreases expression

Arachidonic Acid results in decreased expression of EBP mRNA

NCBI chr X:48,521,808...48,528,716
Ensembl chr X:48,521,799...48,528,716

G

epidermal growth factor receptor

multiple interactions

5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

early growth response 1

increases expression

Arachidonic Acid results in increased expression of EGR1 mRNA

PMID:8764118 PMID:16704987

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

eukaryotic translation initiation factor 4E binding protein 3

multiple interactions

Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of EIF4EBP3 protein]

NCBI chr 5:140,547,662...140,549,576
Ensembl chr 5:140,547,662...140,549,576

G

epoxide hydrolase 2

increases metabolic processing

EPHX2 protein results in increased metabolism of Arachidonic Acid

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

G

ergosterol biosynthesis 28 homolog

decreases expression

Arachidonic Acid results in decreased expression of ERG28 mRNA

NCBI chr14:75,649,791...75,660,876
Ensembl chr14:75,649,791...75,660,876

G

coagulation factor III, tissue factor

increases expression

Arachidonic Acid results in increased expression of F3 protein

NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759

G

fatty acid amide hydrolase

increases chemical synthesis
multiple interactions

FAAH protein results in increased chemical synthesis of Arachidonic Acid
Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid]

NCBI chr 1:46,394,317...46,413,845
Ensembl chr 1:46,394,317...46,413,848

G

Fas associated via death domain

multiple interactions

FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]

NCBI chr11:70,203,296...70,207,390
Ensembl chr11:70,203,296...70,207,390

G

fatty acid desaturase 1

multiple interactions

[geraniol results in decreased activity of FADS1 protein] which results in decreased chemical synthesis of Arachidonic Acid

NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318

G

fatty acid desaturase 2

decreases expression

Arachidonic Acid results in decreased expression of FADS2 mRNA

NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354

G

Fas cell surface death receptor

multiple interactions
increases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]
Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

Fas ligand

multiple interactions
increases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]
Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein

NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876

G

fatty acid synthase

decreases expression

Arachidonic Acid results in decreased expression of FASN mRNA

NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294

G

fibroblast growth factor receptor 3

decreases expression

Arachidonic Acid results in decreased expression of FGFR3 mRNA

NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases phosphorylation

[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]
Arachidonic Acid results in decreased phosphorylation of FOS protein

PMID:8764118 PMID:10864209 PMID:15878913 PMID:16704987 PMID:19720122 More...

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Arachidonic Acid results in increased expression of FOSL1 mRNA

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

growth associated protein 43

increases phosphorylation

Arachidonic Acid results in increased phosphorylation of GAP43 protein

NCBI chr 3:115,623,510...115,721,483
Ensembl chr 3:115,623,510...115,721,490

G

glutamate-cysteine ligase catalytic subunit

increases expression
increases activity

Arachidonic Acid results in increased expression of GCLC mRNA
Arachidonic Acid results in increased activity of GCLC protein

PMID:16704987 PMID:17092368

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

increases expression

Arachidonic Acid results in increased expression of GCLM mRNA
Arachidonic Acid metabolite results in increased expression of GCLM mRNA

PMID:16704987 PMID:27012417

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glutaredoxin

affects response to substance

GLRX protein affects the susceptibility to Arachidonic Acid

NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726

G

glucosamine-6-phosphate deaminase 1

decreases expression

Arachidonic Acid results in decreased expression of GNPDA1 mRNA

NCBI chr 5:142,000,671...142,013,027
Ensembl chr 5:141,991,749...142,013,041

G

glutamic--pyruvic transaminase

multiple interactions

Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

glutathione peroxidase 1

multiple interactions

[Iodoacetates results in decreased activity of GPX1 protein] which affects the metabolism of Arachidonic Acid

NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605

G

glutathione peroxidase 4

multiple interactions

[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein]

PMID:11115402 PMID:14642406

NCBI chr19:1,103,994...1,106,779
Ensembl chr19:1,103,982...1,106,791

G

glycogen synthase kinase 3 beta

multiple interactions

[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression

Arachidonic Acid results in decreased expression of HMGCR mRNA

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

heme oxygenase 1

increases expression
multiple interactions
decreases response to substance

Arachidonic Acid results in increased expression of HMOX1 mRNA
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein]
Arachidonic Acid metabolite results in increased expression of HMOX1 mRNA; Arachidonic Acid metabolite results in increased expression of HMOX1 protein
HMOX1 protein results in decreased susceptibility to Arachidonic Acid

PMID:15036350 PMID:16704987 PMID:17092368 PMID:27012417

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heparan sulfate 2-O-sulfotransferase 1

decreases expression

Arachidonic Acid results in decreased expression of HS2ST1 mRNA

NCBI chr 1:86,914,635...87,109,982
Ensembl chr 1:86,914,635...87,109,982

G

heat shock protein 90 alpha family class B member 1

decreases expression

Arachidonic Acid results in decreased expression of HSP90AB1 mRNA

NCBI chr 6:44,246,194...44,253,883
Ensembl chr 6:44,246,166...44,253,888

G

5-hydroxytryptamine receptor 1A

multiple interactions

Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507

G

inhibitor of DNA binding 3

decreases expression

Arachidonic Acid results in decreased expression of ID3 mRNA

NCBI chr 1:23,557,926...23,559,501
Ensembl chr 1:23,557,926...23,559,501

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Arachidonic Acid results in decreased expression of IDI1 mRNA

NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119

G

intraflagellar transport 25

decreases expression

Arachidonic Acid results in decreased expression of IFT25 mRNA

NCBI chr 1:53,911,576...53,946,305
Ensembl chr 1:53,916,574...53,945,699

G

insulin like growth factor binding protein 7

decreases expression

Arachidonic Acid results in decreased expression of IGFBP7 mRNA

NCBI chr 4:57,030,773...57,110,385
Ensembl chr 4:57,030,773...57,110,385

G

interleukin 12B

multiple interactions

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

interleukin 1 alpha

multiple interactions

[IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 1 beta

multiple interactions

[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 4

multiple interactions

[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 6

increases secretion

Arachidonic Acid results in increased secretion of IL6 protein

PMID:20436887 PMID:21457203

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

ilvB acetolactate synthase like

decreases expression

Arachidonic Acid results in decreased expression of ILVBL mRNA

NCBI chr19:15,114,987...15,125,786
Ensembl chr19:15,114,984...15,125,786

G

insulin

increases secretion
multiple interactions

Arachidonic Acid results in increased secretion of INS protein
Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

ISL LIM homeobox 1

decreases expression

Arachidonic Acid results in decreased expression of ISL1 mRNA

NCBI chr 5:51,383,448...51,394,730
Ensembl chr 5:51,383,448...51,394,730

G

integrin subunit alpha 2b

increases expression
multiple interactions

Arachidonic Acid results in increased expression of ITGA2B protein
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]]

NCBI chr17:44,372,181...44,389,649
Ensembl chr17:44,372,180...44,389,649

G

integrin subunit alpha 6

increases expression

Arachidonic Acid results in increased expression of ITGA6 mRNA

NCBI chr 2:172,427,336...172,506,459
Ensembl chr 2:172,427,354...172,506,459

G

integrin subunit beta 3

multiple interactions
increases expression

Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]

PMID:18413191 PMID:23249183

NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]
Arachidonic Acid results in increased expression of JUN mRNA

PMID:8764118 PMID:16704987 PMID:19720122

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]
Arachidonic Acid results in increased expression of JUNB mRNA

NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315

G

potassium two pore domain channel subfamily K member 10

multiple interactions

Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]

NCBI chr14:88,180,108...88,326,912
Ensembl chr14:88,180,103...88,326,907

G

potassium two pore domain channel subfamily K member 2

multiple interactions

Arachidonic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium]

NCBI chr 1:215,005,542...215,237,090
Ensembl chr 1:215,005,775...215,237,090

G

potassium two pore domain channel subfamily K member 4

multiple interactions

Arachidonic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium]

PMID:10767409 PMID:16075240

NCBI chr11:64,291,302...64,300,031
Ensembl chr11:64,291,302...64,300,031

G

KLF transcription factor 5

increases expression

Arachidonic Acid results in increased expression of KLF5 mRNA

NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541

G

KLF transcription factor 6

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]
Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein

NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281

G

kininogen 1

multiple interactions

Arachidonic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA]

NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410

G

keratin 18

multiple interactions

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein

NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906

G

keratin 8

multiple interactions

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein

NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954

G

lysosomal associated membrane protein 2

decreases expression

Arachidonic Acid results in decreased expression of LAMP2 mRNA

NCBI chr X:120,426,148...120,469,349
Ensembl chr X:120,426,148...120,469,365

G

low density lipoprotein receptor

multiple interactions
decreases response to substance

Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]
LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid
Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

leptin

multiple interactions

Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA]

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

lipase C, hepatic type

decreases abundance
multiple interactions

LIPC gene mutant form results in decreased abundance of Arachidonic Acid
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

decreases abundance
multiple interactions

LIPG gene mutant form results in decreased abundance of Arachidonic Acid
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

G

lecithin retinol acyltransferase

increases expression

Arachidonic Acid results in increased expression of LRAT mRNA

NCBI chr 4:154,740,838...154,753,120
Ensembl chr 4:154,626,945...154,753,120

G

lanosterol synthase

decreases expression

Arachidonic Acid results in decreased expression of LSS mRNA

NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824

G

leukotriene B4 receptor

affects response to substance

LTB4R1 protein affects the susceptibility to Arachidonic Acid

NCBI chr14:24,311,502...24,318,036
Ensembl chr14:24,311,450...24,318,036

G

LUC7 like 3 pre-mRNA splicing factor

decreases expression

Arachidonic Acid results in decreased expression of LUC7L3 mRNA

NCBI chr17:50,719,603...50,756,219
Ensembl chr17:50,719,565...50,756,219

G

MAF bZIP transcription factor F

increases expression

Arachidonic Acid results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

mitogen-activated protein kinase kinase 1

multiple interactions

FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase 1

increases phosphorylation
affects abundance
multiple interactions

Arachidonic Acid results in increased phosphorylation of MAPK1 protein
MAPK1 protein affects the abundance of Arachidonic Acid
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]

PMID:16216387 PMID:19464254

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 14

multiple interactions

MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]
MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]

PMID:16120751 PMID:19540902

NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236

G

mitogen-activated protein kinase 3

multiple interactions
affects abundance
increases phosphorylation

[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein]
MAPK3 protein affects the abundance of Arachidonic Acid

PMID:16216387 PMID:19464254

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

mitogen-activated protein kinase 8

multiple interactions

MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]

NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360

G

microtubule associated protein tau

increases phosphorylation
multiple interactions

Arachidonic Acid results in increased phosphorylation of MAPT protein
Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein]

NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334

G

matrix metallopeptidase 13

increases secretion
multiple interactions
increases expression

Arachidonic Acid results in increased secretion of MMP13 protein
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein]

NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732

G

matrix metallopeptidase 2

multiple interactions
increases expression
increases secretion

Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein]

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 9

increases expression
multiple interactions
increases secretion

Arachidonic Acid results in increased expression of MMP9 mRNA
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

myeloperoxidase

increases secretion
multiple interactions
increases expression

Arachidonic Acid results in increased secretion of MPO protein
5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein]

PMID:3111576 PMID:9831321

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

metallothionein 2A

multiple interactions

Arachidonic Acid promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

mechanistic target of rapamycin kinase

multiple interactions

[Quercetin co-treated with Arachidonic Acid] results in decreased phosphorylation of MTOR protein

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

neutrophil cytosolic factor 1

multiple interactions
increases localization

Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]

PMID:12101222 PMID:20832062

NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315

G

neutrophil cytosolic factor 2

multiple interactions

Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein]

NCBI chr 1:183,555,562...183,601,849
Ensembl chr 1:183,554,461...183,590,905

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

Arachidonic Acid metabolite results in increased expression of NFE2L2 protein
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NADPH oxidase 1

multiple interactions

Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]]

NCBI chr X:100,843,324...100,874,359
Ensembl chr X:100,843,324...100,874,359

G

NAD(P)H quinone dehydrogenase 1

increases expression

Arachidonic Acid metabolite results in increased expression of NQO1 mRNA

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group H member 4

affects binding
multiple interactions

Arachidonic Acid binds to NR1H4 protein
Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]

NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414

G

nuclear receptor subfamily 2 group F member 1

decreases expression

Arachidonic Acid results in decreased expression of NR2F1 mRNA

NCBI chr 5:93,583,222...93,594,611
Ensembl chr 5:93,583,222...93,594,611

G

nuclear receptor subfamily 4 group A member 2

decreases expression

Arachidonic Acid results in decreased expression of NR4A2 mRNA

NCBI chr 2:156,324,437...156,332,721
Ensembl chr 2:156,324,437...156,342,348

G

nuclear receptor subfamily 5 group A member 2

multiple interactions
decreases chemical synthesis

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog
NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid

NCBI chr 1:200,027,710...200,177,415
Ensembl chr 1:200,027,614...200,177,420

G

neurturin

decreases expression

Arachidonic Acid results in decreased expression of NRTN mRNA

NCBI chr19:5,805,067...5,828,324
Ensembl chr19:5,805,067...5,828,324

G

poly(ADP-ribose) polymerase 1

multiple interactions
increases cleavage

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]

PMID:10403056 PMID:19540902 PMID:21132278 PMID:30626086

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

phosphodiesterase 4D interacting protein

decreases expression

Arachidonic Acid results in decreased expression of PDE4DIP mRNA

NCBI chr 1:148,808,434...149,033,016
Ensembl chr 1:148,808,140...149,048,286

G

decaprenyl diphosphate synthase subunit 2

decreases expression

Arachidonic Acid results in decreased expression of PDSS2 mRNA

NCBI chr 6:107,152,562...107,459,564
Ensembl chr 6:107,152,562...107,459,564

G

pleckstrin homology like domain family A member 1

increases expression

Arachidonic Acid results in increased expression of PHLDA1 mRNA

NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776

G

phospholipase A2 group IVA

increases expression
multiple interactions

Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein
PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]

PMID:15878913 PMID:16120751 PMID:19162293

NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981

G

phospholipase A2 group V

multiple interactions

PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid]

NCBI chr 1:20,028,408...20,091,911
Ensembl chr 1:20,028,179...20,091,911

G

phospholipase A2 group VI

multiple interactions

PLA2G6 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]

NCBI chr22:38,111,495...38,181,830
Ensembl chr22:38,111,495...38,214,778

G

phospholipase A2 activating protein

multiple interactions

PLAA protein promotes the reaction [Lipopolysaccharides results in increased abundance of Arachidonic Acid]

NCBI chr 9:26,903,372...26,947,242
Ensembl chr 9:26,903,372...26,947,242

G

perilipin 2

increases expression

Arachidonic Acid results in increased expression of PLIN2 mRNA
Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein

NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

Arachidonic Acid results in increased expression of PMAIP1 mRNA

NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305

G

paraoxonase 1

multiple interactions
decreases activity

Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]
Arachidonic Acid results in decreased activity of PON1 protein

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein
Arachidonic Acid binds to and results in increased activity of PPARA protein

PMID:10403814 PMID:11172467 PMID:15491415

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor delta

increases expression

Arachidonic Acid results in increased expression of PPARD mRNA

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

peroxisome proliferator activated receptor gamma

decreases expression
increases expression
multiple interactions

Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein
Arachidonic Acid results in increased expression of PPARG protein
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]

PMID:11172467 PMID:12604186 PMID:19063610

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

protein phosphatase 1 catalytic subunit alpha

decreases expression

Arachidonic Acid results in decreased expression of PPP1CA mRNA

NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183

G

pre-mRNA splicing tri-snRNP complex factor PRPF4

decreases expression

Arachidonic Acid results in decreased expression of PRPF4 mRNA

NCBI chr 9:113,275,658...113,292,905
Ensembl chr 9:113,275,642...113,294,009

G

phosphoserine aminotransferase 1

increases expression

Arachidonic Acid results in increased expression of PSAT1 mRNA

NCBI chr 9:78,297,125...78,330,093
Ensembl chr 9:78,297,125...78,330,093

G

platelet activating factor receptor

multiple interactions

[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA]

NCBI chr 1:28,147,166...28,193,856
Ensembl chr 1:28,147,166...28,193,936

G

prostaglandin-endoperoxide synthase 1

increases activity
increases response to substance
increases metabolic processing
multiple interactions

Arachidonic Acid results in increased activity of PTGS1 protein
PTGS1 results in increased susceptibility to Arachidonic Acid
PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid
[[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]

PMID:15863457 PMID:16141368 PMID:19751497 PMID:20933508 PMID:21163909

NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing
increases response to substance
increases activity

[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid results in increased expression of PTGS2 protein
PTGS2 results in increased susceptibility to Arachidonic Acid
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein

PMID:9013627 PMID:9146894 PMID:11112151 PMID:12538810 PMID:12757841 More...

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

protein tyrosine phosphatase 4A1

increases expression

Arachidonic Acid results in increased expression of PTP4A1 mRNA

NCBI chr 6:63,516,440...63,583,588
Ensembl chr 6:63,521,746...63,583,588

G

Rap guanine nucleotide exchange factor 2

increases expression

Arachidonic Acid results in increased expression of RAPGEF2 mRNA

NCBI chr 4:159,103,079...159,360,173
Ensembl chr 4:159,103,013...159,360,174

G

resistin

decreases expression

Arachidonic Acid results in decreased expression of RETN mRNA

NCBI chr19:7,669,049...7,670,455
Ensembl chr19:7,669,049...7,670,455

G

ribosomal protein S6 kinase B1

multiple interactions

Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of RPS6KB1 protein]

NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574

G

retinoid X receptor alpha

affects binding

Arachidonic Acid binds to RXRA protein

NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585

G

stearoyl-CoA desaturase

increases expression

Arachidonic Acid results in increased expression of SCD mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

selectin P

increases expression
multiple interactions

Arachidonic Acid results in increased expression of SELP protein
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]

PMID:17543677 PMID:18413191 PMID:23249183

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

serpin family B member 2

increases expression

Arachidonic Acid results in increased expression of SERPINB2 mRNA

NCBI chr18:63,887,705...63,903,888
Ensembl chr18:63,871,692...63,903,888

G

S-phase kinase associated protein 2

decreases expression

Arachidonic Acid results in decreased expression of SKP2 mRNA

NCBI chr 5:36,152,111...36,193,530
Ensembl chr 5:36,151,989...36,196,849

G

solute carrier family 4 member 2

increases expression

Arachidonic Acid results in increased expression of SLC4A2 mRNA

NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526

G

solute carrier family 7 member 11

increases expression

Arachidonic Acid results in increased expression of SLC7A11 mRNA

NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349

G

snail family transcriptional repressor 2

increases expression

Arachidonic Acid results in increased expression of SNAI2 mRNA

NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740

G

suppressor of cytokine signaling 3

multiple interactions

Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA]

NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077

G

superoxide dismutase 1

decreases activity
increases activity
multiple interactions

Arachidonic Acid results in decreased activity of SOD1 protein
Arachidonic Acid results in increased activity of SOD1 protein
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

superoxide dismutase 2

multiple interactions
increases activity
increases expression

[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]
Arachidonic Acid results in increased activity of SOD2 protein
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]

PMID:12031898 PMID:16982041

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

SRY-box transcription factor 9

decreases expression

Arachidonic Acid results in decreased expression of SOX9 mRNA

NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416

G

secreted protein acidic and cysteine rich

decreases expression

Arachidonic Acid results in decreased expression of SPARC mRNA

NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975

G

spastin

decreases expression

Arachidonic Acid results in decreased expression of SPAST mRNA

NCBI chr 2:32,063,556...32,157,637
Ensembl chr 2:32,063,556...32,157,637

G

sequestosome 1

increases expression

Arachidonic Acid results in increased expression of SQSTM1 mRNA

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

SLIT-ROBO Rho GTPase activating protein 2

decreases expression

Arachidonic Acid results in decreased expression of SRGAP2 mRNA

NCBI chr 1:206,203,541...206,464,436
Ensembl chr 1:206,203,346...206,464,436

G

sulfiredoxin 1

increases expression

Arachidonic Acid metabolite results in increased expression of SRXN1 mRNA

NCBI chr20:646,615...653,200
Ensembl chr20:646,615...653,200

G

signal sequence receptor subunit 2

decreases expression

Arachidonic Acid results in decreased expression of SSR2 mRNA

NCBI chr 1:156,009,048...156,020,951
Ensembl chr 1:156,009,048...156,020,951

G

steroidogenic acute regulatory protein

multiple interactions
increases expression

Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein]
Arachidonic Acid results in increased expression of STAR protein

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

stanniocalcin 2

increases expression

Arachidonic Acid results in increased expression of STC2 mRNA

NCBI chr 5:173,314,723...173,328,414
Ensembl chr 5:173,314,723...173,328,447

G

serine/threonine kinase 11

multiple interactions

STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]]

NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431

G

transcription factor EB

decreases expression

Arachidonic Acid results in decreased expression of TFEB mRNA

NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259

G

transforming growth factor beta 1

multiple interactions

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

thyroid hormone responsive

decreases expression
multiple interactions

Arachidonic Acid results in decreased expression of THRSP mRNA
Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA]

NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

toll like receptor 4

multiple interactions

[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

multiple interactions
increases abundance
increases secretion

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid]
TNF protein results in increased abundance of Arachidonic Acid
Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]

PMID:1515551 PMID:10588948 PMID:15684433

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF receptor superfamily member 12A

increases expression

Arachidonic Acid results in increased expression of TNFRSF12A mRNA

NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383

G

TNF receptor superfamily member 1A

multiple interactions

TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]

NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114

G

tensin 3

decreases expression

Arachidonic Acid results in decreased expression of TNS3 mRNA

NCBI chr 7:47,275,154...47,582,586
Ensembl chr 7:47,275,154...47,582,558

G

DNA topoisomerase II alpha

decreases expression

Arachidonic Acid results in decreased expression of TOP2A mRNA

NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896

G

tumor protein p53

multiple interactions

[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

transient receptor potential cation channel subfamily A member 1

increases activity
multiple interactions

Arachidonic Acid results in increased activity of TRPA1 protein
Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein]

NCBI chr 8:72,021,250...72,090,010
Ensembl chr 8:72,019,917...72,075,584

G

transient receptor potential cation channel subfamily C member 4

multiple interactions

TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium]

NCBI chr13:37,632,063...37,869,772
Ensembl chr13:37,632,063...37,869,802

G

transient receptor potential cation channel subfamily V member 1

multiple interactions

[Arachidonic Acid co-treated with Phorbol 12,13-Dibutyrate] results in increased activity of TRPV1 protein

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

transient receptor potential cation channel subfamily V member 4

increases activity

Arachidonic Acid results in increased activity of TRPV4 protein

NCBI chr12:109,783,087...109,833,398
Ensembl chr12:109,783,087...109,833,406

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

UDP glucuronosyltransferase family 1 member A10

increases glucuronidation

UGT1A10 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 2:233,636,448...233,773,300
Ensembl chr 2:233,636,448...233,773,300

G

UDP glucuronosyltransferase family 1 member A3

increases glucuronidation

UGT1A3 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,042...233,773,300

G

UDP glucuronosyltransferase family 1 member A4

increases glucuronidation

UGT1A4 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 2:233,718,736...233,773,300
Ensembl chr 2:233,718,736...233,773,300

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

UGT1A9 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300

G

UDP glucuronosyltransferase family 2 member B7

increases glucuronidation

UGT2B7 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987

G

vascular endothelial growth factor A

multiple interactions
increases expression

[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]
Arachidonic Acid results in increased expression of VEGFA mRNA

PMID:12821125 PMID:18388244 PMID:19464254

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta

increases expression

Arachidonic Acid results in increased expression of YWHAZ mRNA

NCBI chr 8:100,916,523...100,953,382
Ensembl chr 8:100,916,523...100,953,388

G

zinc finger BED-type containing 2

decreases expression

Arachidonic Acid results in decreased expression of ZBED2 mRNA

NCBI chr 3:111,592,900...111,595,346
Ensembl chr 3:111,592,900...111,595,346

G

ZFP36 ring finger protein

increases expression

Arachidonic Acid results in increased expression of ZFP36 mRNA

NCBI chr19:39,406,847...39,409,407
Ensembl chr19:39,406,847...39,409,412

arachidonoyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisome proliferator activated receptor alpha

multiple interactions

arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

arachidonyl-2'-chloroethylamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

decreases expression

arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA

NCBI chr16:67,482,571...67,483,547
Ensembl chr16:67,482,571...67,483,547

G

AKT serine/threonine kinase 1

decreases phosphorylation

arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

angiopoietin 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein]

NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055

G

angiopoietin 2

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein]

NCBI chr 8:6,499,632...6,563,245
Ensembl chr 8:6,499,632...6,563,409

G

arginine vasopressin

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724

G

BCL2 apoptosis regulator

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

CART prepropeptide

multiple interactions
decreases expression

[arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA

NCBI chr 5:71,719,275...71,721,045
Ensembl chr 5:71,719,275...71,721,048

G

caspase 3

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-C motif chemokine ligand 4

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

CD86 molecule

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

cannabinoid receptor 1

multiple interactions

CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12734338 PMID:27455076 PMID:29033935

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

diacylglycerol lipase alpha

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein

NCBI chr11:61,680,391...61,747,001
Ensembl chr11:61,680,391...61,747,001

G

diacylglycerol lipase beta

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]

NCBI chr 7:6,409,129...6,447,954
Ensembl chr 7:6,409,126...6,484,190

G

DNA damage inducible transcript 3

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein]

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

dopamine receptor D2

decreases expression

arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA

NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691

G

estrogen related receptor gamma

multiple interactions
increases expression

ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein

PMID:27455076 PMID:30019168 PMID:31912162

NCBI chr 1:216,503,246...217,137,702
Ensembl chr 1:216,503,246...217,137,755

G

fibrinogen alpha chain

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]

NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742

G

fibrinogen beta chain

multiple interactions
increases expression

GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA]

NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807

G

fibroblast growth factor 21

increases secretion
multiple interactions
increases expression

arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]

NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333

G

fibrinogen gamma chain

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]

NCBI chr 4:154,604,136...154,612,656
Ensembl chr 4:154,604,134...154,612,967

G

forkhead box O1

decreases phosphorylation
multiple interactions

arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]

NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

glutathione-disulfide reductase

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

hypocretin neuropeptide precursor

increases expression

arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA

NCBI chr17:42,184,060...42,185,452
Ensembl chr17:42,184,060...42,185,452

G

interleukin 6

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

INS-IGF2 readthrough

multiple interactions

[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

PMID:26671069 PMID:26847930 PMID:30761839

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

myeloperoxidase

increases activity
multiple interactions

arachidonyl-2-chloroethylamide results in increased activity of MPO protein
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nitric oxide synthase 2

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NPHS1 adhesion molecule, nephrin

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Tretinoin results in increased expression of NPHS1 mRNA]

NCBI chr19:35,825,372...35,852,504
Ensembl chr19:35,825,372...35,869,287

G

nuclear respiratory factor 1

decreases expression
multiple interactions

arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]

NCBI chr 7:129,611,720...129,757,076
Ensembl chr 7:129,611,720...129,757,082

G

oxytocin/neurophysin I prepropeptide

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr20:3,071,620...3,072,517
Ensembl chr20:3,071,620...3,072,517

G

poly(ADP-ribose) polymerase 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

pro-melanin concentrating hormone

multiple interactions
increases expression

arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]
arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA

NCBI chr12:102,196,459...102,197,833
Ensembl chr12:102,196,459...102,197,833

G

proopiomelanocortin

decreases expression
multiple interactions

arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]

NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

ras homolog family member A

increases activity
multiple interactions

arachidonyl-2-chloroethylamide results in increased activity of RHOA protein
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]

NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998

G

transcription factor A, mitochondrial

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]

NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220

G

tumor necrosis factor

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein]

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

vascular endothelial growth factor A

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vascular endothelial growth factor C

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]

NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922

castor oil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

platelet activating factor acetylhydrolase 1b regulatory subunit 1

multiple interactions
increases expression

isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein]

PMID:1354728 PMID:2743081 PMID:8738301

NCBI chr17:2,593,183...2,685,615
Ensembl chr17:2,593,210...2,685,615

cholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases export
affects expression
multiple interactions
affects export
increases transport

ABCA1 protein results in increased export of Cholesterol
cholesterol cotreated with 25-hydroxycholesterol decreases expression of abca1 mrna and protein in rat hepatoma cells; and increases expression of abca1 mRNA in rat fibroblasts
1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; 1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Resveratrol results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; glycolaldehyde inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Glyoxal inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA; Cholesterol inhibits the reaction [bisphenol A results in decreased expression of ABCA1 mRNA]
ABCA1 protein affects the export of Cholesterol
[[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [[Plant Preparations co-treated with Cholesterol, Dietary] results in increased expression of ABCA1 mRNA] which results in increased secretion of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; [Cholesterol co-treated with Dietary Fats] results in increased expression of ABCA1 mRNA; [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCA1 mRNA

CTD
RGD

PMID:14993927 PMID:15694933 PMID:15983222 PMID:16118212 PMID:17526932 More...

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 11

increases secretion

ABCB11 protein results in increased secretion of Cholesterol

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily B member 4

affects export

ABCB4 protein affects the export of Cholesterol

NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435

G

ATP binding cassette subfamily G member 1

multiple interactions

[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]
[resveratrol results in increased expression of ABCG1 protein] which results in increased secretion of Cholesterol

PMID:20372816 PMID:21317532

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

ATP binding cassette subfamily G member 2 (JR blood group)

increases activity
multiple interactions

Cholesterol results in increased activity of ABCG2 protein
Sulfasalazine promotes the reaction [Cholesterol results in increased activity of ABCG2 protein]

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

ATP binding cassette subfamily G member 5

affects export
multiple interactions
increases expression
decreases expression
increases secretion

ABCG5 protein affects the export of Cholesterol
[Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG5 mRNA] which results in decreased secretion of Cholesterol
Cholesterol results in increased expression of ABCG5 mRNA
Cholesterol results in decreased expression of ABCG5 mRNA
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG5 mRNA; Cholates promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]

PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535

NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865

G

ATP binding cassette subfamily G member 8

increases secretion
multiple interactions
increases expression
decreases expression
affects export

ABCG8 protein results in increased secretion of Cholesterol
[Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG8 mRNA] which results in decreased secretion of Cholesterol
Cholesterol results in increased expression of ABCG8 mRNA
Cholesterol results in decreased expression of ABCG8 mRNA
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG8 mRNA; Cholates promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]
ABCG8 protein affects the export of Cholesterol

PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535

NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988

G

acetyl-CoA carboxylase alpha

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACACA mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACACA mRNA

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

acyl-CoA dehydrogenase medium chain

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA]

NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575

G

acetylcholinesterase (Yt blood group)

multiple interactions

[Copper co-treated with Cholesterol] results in increased activity of ACHE protein; Clioquinol inhibits the reaction [[Copper co-treated with Cholesterol] results in increased activity of ACHE protein]

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

ATP citrate lyase

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA

NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542

G

acyl-CoA oxidase 1

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

actin alpha 2, smooth muscle

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

advanced glycosylation end-product specific receptor

affects abundance

AGER protein affects the abundance of Cholesterol

NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322

G

angiotensinogen

multiple interactions
affects abundance
increases expression

Cholesterol inhibits the reaction [irbesartan results in increased expression of AGT protein]
[Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGT mRNA; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Losartan inhibits the reaction [AGT protein affects the abundance of Cholesterol]
Cholesterol results in increased expression of AGT protein

PMID:12495295 PMID:19028402 PMID:19109942

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

angiotensin II receptor type 1

increases expression
multiple interactions

Cholesterol results in increased expression of AGTR1 mRNA
Cholesterol inhibits the reaction [irbesartan results in increased expression of AGTR1 mRNA]

NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008

G

angiotensin II receptor type 2

multiple interactions

[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA; [Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein; [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGTR2 mRNA; rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA]; rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein]

PMID:12495295 PMID:21269478

NCBI chr X:116,170,744...116,174,974
Ensembl chr X:116,170,744...116,174,974

G

aryl hydrocarbon receptor

multiple interactions

[beta-Naphthoflavone results in increased activity of AHR protein] which results in decreased chemical synthesis of and results in decreased secretion of Cholesterol

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

AKT serine/threonine kinase 1

multiple interactions

Cholesterol inhibits the reaction [irbesartan results in increased expression of AKT1 protein]
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]
Cholesterol results in increased expression of and results in increased phosphorylation of AKT1 protein

PMID:19028402 PMID:19672739 PMID:31877369

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

albumin

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein; [lard co-treated with Cholesterol] results in increased expression of ALB protein

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

annexin A2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ANXA2 mRNA

NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883

G

apoptotic peptidase activating factor 1

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]

NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,290...98,735,433

G

apolipoprotein A1

multiple interactions
increases export
affects transport
decreases expression
increases secretion

1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [Acrolein affects the metabolism of APOA1 protein] which results in decreased secretion of Cholesterol; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Acrolein inhibits the reaction [APOA1 protein affects the transport of Cholesterol]; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Fingolimod Hydrochloride promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; isosilybin A promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; Resveratrol inhibits the reaction [APOA1 protein results in increased export of Cholesterol]
[Ethanol co-treated with APOA1 protein] results in decreased abundance of Cholesterol
APOA1 affects the transport of Cholesterol
Cholesterol results in decreased expression of APOA1 protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; [Glutathione co-treated with Quercetin] promotes the reaction [APOA1 protein results in increased export of Cholesterol]; [T0901317 co-treated with APOA1 protein] results in increased secretion of Cholesterol; Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Quercetin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]

PMID:12531903 PMID:12595494 PMID:15983222 PMID:16037261 PMID:16115471 More...

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein B

increases expression
multiple interactions

Cholesterol results in increased expression of APOB protein
Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein]

PMID:16271152 PMID:16581047

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

apolipoprotein E

affects response to substance
affects localization
multiple interactions
increases abundance
increases export

APOE protein affects the susceptibility to Cholesterol
Cholesterol affects the localization of APOE protein
Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]
APOE gene mutant form results in increased abundance of Cholesterol
APOE protein results in increased export of Cholesterol
24-diamino-5-phenylthiazole inhibits the reaction [T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]]; [[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol; [APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol; APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]; APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]; N-butyloxycarbonyl-methionyl-aspartyl-glycyl-cysteinyl-glutamyl-leucine inhibits the reaction [[[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]

PMID:11397713 PMID:12472773 PMID:16179587 PMID:21169230 PMID:21908651 More...

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions
increases oxidation

[Copper co-treated with Cholesterol] results in increased expression of APP mRNA
APP protein results in increased oxidation of Cholesterol

PMID:15591071 PMID:17134702

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

aquaporin 9

increases expression

Cholesterol results in increased expression of AQP9 mRNA

NCBI chr15:58,138,169...58,185,911
Ensembl chr15:58,138,169...58,185,911

G

amphiregulin

increases expression
multiple interactions

Cholesterol results in increased expression of AREG mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]

NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005

G

ATPase copper transporting beta

increases abundance

ATP7B gene mutant form results in increased abundance of Cholesterol

NCBI chr13:51,932,669...52,012,132
Ensembl chr13:51,930,436...52,012,125

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

Cholesterol analog results in decreased expression of BAX mRNA
Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]

PMID:19477266 PMID:29486218

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

Cholesterol analog results in decreased expression of BCL2 mRNA
Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]

PMID:19477266 PMID:29486218

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 related protein A1

increases expression

Cholesterol analog results in increased expression of BCL2A1 mRNA

NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196

G

BCL2 like 1

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of BCL2L1 mRNA]

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989

G

brain derived neurotrophic factor

multiple interactions

[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein]

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

BCL2 interacting killer

increases expression

Cholesterol analog results in increased expression of BIK mRNA

NCBI chr22:43,110,750...43,129,712
Ensembl chr22:43,110,750...43,129,712

G

chromosome 15 open reading frame 48

increases expression

Cholesterol results in increased expression of C15ORF48 mRNA

NCBI chr15:45,430,610...45,433,340
Ensembl chr15:45,430,579...45,448,761

G

caspase 1

increases expression
increases cleavage
increases activity
affects localization
multiple interactions

Cholesterol analog results in increased expression of CASP1 mRNA
Cholesterol results in increased cleavage of CASP1 protein
Cholesterol analog results in increased activity of CASP1 protein
Cholesterol analog affects the localization of CASP1 protein
Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein]

PMID:19477266 PMID:25833014 PMID:28633109 PMID:33239236

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

multiple interactions
increases cleavage
increases activity
increases expression

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; [Copper co-treated with Cholesterol] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein modified form]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol results in increased activity of CASP3 protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein
Cholesterol results in increased cleavage of CASP3 protein
Cholesterol analog results in increased expression of CASP3 mRNA
Cholesterol analog results in increased cleavage of CASP3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]

PMID:17134702 PMID:19477266 PMID:21872649 PMID:28275691 PMID:29486218 More...

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 4

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]

NCBI chr11:104,942,866...104,968,574
Ensembl chr11:104,942,866...104,969,366

G

caspase 8

multiple interactions
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of CASP8 protein]
Cholesterol analog results in increased expression of CASP8 mRNA; Cholesterol results in increased expression of CASP8 protein

PMID:19477266 PMID:20946910

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

multiple interactions
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]

PMID:19477266 PMID:35385781

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catalase

multiple interactions
increases expression

[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]
Cholesterol results in increased expression of CAT protein

PMID:16933029 PMID:29486218 PMID:35385781

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolin 1

increases transport
multiple interactions

CAV1 protein results in increased transport of Cholesterol
CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]
Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]

PMID:12640124 PMID:21169230

NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,524,994...116,561,179

G

caveolin 3

affects import

CAV3 protein affects the import of Cholesterol

NCBI chr 3:8,733,802...8,746,758
Ensembl chr 3:8,733,802...8,841,808

G

C-C motif chemokine ligand 1

increases expression

Cholesterol results in increased expression of CCL1 mRNA

NCBI chr17:34,360,328...34,363,233
Ensembl chr17:34,360,328...34,363,233

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL2 mRNA; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of CCL2 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein]
Cholesterol results in increased expression of CCL2 mRNA; Cholesterol results in increased expression of CCL2 protein

PMID:19028402 PMID:22129739 PMID:25833014 PMID:26606054 PMID:33239236

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 4

multiple interactions
increases expression

CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 7

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL7 mRNA

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

CD36 molecule (CD36 blood group)

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; [Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]; Losartan promotes the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]

PMID:18302760 PMID:35622622

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

CD40 ligand

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]

NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390

G

cyclin dependent kinase 4

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of CDK4 mRNA]

NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013

G

cyclin dependent kinase 5 regulatory subunit 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDK5R2 mRNA

NCBI chr 2:218,959,666...218,962,155
Ensembl chr 2:218,959,666...218,962,155

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDKN1A mRNA

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

CCAAT enhancer binding protein alpha

multiple interactions

[[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

carboxylesterase 1

increases expression
increases abundance
increases metabolic processing

Cholesterol results in increased expression of CES1 mRNA
CES1 protein results in increased abundance of Cholesterol
CES1 protein results in increased metabolism of Cholesterol

PMID:8049197 PMID:11015575 PMID:12773168 PMID:15825828

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

cholesteryl ester transfer protein

multiple interactions

Teniposide promotes the reaction [CETP protein results in decreased abundance of Cholesterol]

NCBI chr16:56,961,950...56,983,845
Ensembl chr16:56,961,923...56,983,845

G

C-type lectin domain family 4 member E

multiple interactions
increases response to substance

[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein; [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; Cholesterol binds to and results in increased activity of CLEC4E protein; CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA]
CLEC4E protein results in increased susceptibility to Cholesterol

NCBI chr12:8,533,275...8,540,905
Ensembl chr12:8,533,305...8,540,905

G

C-type lectin domain containing 5A

increases expression
multiple interactions

Cholesterol results in increased expression of CLEC5A mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]

NCBI chr 7:141,927,357...141,946,974
Ensembl chr 7:141,927,357...141,947,007

G

carnitine palmitoyltransferase 1A

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

cAMP responsive element binding protein 1

multiple interactions

[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein]

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

crystallin beta B3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CRYBB3 mRNA

NCBI chr22:25,199,858...25,207,359
Ensembl chr22:25,199,858...25,207,359

G

citrate synthase

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CS mRNA

NCBI chr12:56,271,699...56,300,330
Ensembl chr12:56,271,699...56,300,391

G

colony stimulating factor 1

increases expression
multiple interactions

Cholesterol results in increased expression of CSF1 mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]

NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992

G

cystatin C

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein

NCBI chr20:23,626,706...23,637,955
Ensembl chr20:23,626,706...23,638,473

G

cathepsin B

decreases activity

Cholesterol results in decreased activity of CTSB protein

NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533

G

C-X-C motif chemokine ligand 2

multiple interactions

[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 8

multiple interactions

[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

C-X-C motif chemokine ligand 9

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

cytochrome b-245 beta chain

multiple interactions
affects localization

[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein]
Cholesterol analog affects the localization of CYBB protein

PMID:26606054 PMID:28633109 PMID:30672636

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

cytochrome P450 family 11 subfamily A member 1

affects metabolic processing
increases metabolic processing

CYP11A1 protein affects the metabolism of Cholesterol
CYP11A1 protein results in increased metabolism of Cholesterol

PMID:16054388 PMID:19900470

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

cytochrome P450 family 17 subfamily A member 1

affects chemical synthesis

CYP17A1 protein affects the chemical synthesis of Cholesterol

NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472

G

cytochrome P450 family 1 subfamily A member 1

decreases activity

Cholesterol results in decreased activity of CYP1A1 protein

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 27 subfamily A member 1

decreases chemical synthesis
multiple interactions
increases secretion

CYP27A1 protein results in decreased chemical synthesis of Cholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; CYP27A1 protein results in increased hydroxylation of and results in decreased abundance of Cholesterol
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of CYP27A1 mRNA
CYP27A1 protein results in increased secretion of Cholesterol

PMID:8078928 PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 More...

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 2 subfamily A member 7

decreases activity

Cholesterol results in decreased activity of CYP2A4 protein

NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752

G

cytochrome P450 family 2 subfamily B member 6

decreases activity

Cholesterol results in decreased activity of CYP2B10 protein

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 9

decreases activity

Cholesterol results in decreased activity of CYP2C9 protein

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

decreases activity

Cholesterol results in decreased activity of CYP2E1 protein

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions

[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol; Cholesterol promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol

PMID:11514559 PMID:19299527 PMID:34461081

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 46 subfamily A member 1

multiple interactions
increases hydroxylation

CYP46A1 gene SNP affects the metabolism of and affects the abundance of Cholesterol
CYP46A1 protein results in increased hydroxylation of Cholesterol

PMID:14640697 PMID:19286353

NCBI chr14:99,684,298...99,727,301
Ensembl chr14:99,684,298...99,727,301

G

cytochrome P450 family 7 subfamily A member 1

affects metabolic processing
multiple interactions
increases metabolic processing
increases expression

CYP7A1 protein affects the metabolism of Cholesterol
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]; CYP7A1 mRNA inhibits the reaction [Tretinoin results in increased abundance of Cholesterol]
CYP7A1 protein results in increased metabolism of Cholesterol
Cholesterol results in increased expression of CYP7A1 mRNA
turmeric extract promotes the reaction [Cholesterol results in increased expression of CYP7A1 mRNA]

PMID:1175606 PMID:7925343 PMID:11013305 PMID:15696852 PMID:21535835 More...

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases activity
increases expression

Cholesterol results in increased activity of CYP7B1 protein
Cholesterol results in increased expression of CYP7B1 mRNA

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

cholesterol decreases expression of Cyp8b1 mRNA in liver

RGD

NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898

G

death associated protein kinase 1

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]

NCBI chr 9:87,497,228...87,708,634
Ensembl chr 9:87,497,228...87,708,634

G

dendrocyte expressed seven transmembrane protein

multiple interactions
increases expression

CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA]

NCBI chr 8:104,339,796...104,356,689
Ensembl chr 8:104,339,087...104,356,689

G

DNA damage inducible transcript 3

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein]

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

diacylglycerol O-acyltransferase 1

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of DGAT1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of DGAT1 mRNA

NCBI chr 8:144,314,584...144,326,852
Ensembl chr 8:144,314,584...144,326,910

G

diacylglycerol O-acyltransferase 2

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]

NCBI chr11:75,768,778...75,801,534
Ensembl chr11:75,759,512...75,801,535

G

24-dehydrocholesterol reductase

affects abundance
multiple interactions

DHCR24 protein affects the abundance of Cholesterol
[DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol

PMID:19260826 PMID:23042211

NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195

G

7-dehydrocholesterol reductase

decreases abundance
multiple interactions
increases chemical synthesis
affects response to substance

DHCR7 mutant form results in decreased abundance of Cholesterol
Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol]
DHCR7 mutant form affects the susceptibility to Cholesterol

PMID:15896653 PMID:16446309 PMID:19365639

NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868

G

iodothyronine deiodinase 1

affects expression
decreases expression
decreases activity

Cholesterol affects the expression of DIO1 mRNA
Cholesterol results in decreased expression of DIO1 mRNA
Cholesterol results in decreased activity of DIO1 protein

PMID:16271152 PMID:16874406

NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086

G

iodothyronine deiodinase 2

increases degradation

Cholesterol results in increased degradation of DIO2 protein

NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757

G

epidermal growth factor

multiple interactions

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the abundance of Reactive Oxygen Species; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the abundance of Reactive Oxygen Species]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased susceptibility to Silver Compounds; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]; EGF protein affects the susceptibility to [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds]; EGF protein inhibits the reaction [[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species]

NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766

G

epidermal growth factor receptor

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

eukaryotic translation initiation factor 2 subunit alpha

decreases abundance

EIF2S1 protein modified form results in decreased abundance of Cholesterol

NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516

G

eukaryotic translation initiation factor 4A1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EIF4A1 mRNA

NCBI chr17:7,572,825...7,579,006
Ensembl chr17:7,572,824...7,579,006

G

eukaryotic translation initiation factor 4E binding protein 1

increases phosphorylation
multiple interactions

Cholesterol results in increased phosphorylation of EIF4EBP1 protein
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]

NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365

G

erythrocyte membrane protein band 4.1

multiple interactions

[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein; [Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]

NCBI chr 1:28,887,100...29,120,041
Ensembl chr 1:28,887,091...29,120,046

G

endothelial cell specific molecule 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ESM1 mRNA

NCBI chr 5:54,977,867...54,985,593
Ensembl chr 5:54,977,867...55,022,671

G

fatty acid binding protein 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

Fas associated via death domain

multiple interactions
increases expression

Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of FADD protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of FADD protein]

NCBI chr11:70,203,296...70,207,390
Ensembl chr11:70,203,296...70,207,390

G

Fas cell surface death receptor

multiple interactions
increases expression

Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAS mRNA
Cholesterol analog results in increased expression of FAS mRNA
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]

PMID:16162944 PMID:19477266 PMID:22129739

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

Fas ligand

increases expression

Cholesterol analog results in increased expression of FASLG protein

NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876

G

farnesyl-diphosphate farnesyltransferase 1

increases chemical synthesis

FDFT1 protein results in increased chemical synthesis of Cholesterol

NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395

G

fibroblast growth factor 19

multiple interactions

[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

fibroblast growth factor 7

multiple interactions

Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]; Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA]
[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of FGF7 protein

PMID:16034455 PMID:16162944

NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775

G

fibroblast growth factor receptor 4

affects metabolic processing
decreases metabolic processing

FGFR4 protein affects the metabolism of Cholesterol
FGFR4 protein results in decreased metabolism of Cholesterol

PMID:11956156 PMID:15750181

NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144

G

fms related receptor tyrosine kinase 1

increases expression

Cholesterol results in increased expression of FLT1 mRNA

NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145

G

growth arrest and DNA damage inducible gamma

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GADD45G mRNA

NCBI chr 9:89,605,012...89,606,555
Ensembl chr 9:89,605,012...89,606,555

G

guanylate binding protein 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP2 mRNA

NCBI chr 1:89,106,132...89,126,114
Ensembl chr 1:89,106,132...89,150,456

G

guanylate binding protein 4

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP4 mRNA

NCBI chr 1:89,181,144...89,198,942
Ensembl chr 1:89,181,144...89,198,942

G

guanylate binding protein family member 6

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP9 mRNA

NCBI chr 1:89,364,059...89,388,160
Ensembl chr 1:89,364,059...89,388,160

G

glutamate-cysteine ligase catalytic subunit

increases expression

Cholesterol results in increased expression of GCLC protein

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

gap junction protein beta 1

decreases abundance

GJB1 protein results in decreased abundance of Cholesterol

NCBI chr X:71,215,239...71,225,516
Ensembl chr X:71,212,811...71,225,516

G

G protein subunit alpha i3

multiple interactions

Cholesterol inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]

NCBI chr 1:109,548,615...109,600,195
Ensembl chr 1:109,548,615...109,600,195

G

GNAS complex locus

multiple interactions

Cholesterol inhibits the reaction [Progesterone results in increased expression of GNAS protein]

NCBI chr20:58,839,748...58,911,192
Ensembl chr20:58,839,718...58,911,192

G

glycoprotein Ib platelet subunit alpha

increases expression

Cholesterol results in increased expression of GP1BA mRNA

NCBI chr17:4,932,277...4,935,023
Ensembl chr17:4,932,277...4,935,023

G

glycerol-3-phosphate acyltransferase, mitochondrial

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of GPAM mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of GPAM mRNA

NCBI chr10:112,149,865...112,227,677
Ensembl chr10:112,149,865...112,215,377

G

glutathione peroxidase 2

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]

PMID:28275691 PMID:31877369

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

general transcription factor IIIC subunit 6

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GTF3C6 mRNA

NCBI chr 6:110,958,706...110,967,872
Ensembl chr 6:110,958,706...110,967,890

G

granzyme A

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMA mRNA

NCBI chr 5:55,102,646...55,110,252
Ensembl chr 5:55,102,646...55,110,252

G

granzyme B

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMB mRNA

NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267

G

H2A.X variant histone

multiple interactions
increases phosphorylation

bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]]

NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465

G

2-hydroxyacyl-CoA lyase 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of HACL1 mRNA

NCBI chr 3:15,560,699...15,601,569
Ensembl chr 3:15,560,699...15,601,852

G

hepatitis A virus cellular receptor 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

heparin binding EGF like growth factor

increases expression

Cholesterol results in increased expression of HBEGF mRNA

NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603

G

hydroxycarboxylic acid receptor 2

multiple interactions

[HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol

NCBI chr12:122,701,293...122,703,357
Ensembl chr12:122,701,293...122,703,357

G

hydroxycarboxylic acid receptor 3

multiple interactions

[[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]

PMID:20655299 PMID:21317532

NCBI chr12:122,714,756...122,716,811
Ensembl chr12:122,714,756...122,716,811

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
decreases expression
multiple interactions

Cholesterol results in decreased activity of HMGCR protein
cholesterol decreases expression of Hmgcr mRNA in liver
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; [turmeric extract co-treated with Cholesterol] results in decreased expression of HMGCR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Selenium promotes the reaction [Cholesterol results in decreased expression of HMGCR mRNA]
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol; [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [artemisic acid results in decreased expression of HMGCR protein] which results in decreased chemical synthesis of Cholesterol; [Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]

CTD
RGD

PMID:11408283 PMID:12477733 PMID:16027736 PMID:16581047 PMID:17516993 More...

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

heme oxygenase 1

multiple interactions
increases expression
decreases expression

[Cholesterol co-treated with Particulate Matter] results in increased expression of HMOX1 mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of HMOX1 mRNA]

PMID:21535835 PMID:26606054 PMID:30672636

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

hepatocyte nuclear factor 4 alpha

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]

NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845

G

intercellular adhesion molecule 1

multiple interactions

[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein]

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interferon induced protein 44

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFI44 mRNA

NCBI chr 1:78,649,789...78,664,078
Ensembl chr 1:78,649,796...78,664,078

G

interferon induced protein with tetratricopeptide repeats 3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFIT3 mRNA

NCBI chr10:89,327,997...89,340,968
Ensembl chr10:89,327,307...89,377,473

G

interferon gamma

multiple interactions

[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

insulin like growth factor 1

multiple interactions

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGF1 protein

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor 2 receptor

multiple interactions

[IGF2R protein alternative form results in increased susceptibility to Streptozocin] which results in increased abundance of Cholesterol

NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507

G

insulin like growth factor binding protein 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IGFBP1 mRNA

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

insulin like growth factor binding protein 3

multiple interactions

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGFBP3 protein

NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874

G

interleukin 10

multiple interactions

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased secretion of IL10 protein

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 18 binding protein

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IL18BP mRNA

NCBI chr11:71,998,909...72,008,200
Ensembl chr11:71,998,613...72,007,315

G

interleukin 1 beta

multiple interactions
increases expression

[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Cholesterol results in increased expression of IL1B protein
Cholesterol analog results in increased expression of IL1B protein
[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL1B protein; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein]; bisphenol A promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; Quercetin inhibits the reaction [Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; [Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA]
Cholesterol results in increased expression of IL1B mRNA

PMID:22869926 PMID:25833014 PMID:26296894 PMID:26606054 PMID:28633109 More...

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 1 receptor antagonist

increases expression

Cholesterol results in increased expression of IL1RN mRNA

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 6

multiple interactions
increases expression

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL6 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 protein]
[Cholesterol co-treated with Particulate Matter] results in increased expression of IL6 mRNA; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]
Cholesterol results in increased expression of IL6 mRNA; Cholesterol results in increased expression of IL6 protein

PMID:19028402 PMID:30672636 PMID:33239236

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

inhibin subunit beta A

increases expression

Cholesterol results in increased expression of INHBA mRNA

NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834

G

insulin

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

INS-IGF2 readthrough

multiple interactions

[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

interferon regulatory factor 7

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IRF7 mRNA

NCBI chr11:612,555...615,950
Ensembl chr11:612,553...615,983

G

insulin receptor substrate 1

affects abundance

IRS1 gene polymorphism affects the abundance of Cholesterol

NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820

G

ISG15 ubiquitin like modifier

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ISG15 mRNA

NCBI chr 1:1,013,497...1,014,540
Ensembl chr 1:1,001,138...1,014,540

G

integrin subunit alpha M

increases expression

Cholesterol increases expression of ITGAM protein on monocytes and granulocytes

RGD

NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892

G

potassium voltage-gated channel subfamily H member 2

decreases localization

Cholesterol results in decreased localization of KCNH2 protein

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

G

KIT ligand

increases expression

Cholesterol results in increased expression of KITLG mRNA

NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851

G

keratin 19

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in increased expression of KRT19 mRNA]

NCBI chr17:41,523,617...41,528,308
Ensembl chr17:41,523,617...41,528,308

G

lysosomal associated membrane protein 1

increases expression

Cholesterol results in increased expression of LAMP1 protein

NCBI chr13:113,297,239...113,323,672
Ensembl chr13:113,297,239...113,323,672

G

lecithin-cholesterol acyltransferase

increases acylation
multiple interactions

LCAT protein results in increased acylation of Cholesterol
[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]

PMID:4847537 PMID:30273964

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

lipocalin 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LCN2 mRNA

NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453

G

low density lipoprotein receptor

increases uptake
affects abundance
increases response to substance
multiple interactions
decreases expression
decreases activity

LDLR protein results in increased uptake of Cholesterol
LDLR protein affects the abundance of Cholesterol
LDLR gene mutant form results in increased susceptibility to Cholesterol
(+)-JQ1 compound inhibits the reaction [LDLR gene mutant form results in increased susceptibility to Cholesterol]; [LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol; [Tobacco Smoke Pollution promotes the reaction [LDLR protein affects the susceptibility to Dietary Fats]] which results in increased abundance of Cholesterol; argatroban inhibits the reaction [[LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]; Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]
Cholesterol results in decreased expression of LDLR mRNA
[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; [turmeric extract co-treated with Cholesterol] results in increased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Selenium inhibits the reaction [Cholesterol results in decreased activity of LDLR protein]; Selenium inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]
[CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]

PMID:12477733 PMID:16271152 PMID:16317514 PMID:16477808 PMID:16937255 More...

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

leptin receptor

multiple interactions
increases abundance

Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Cholesterol]

NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559

G

lipoprotein lipase

increases expression
multiple interactions

Cholesterol results in increased expression of LPL mRNA
[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]

PMID:26296894 PMID:30273964

NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259

G

LDL receptor related protein 1

multiple interactions

[Capsaicin results in decreased expression of LRP1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in decreased expression of LRP1 protein] which results in increased secretion of Cholesterol

NCBI chr12:57,128,483...57,213,361
Ensembl chr12:57,128,483...57,213,361

G

lymphocyte antigen 6 family member E

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6E mRNA

NCBI chr 8:143,018,529...143,022,409
Ensembl chr 8:143,017,982...143,023,832

G

lymphocyte antigen 6 family member S

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6A mRNA

NCBI chr 8:143,040,839...143,076,471
Ensembl chr 8:143,041,844...143,045,678

G

microtubule associated protein 1 light chain 3 beta

increases expression
multiple interactions

Cholesterol results in increased expression of MAP1LC3B protein modified form
Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of MAP1LC3B protein]

PMID:28275691 PMID:29486218

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mitogen-activated protein kinase 14

multiple interactions

[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA]

NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236

G

microtubule associated protein tau

multiple interactions

[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form]

NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334

G

membrane associated ring-CH-type finger 6

multiple interactions
increases stability

Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [Glycerol results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [MARCHF6 protein results in increased ubiquitination of and results in increased degradation of MARCHF6 protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]
Cholesterol results in increased stability of MARCHF6 protein

NCBI chr 5:10,353,695...10,440,388
Ensembl chr 5:10,353,695...10,440,388

G

macrophage receptor with collagenous structure

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MARCO mRNA

NCBI chr 2:118,942,194...118,994,660
Ensembl chr 2:118,942,194...118,994,660

G

MIA SH3 domain ER export factor 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MIA2 mRNA

NCBI chr14:39,233,915...39,388,522
Ensembl chr14:39,230,231...39,388,513

G

microRNA 125a

decreases export

MIR125A mRNA results in decreased export of Cholesterol

NCBI chr19:51,693,254...51,693,339
Ensembl chr19:51,693,254...51,693,339

G

marker of proliferation Ki-67

multiple interactions

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

MLX interacting protein like

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA]

NCBI chr 7:73,593,202...73,647,907
Ensembl chr 7:73,593,194...73,624,543

G

macrophage expressed 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MPEG1 mRNA

NCBI chr11:59,208,510...59,212,927
Ensembl chr11:59,208,510...59,212,927

G

macrophage scavenger receptor 1

multiple interactions

[resveratrol results in decreased expression of MSR1 protein] which results in decreased uptake of Cholesterol

NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490

G

metallothionein 1X

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT1 mRNA

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

metallothionein 2A

multiple interactions
increases expression

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT2 mRNA
Cholesterol results in increased expression of MT2 protein

PMID:22129739 PMID:29486218

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

mechanistic target of rapamycin kinase

increases phosphorylation

Cholesterol results in increased phosphorylation of MTOR protein

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

mevalonate kinase

decreases chemical synthesis

MVK protein mutant form results in decreased chemical synthesis of Cholesterol

NCBI chr12:109,573,272...109,598,125
Ensembl chr12:109,573,255...109,598,125

G

NGFI-A binding protein 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of NAB2 mRNA

NCBI chr12:57,089,114...57,095,476
Ensembl chr12:57,089,043...57,095,476

G

N-acetyl-alpha-glucosaminidase

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein

NCBI chr17:42,536,241...42,544,449
Ensembl chr17:42,536,241...42,544,449

G

nibrin

multiple interactions

[Cholesterol co-treated with Resveratrol] inhibits the reaction [bisphenol A results in decreased expression of NBN protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]

NCBI chr 8:89,933,331...89,984,667
Ensembl chr 8:89,924,515...90,003,228

G

neutrophil cytosolic factor 1

multiple interactions
increases expression

Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 protein]
Cholesterol results in increased expression of NCF1 mRNA; Cholesterol results in increased expression of NCF1 protein

NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315

G

nuclear receptor coactivator 2

affects metabolic processing

NCOA2 protein affects the metabolism of Cholesterol

NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808

G

nectin cell adhesion molecule 2

affects expression

Cholesterol affects the expression of NECTIN2

NCBI chr19:44,846,297...44,889,223
Ensembl chr19:44,846,175...44,889,223

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

Cholesterol results in increased expression of NFE2L2 mRNA
alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

Cholesterol results in increased expression of NFKB1 protein
Cholesterol inhibits the reaction [irbesartan results in increased expression of NFKB1 protein]

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor beta

multiple interactions
increases phosphorylation

Cholesterol inhibits the reaction [irbesartan results in increased phosphorylation of NFKBIB protein]
Cholesterol results in increased phosphorylation of NFKBIB protein

NCBI chr19:38,899,666...38,908,889
Ensembl chr19:38,899,700...38,908,893

G

NLR family pyrin domain containing 3

multiple interactions
affects localization

[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein]
[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]

PMID:25833014 PMID:28633109 PMID:33239236

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108

G

NPC intracellular cholesterol transporter 1

increases secretion
affects localization
affects abundance
multiple interactions

NPC1 protein results in increased secretion of Cholesterol
NPC1 affects the localization of Cholesterol
NPC1 protein affects the abundance of Cholesterol
Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Cholesterol]

PMID:12183525 PMID:16174794 PMID:18483620

NCBI chr18:23,506,184...23,586,506
Ensembl chr18:23,506,184...23,586,506

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of NPC1L1 mRNA

NCBI chr 7:44,512,535...44,541,330
Ensembl chr 7:44,512,535...44,541,330

G

NPHS1 adhesion molecule, nephrin

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA

NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Cholesterol results in increased expression of NQO1 mRNA
alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NQO1 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group H member 2

multiple interactions
increases activity

[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol; NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]
Cholesterol results in increased activity of NR1H2 protein

PMID:14993927 PMID:16415093 PMID:21543282

NCBI chr19:50,376,457...50,383,388
Ensembl chr19:50,329,653...50,383,388

G

nuclear receptor subfamily 1 group H member 3

multiple interactions
increases expression
decreases expression

[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Cholesterol co-treated with Ozone] results in increased lipidation of NR1H3 protein
Cholesterol increases expression of NR1H3 mRNA in epithelial cells
cholesterol decreases expression of LXR mRNA in liver
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]

CTD
RGD

PMID:12595494 PMID:16415093 PMID:27703007 PMID:37061692 PMID:25263431

RGD:401842388, RGD:15045610

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

nuclear receptor subfamily 1 group H member 4

multiple interactions
decreases expression
increases export

[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]
cholesterol decreases expression of Nr1h4 mRNA in liver
NR1H4 protein results in increased export of Cholesterol

CTD
RGD

PMID:30996006 PMID:25263431

NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414

G

nuclear receptor subfamily 1 group I member 2

affects metabolic processing

NR1I2 protein affects the metabolism of Cholesterol

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

G

nuclear receptor subfamily 1 group I member 3

affects metabolic processing
multiple interactions
affects binding

NR1I3 protein affects the metabolism of Cholesterol
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased abundance of Cholesterol
Cholesterol metabolite binds to NR1I3 protein

PMID:15684063 PMID:16051528 PMID:22101211

NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244

G

nuclear receptor subfamily 5 group A member 2

affects abundance

NR5A2 gene mutant form affects the abundance of Cholesterol

NCBI chr 1:200,027,710...200,177,415
Ensembl chr 1:200,027,614...200,177,420

G

2'-5'-oligoadenylate synthetase 3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OAS3 mRNA

NCBI chr12:112,938,474...112,973,251
Ensembl chr12:112,938,051...112,976,460

G

2'-5' oligoadenylate synthetase like 2, pseudogene

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OASL2 mRNA

NCBI chr12:121,053,732...121,059,670
Ensembl chr12:121,053,732...121,059,670

G

osteoclast stimulatory transmembrane protein

increases expression

Cholesterol results in increased expression of OCSTAMP mRNA

NCBI chr20:46,540,946...46,550,654
Ensembl chr20:46,540,946...46,550,654

G

oxidized low density lipoprotein receptor 1

multiple interactions

[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein]

NCBI chr12:10,158,301...10,176,266
Ensembl chr12:10,158,301...10,172,138

G

olfactory receptor family 52 subfamily R member 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OR52R1 mRNA

NCBI chr11:4,803,433...4,804,380
Ensembl chr11:4,803,433...4,804,380

G

otoferlin

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OTOF mRNA

NCBI chr 2:26,457,203...26,558,756
Ensembl chr 2:26,457,203...26,558,756

G

purinergic receptor P2X 1

decreases activity
multiple interactions

Cholesterol deficiency results in decreased activity of P2RX1 protein
jasplakinolide inhibits the reaction [Cholesterol deficiency results in decreased activity of P2RX1 protein]

NCBI chr17:3,896,592...3,916,465
Ensembl chr17:3,896,592...3,916,476

G

poly(ADP-ribose) polymerase 1

multiple interactions
increases cleavage

bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]]

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

poly(rC) binding protein 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PCBP1 mRNA

NCBI chr 2:70,087,477...70,089,203
Ensembl chr 2:70,087,477...70,089,203

G

pyruvate kinase L/R

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of PKLR mRNA

NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438

G

phospholipase D2

multiple interactions

PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr17:4,807,152...4,823,430
Ensembl chr17:4,807,152...4,823,434

G

paraoxonase 1

decreases chemical synthesis
multiple interactions
increases export
decreases activity

PON1 protein results in decreased chemical synthesis of Cholesterol
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]
PON1 protein results in increased export of Cholesterol
Cholesterol results in decreased activity of PON1 protein

PMID:12615663 PMID:16115471 PMID:16229851 PMID:16331452 PMID:30273964

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]
Cholesterol results in decreased expression of PPARA mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]

PMID:11779144 PMID:12595494 PMID:21088444 PMID:24440342 PMID:25689681

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor gamma

multiple interactions

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [resveratrol results in decreased abundance of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [[troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol; Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol]
[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA; [lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA]; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]

PMID:12044893 PMID:12595494 PMID:16946405 PMID:18302760 PMID:19797938 More...

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

protein phosphatase 1 regulatory subunit 3G

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PPP1R3G mRNA

NCBI chr 6:5,085,341...5,089,487
Ensembl chr 6:5,085,341...5,089,487

G

phosphoserine aminotransferase 1

increases expression

Cholesterol results in increased expression of PSAT1 mRNA

NCBI chr 9:78,297,125...78,330,093
Ensembl chr 9:78,297,125...78,330,093

G

proline and serine rich coiled-coil 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PSRC1 mRNA

NCBI chr 1:109,279,556...109,283,145
Ensembl chr 1:109,279,556...109,283,186

G

PYD and CARD domain containing

increases expression
affects localization
multiple interactions

Cholesterol analog results in increased expression of PYCARD mRNA
Cholesterol analog affects the localization of PYCARD protein
[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PYCARD mRNA; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]

PMID:19477266 PMID:22129739 PMID:25833014 PMID:28633109

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

Rac family small GTPase 1

multiple interactions
increases expression

Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]
Cholesterol results in increased expression of RAC1 mRNA; Cholesterol results in increased expression of RAC1 protein
Cholesterol inhibits the reaction [irbesartan results in increased expression of RAC1 mRNA]

PMID:19028402 PMID:21334995

NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression

Cholesterol inhibits the reaction [irbesartan results in increased expression of RELA protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein]
[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]
Cholesterol results in increased expression of RELA protein

PMID:19028402 PMID:23274767 PMID:25833014

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

regulator of cell cycle

increases expression

Cholesterol results in increased expression of RGCC mRNA

NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871

G

regulator of G protein signaling 2

increases degradation

Cholesterol results in increased degradation of RGS2 protein

NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275

G

receptor interacting serine/threonine kinase 2

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]

NCBI chr 8:89,757,816...89,791,064
Ensembl chr 8:89,757,806...89,791,064

G

ribosomal protein S21

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of RPS21 mRNA

NCBI chr20:62,387,103...62,388,520
Ensembl chr20:62,387,103...62,388,520

G

ribosomal protein S6

multiple interactions
increases phosphorylation

CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]
Cholesterol inhibits the reaction [Nicotine results in increased phosphorylation of RPS6 protein]

PMID:28275691 PMID:31629012

NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236

G

ribosomal protein S6 kinase B1

multiple interactions
increases phosphorylation

Trehalose inhibits the reaction [Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of RPS6KB1 protein]]; Trehalose inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6KB1 protein]

NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574

G

regulatory associated protein of MTOR complex 1

increases expression

Cholesterol results in increased expression of RPTOR protein

NCBI chr17:80,544,838...80,966,368
Ensembl chr17:80,544,819...80,966,371

G

retinoid X receptor alpha

multiple interactions

Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]

NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585

G

retinoid X receptor beta

multiple interactions

[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol

NCBI chr 6:33,193,588...33,200,853
Ensembl chr 6:33,193,588...33,200,665

G

S100 calcium binding protein A8

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

serum amyloid A1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SAA1 mRNA

NCBI chr11:18,266,264...18,269,967
Ensembl chr11:18,266,260...18,269,977

G

serum amyloid A2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SAA2 mRNA

NCBI chr11:18,238,236...18,248,668
Ensembl chr11:18,239,223...18,248,668

G

serum amyloid A3, pseudogene

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SAA3 mRNA

NCBI chr11:18,112,472...18,116,132
Ensembl chr11:18,112,472...18,116,132
Ensembl chr11:18,112,472...18,116,132

G

scavenger receptor class B member 1

multiple interactions
affects transport

[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA]
SCARB1 protein affects the transport of Cholesterol

PMID:18302760 PMID:26651060

NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668

G

stearoyl-CoA desaturase

multiple interactions

Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA]

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

shisa family member 5

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SHISA5 mRNA

NCBI chr 3:48,467,876...48,504,810
Ensembl chr 3:48,467,798...48,504,826

G

sirtuin 1

multiple interactions

[6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA]
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein; Resveratrol inhibits the reaction [[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein]

PMID:21212096 PMID:25833014 PMID:33239236

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

solute carrier family 1 member 3

increases expression

Cholesterol results in increased expression of SLC1A3 mRNA

NCBI chr 5:36,606,606...36,688,334
Ensembl chr 5:36,596,588...36,688,334

G

solute carrier family 28 member 3

increases expression

Cholesterol results in increased expression of SLC28A3 mRNA

NCBI chr 9:84,275,457...84,368,727
Ensembl chr 9:84,275,457...84,340,758

G

solute carrier family 2 member 2

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]

NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743

G

solute carrier family 4 member 1 (Diego blood group)

multiple interactions

[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein]

NCBI chr17:44,248,390...44,268,135
Ensembl chr17:44,248,390...44,268,141

G

solute carrier family 7 member 5

increases expression

Cholesterol results in increased expression of SLC7A5 mRNA

NCBI chr16:87,830,023...87,869,507
Ensembl chr16:87,830,023...87,869,507

G

SMAD family member 3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMAD3 mRNA

NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173

G

sphingomyelin phosphodiesterase 1

multiple interactions

SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein]

NCBI chr11:6,390,474...6,394,996
Ensembl chr11:6,390,440...6,394,998

G

sphingomyelin phosphodiesterase 3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMPD3 mRNA

NCBI chr16:68,358,327...68,448,508
Ensembl chr16:68,358,327...68,448,508

G

superoxide dismutase 2

multiple interactions

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

sortilin 1

decreases abundance
multiple interactions

SORT1 protein results in decreased abundance of Cholesterol
Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]

PMID:25805502 PMID:30950489

NCBI chr 1:109,309,575...109,397,918
Ensembl chr 1:109,309,568...109,397,918

G

squalene epoxidase

increases degradation
multiple interactions

Cholesterol results in increased degradation of SQLE protein
Cholesterol inhibits the reaction [Hydroxymethylglutaryl-CoA Reductase Inhibitors results in decreased degradation of SQLE protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]

NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283

G

sequestosome 1

increases expression
multiple interactions

Cholesterol results in increased expression of SQSTM1 protein
Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of SQSTM1 protein]

PMID:28275691 PMID:29486218

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

sterol regulatory element binding transcription factor 1

multiple interactions

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SREBF1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of SREBF1 mRNA
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein

PMID:24440342 PMID:27324795

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

sterol regulatory element binding transcription factor 2

multiple interactions
increases abundance

[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; [[Troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; betadex inhibits the reaction [SREBF2 protein results in increased abundance of Cholesterol]; SREBF2 promotes the reaction [bisphenol A results in increased import of Cholesterol]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased abundance of Cholesterol]
[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein]

PMID:16946405 PMID:20578043 PMID:27324795 PMID:28057006 PMID:33677747

NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306

G

steroidogenic acute regulatory protein

affects transport
increases transport
increases export
multiple interactions

STAR protein affects the transport of Cholesterol
STAR protein results in increased transport of Cholesterol
STAR protein results in increased export of Cholesterol
[[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR protein]
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]

PMID:14630719 PMID:15819722 PMID:17934701 PMID:19900470 PMID:20083572 More...

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

signal transducer and activator of transcription 1

increases expression

Cholesterol results in increased expression of STAT1 protein

NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960

G

signal transducer and activator of transcription 5A

multiple interactions

Cholesterol inhibits the reaction [Nicotine results in decreased phosphorylation of STAT5 protein]

NCBI chr17:42,287,439...42,311,943
Ensembl chr17:42,287,547...42,311,943

G

synaptic vesicle glycoprotein 2A

multiple interactions

[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] promotes the reaction [SV2A protein binds to Botulinum Toxins, Type A]

NCBI chr 1:149,903,318...149,917,844
Ensembl chr 1:149,903,318...149,917,844

G

synaptopodin

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SYNPO mRNA

NCBI chr 5:150,586,010...150,659,207
Ensembl chr 5:150,601,080...150,659,207

G

TAFA chemokine like family member 2

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TAFA2 mRNA

NCBI chr12:61,708,273...62,260,034
Ensembl chr12:61,708,273...62,279,150

G

transcription factor AP-2 epsilon

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFAP2E mRNA

NCBI chr 1:35,573,314...35,595,591
Ensembl chr 1:35,573,314...35,595,328

G

trefoil factor 3

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFF3 mRNA

NCBI chr21:42,311,667...42,315,409
Ensembl chr21:42,311,667...42,315,409

G

transforming growth factor beta 1

increases expression
multiple interactions

Cholesterol results in increased expression of TGFB1 mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA

PMID:19110552 PMID:26606054

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

TIMP metallopeptidase inhibitor 3

multiple interactions
increases expression

CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]

NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041

G

toll like receptor 4

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

transmembrane 4 L six family member 19

increases expression

Cholesterol results in increased expression of TM4SF19 mRNA

NCBI chr 3:196,323,547...196,338,388
Ensembl chr 3:196,319,342...196,338,503

G

transmembrane protein 97

affects metabolic processing

TMEM97 protein affects the metabolism of Cholesterol

NCBI chr17:28,319,200...28,328,685
Ensembl chr17:28,319,200...28,328,685

G

tumor necrosis factor

multiple interactions
increases expression

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of TNF protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF protein]
[Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]
Cholesterol analog results in increased expression of TNF mRNA
[Cholesterol co-treated with Particulate Matter] results in increased expression of TNF mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]
Cholesterol results in increased expression of TNF mRNA; Cholesterol results in increased expression of TNF protein

PMID:19028402 PMID:19477266 PMID:23274767 PMID:26296894 PMID:26606054 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF receptor superfamily member 1A

increases expression

Cholesterol analog results in increased expression of TNFRSF1A protein

NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114

G

TNF superfamily member 10

increases expression

Cholesterol analog results in increased expression of TNFSF10 mRNA; Cholesterol analog results in increased expression of TNFSF10 protein

NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475

G

tumor protein p53

multiple interactions

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

TNF receptor associated factor 1

increases expression

Cholesterol analog results in increased expression of TRAF1 mRNA

NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173

G

tribbles pseudokinase 3

multiple interactions

TRIB3 protein results in increased abundance of and results in increased secretion of Cholesterol

NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559

G

ubiquitin D

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of UBD mRNA

NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732

G

ubiquitin conjugating enzyme E2 I

multiple interactions

UBE2I protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Cholesterol]

NCBI chr16:1,309,152...1,327,017
Ensembl chr16:1,291,444...1,327,018

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

Cholesterol results in increased expression of VCAM1 mRNA; Cholesterol results in increased expression of VCAM1 protein
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA
Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 protein]

PMID:19028402 PMID:26606054

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vitamin D receptor

affects binding
affects abundance

Cholesterol metabolite binds to VDR protein
VDR gene SNP affects the abundance of Cholesterol

PMID:16051528 PMID:25498546

NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048

G

vascular endothelial growth factor A

multiple interactions

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vimentin

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of VIM mRNA]

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

von Willebrand factor

multiple interactions

[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein]

NCBI chr12:5,948,877...6,124,670
Ensembl chr12:5,948,877...6,124,770

G

Z-DNA binding protein 1

multiple interactions

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ZBP1 mRNA

NCBI chr20:57,603,852...57,620,426
Ensembl chr20:57,603,846...57,620,576

G

zinc finger E-box binding homeobox 1

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB1 mRNA]

NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814

G

zinc finger E-box binding homeobox 2

multiple interactions

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB2 mRNA]

NCBI chr 2:144,384,081...144,520,119
Ensembl chr 2:144,364,364...144,521,057

cholesterol sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 11 subfamily A member 1

decreases expression

cholesteryl sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

steroidogenic acute regulatory protein

decreases expression

cholesteryl sulfate results in decreased expression of STAR mRNA; cholesteryl sulfate results in decreased expression of STAR protein

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

sulfotransferase family 2B member 1

increases abundance

SULT2B1 protein results in increased abundance of cholesteryl sulfate

NCBI chr19:48,552,172...48,599,427
Ensembl chr19:48,552,172...48,599,425

cholesteryl arachidonate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions
decreases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate
LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl linoleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions
affects abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate
LIPG gene mutant form affects the abundance of cholesteryl linoleate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl linolenate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate
LIPG gene mutant form results in increased abundance of cholesteryl linolenate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl myristate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

affects abundance
multiple interactions

LIPG gene mutant form affects the abundance of cholesteryl myristate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl oleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate
LIPG gene mutant form results in increased abundance of cholesteryl oleate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl palmitate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate
LIPG gene mutant form results in increased abundance of cholesteryl palmitate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

cholesteryl stearate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

decreases abundance

LIPG gene mutant form results in decreased abundance of cholesterol stearate

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

corn oil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 8

affects expression

Corn Oil affects the expression of ABCG8 mRNA

NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988

G

acetyl-CoA carboxylase alpha

increases expression

Corn Oil results in increased expression of ACACA mRNA

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

ATP citrate lyase

affects expression

Corn Oil affects the expression of ACLY mRNA

NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542

G

acyl-CoA thioesterase 2

affects expression

Corn Oil affects the expression of ACOT2 mRNA

NCBI chr14:73,567,620...73,575,658
Ensembl chr14:73,567,620...73,575,658

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Corn Oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein]

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

aldehyde dehydrogenase 1 family member A1

affects expression

Corn Oil affects the expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

angiopoietin like 4

affects expression

Corn Oil affects the expression of ANGPTL4 mRNA

NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370

G

amphiregulin

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of AREG mRNA

NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005

G

BCL2 associated agonist of cell death

increases expression

Corn Oil results in increased expression of BAD mRNA

NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704

G

bradykinin receptor B1

multiple interactions

Corn Oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein]

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

basic helix-loop-helix family member e40

affects expression

Corn Oil affects the expression of BHLHE40 mRNA

NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323

G

betaine--homocysteine S-methyltransferase

affects expression

Corn Oil affects the expression of BHMT mRNA

NCBI chr 5:79,111,809...79,132,288
Ensembl chr 5:79,111,809...79,132,288

G

baculoviral IAP repeat containing 3

increases expression

Corn Oil results in increased expression of BIRC3 mRNA

NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403

G

bone morphogenetic protein 1

affects expression

Corn Oil affects the expression of BMP1 mRNA

NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326

G

bone morphogenetic protein 2

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of BMP2 mRNA

NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246

G

carbonic anhydrase 6

increases expression

Corn Oil results in increased expression of CAR6 mRNA

NCBI chr 1:8,945,868...8,975,092
Ensembl chr 1:8,945,867...8,975,092

G

cell adhesion molecule 1

affects expression

Corn Oil affects the expression of CADM1 mRNA

NCBI chr11:115,169,236...115,504,415
Ensembl chr11:115,169,218...115,504,957

G

calcitonin related polypeptide alpha

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of CALCA mRNA

NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354

G

caspase recruitment domain family member 9

increases expression

Corn Oil results in increased expression of CARD9 mRNA

NCBI chr 9:136,363,956...136,373,669
Ensembl chr 9:136,363,956...136,373,681

G

catalase

decreases expression
multiple interactions

Corn Oil results in decreased expression of CAT protein
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in decreased expression of CAT protein

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolin 3

decreases expression

Corn Oil results in decreased expression of CAV3 mRNA

NCBI chr 3:8,733,802...8,746,758
Ensembl chr 3:8,733,802...8,841,808

G

C-C motif chemokine ligand 3

decreases expression
increases expression

Corn Oil results in decreased expression of CCL3 mRNA
Corn Oil results in increased expression of CCL3 mRNA

PMID:22760963 PMID:23409006

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

cyclin D1

affects expression

Corn Oil affects the expression of CCND1 mRNA

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

CD36 molecule (CD36 blood group)

decreases expression

Corn Oil results in decreased expression of CD36 mRNA

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

cadherin related family member 1

increases expression

Corn Oil results in increased expression of CDHR1 mRNA

NCBI chr10:84,194,537...84,219,621
Ensembl chr10:84,194,537...84,219,621

G

cyclin dependent kinase inhibitor 1A

increases expression
affects expression

Corn Oil results in increased expression of CDKN1A mRNA
Corn Oil affects the expression of CDKN1A mRNA

PMID:16360708 PMID:22760963

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

centromere protein T

increases expression

Corn Oil results in increased expression of CENPT mRNA

NCBI chr16:67,828,157...67,847,693
Ensembl chr16:67,828,157...67,847,811

G

complement factor B

increases expression

Corn Oil results in increased expression of CFB mRNA

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

claudin 1

decreases expression

Corn Oil results in decreased expression of CLDN1 mRNA

NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446

G

claudin 9

increases expression

Corn Oil results in increased expression of CLDN9 mRNA

NCBI chr16:3,012,923...3,014,505
Ensembl chr16:3,012,923...3,014,505

G

cytochrome c oxidase subunit 7A1

decreases expression

Corn Oil results in decreased expression of COX7A1 mRNA

NCBI chr19:36,150,922...36,152,447
Ensembl chr19:36,150,922...36,152,449

G

cytochrome c oxidase subunit 8B, pseudogene

decreases expression

Corn Oil results in decreased expression of COX8B mRNA

NCBI chr11:253,417...256,972
Ensembl chr11:253,446...253,558

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions
affects expression

Corn Oil results in increased expression of CPT1A mRNA
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT1A mRNA
Corn Oil affects the expression of CPT1A mRNA

PMID:16360708 PMID:22760963 PMID:36432690

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

carnitine palmitoyltransferase 2

multiple interactions

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT2 mRNA

NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197

G

carnitine O-octanoyltransferase

affects expression
multiple interactions

Corn Oil affects the expression of CROT mRNA
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CROT mRNA

PMID:16360708 PMID:36432690

NCBI chr 7:87,345,664...87,399,794
Ensembl chr 7:87,345,664...87,399,794

G

cathepsin G

increases expression

Corn Oil results in increased expression of CTSG mRNA

NCBI chr14:24,573,518...24,576,250
Ensembl chr14:24,573,518...24,576,250

G

cytochrome P450 family 17 subfamily A member 1

affects expression

Corn Oil affects the expression of CYP17A1 mRNA

NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472

G

cytochrome P450 family 7 subfamily A member 1

affects expression

Corn Oil affects the expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 8 subfamily B member 1

affects expression

Corn Oil affects the expression of CYP8B1 mRNA

NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898

G

epoxide hydrolase 2

affects expression

Corn Oil affects the expression of EPHX2 mRNA

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

G

ETS proto-oncogene 1, transcription factor

decreases expression

Corn Oil results in decreased expression of ETS1 mRNA

NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558

G

fatty acid binding protein 1

multiple interactions

[Ethanol co-treated with Corn Oil] results in decreased expression of FABP1 mRNA

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

fatty acid binding protein 2

affects expression

Corn Oil affects the expression of FABP2 mRNA

NCBI chr 4:119,317,250...119,322,138
Ensembl chr 4:119,317,250...119,322,138

G

fatty acid binding protein 7

affects expression

Corn Oil affects the expression of FABP7 mRNA

NCBI chr 6:122,749,201...122,784,074
Ensembl chr 6:122,779,716...122,784,074

G

fatty acid synthase

affects expression

Corn Oil affects the expression of FASN mRNA

NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294

G

Fc gamma receptor and transporter

decreases expression

Corn Oil results in decreased expression of FCGRT mRNA

NCBI chr19:49,512,661...49,526,428
Ensembl chr19:49,506,816...49,526,428

G

fibrinogen beta chain

affects expression

Corn Oil affects the expression of FGB mRNA

NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807

G

fibroblast growth factor 21

affects expression

Corn Oil affects the expression of FGF21 mRNA

NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333

G

follistatin

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of FST mRNA

NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134

G

G0/G1 switch 2

affects expression

Corn Oil affects the expression of G0S2 mRNA

NCBI chr 1:209,675,412...209,676,390
Ensembl chr 1:209,675,412...209,676,390

G

growth arrest and DNA damage inducible alpha

affects expression

Corn Oil affects the expression of GADD45A mRNA

NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334

G

galanin and GMAP prepropeptide

increases expression

Corn Oil results in increased expression of GAL mRNA

NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175

G

glucokinase

affects expression

Corn Oil affects the expression of GCK mRNA

NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170

G

gap junction protein delta 2

increases expression

Corn Oil results in increased expression of GJD2 mRNA

NCBI chr15:34,751,032...34,754,998
Ensembl chr15:34,751,032...34,754,998

G

glutamic-oxaloacetic transaminase 1

affects expression

Corn Oil affects the expression of GOT1 mRNA

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

glutamic-oxaloacetic transaminase 2

decreases expression

Corn Oil results in decreased expression of GOT2 mRNA

NCBI chr16:58,707,131...58,734,316
Ensembl chr16:58,707,131...58,734,342

G

glycerol-3-phosphate dehydrogenase 2

affects expression

Corn Oil affects the expression of GPD2 mRNA

NCBI chr 2:156,400,281...156,586,403
Ensembl chr 2:156,435,290...156,613,735

G

glutamic--pyruvic transaminase

multiple interactions

[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein; Dactinomycin inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]; Orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

H2A clustered histone 25

affects expression

Corn Oil affects the expression of H2A mRNA

NCBI chr 1:228,457,364...228,457,873
Ensembl chr 1:228,434,777...228,457,873

G

histidine ammonia-lyase

affects expression

Corn Oil affects the expression of HAL mRNA

NCBI chr12:95,972,662...95,996,344
Ensembl chr12:95,972,662...95,996,365

G

hepcidin antimicrobial peptide

affects expression

Corn Oil affects the expression of HAMP mRNA

NCBI chr19:35,282,528...35,285,143
Ensembl chr19:35,280,716...35,285,143

G

major histocompatibility complex, class I, A

increases expression

Corn Oil results in increased expression of RT1-CE16 mRNA

NCBI chr 6:29,942,532...29,945,870
Ensembl chr 6:29,941,260...29,949,572

G

major histocompatibility complex, class II, DQ beta 1

increases expression

Corn Oil results in increased expression of RT1-BB mRNA

NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383

G

major histocompatibility complex, class I, F

increases expression

Corn Oil results in increased expression of RT1-CE5 mRNA

NCBI chr 6:29,723,434...29,738,532
Ensembl chr 6:29,722,775...29,738,528

G

3-hydroxy-3-methylglutaryl-CoA reductase

affects expression

Corn Oil affects the expression of HMGCR mRNA

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

homeobox A11

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of HOXA11 mRNA

NCBI chr 7:27,181,157...27,185,232
Ensembl chr 7:27,181,157...27,185,232

G

haptoglobin

increases expression

Corn Oil results in increased expression of HP mRNA

NCBI chr16:72,054,505...72,061,055
Ensembl chr16:72,054,505...72,061,055

G

heat shock protein 90 alpha family class A member 1

increases expression

Corn Oil results in increased expression of HSP90AA1 mRNA

NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699

G

isopentenyl-diphosphate delta isomerase 1

affects expression

Corn Oil affects the expression of IDI1 mRNA

NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119

G

insulin like growth factor 2 mRNA binding protein 2

affects expression
increases expression

Corn Oil affects the expression of IGF2BP2 mRNA
Corn Oil results in increased expression of IGF2BP2 mRNA

NCBI chr 3:185,643,130...185,825,042
Ensembl chr 3:185,643,130...185,825,042

G

insulin like growth factor binding protein 1

affects expression

Corn Oil affects the expression of IGFBP1 mRNA

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

Indian hedgehog signaling molecule

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of IHH mRNA

NCBI chr 2:219,054,424...219,060,921
Ensembl chr 2:219,054,424...219,060,921

G

interleukin 12B

increases secretion

Corn Oil results in increased secretion of IL12B protein

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

interleukin 18

increases expression

Corn Oil results in increased expression of IL18 mRNA

NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096

G

interleukin 1 alpha

increases secretion

Corn Oil results in increased secretion of IL1A protein

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 1 beta

increases secretion

Corn Oil results in increased secretion of IL1B protein

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 1 receptor antagonist

increases expression

Corn Oil results in increased expression of IL1RN mRNA

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 4

increases expression
increases secretion
decreases expression

Corn Oil results in increased expression of IL4 mRNA
Corn Oil results in increased secretion of IL4 protein
Corn Oil results in decreased expression of IL4 mRNA

PMID:23409006 PMID:33263755

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 6 receptor

increases expression

Corn Oil results in increased expression of IL6R mRNA

NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450

G

interleukin 9

increases secretion

Corn Oil results in increased secretion of IL9 protein

NCBI chr 5:135,892,246...135,895,841
Ensembl chr 5:135,892,246...135,895,841

G

inhibin subunit beta E

affects expression

Corn Oil affects the expression of INHBE mRNA

NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280

G

INS-IGF2 readthrough

multiple interactions

Corn Oil inhibits the reaction [Glucose results in increased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

interleukin 1 receptor associated kinase 1

increases expression

Corn Oil results in increased expression of IRAK1 mRNA

NCBI chr X:154,010,507...154,019,902
Ensembl chr X:154,010,506...154,019,902

G

interferon regulatory factor 5

increases expression

Corn Oil results in increased expression of IRF5 mRNA

NCBI chr 7:128,937,032...128,950,038
Ensembl chr 7:128,937,457...128,950,038

G

interferon regulatory factor 7

increases expression

Corn Oil results in increased expression of IRF7 mRNA

NCBI chr11:612,555...615,950
Ensembl chr11:612,553...615,983

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Corn Oil results in increased expression of JUN mRNA

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

KLF transcription factor 2

affects expression

Corn Oil affects the expression of KLF2 mRNA

NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685

G

lecithin-cholesterol acyltransferase

multiple interactions

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of LCAT mRNA

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

lipocalin 2

increases expression

Corn Oil results in increased expression of LCN2 mRNA

NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453

G

leptin

multiple interactions

Corn Oil inhibits the reaction [Glucose results in increased expression of LEP protein]

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

galectin 1

increases expression

Corn Oil results in increased expression of LGALS1 mRNA

NCBI chr22:37,675,636...37,679,802
Ensembl chr22:37,675,636...37,679,802

G

lysyl oxidase

multiple interactions

Corn Oil results in increased activity of and results in increased cleavage of LOX protein

NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413

G

lymphocyte antigen 75

increases expression

Corn Oil results in increased expression of LY75 mRNA

NCBI chr 2:159,803,355...159,904,756
Ensembl chr 2:159,803,355...159,904,756

G

mitogen-activated protein kinase kinase 1

increases expression

Corn Oil results in increased expression of MAP2K1 mRNA

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase kinase 3

increases expression

Corn Oil results in increased expression of MAP2K3 mRNA

NCBI chr17:21,284,711...21,315,240
Ensembl chr17:21,284,672...21,315,232

G

mitogen-activated protein kinase kinase 6

affects expression

Corn Oil affects the expression of MAP2K6 mRNA

NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865

G

mitogen-activated protein kinase kinase kinase 7

increases expression

Corn Oil results in increased expression of MAP3K7 mRNA

NCBI chr 6:90,513,579...90,587,072
Ensembl chr 6:90,513,573...90,587,086

G

mitogen-activated protein kinase 1

increases expression

Corn Oil results in increased expression of MAPK1 mRNA

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 14

increases expression

Corn Oil results in increased expression of MAPK14 mRNA

NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236

G

mitogen-activated protein kinase 3

increases expression

Corn Oil results in increased expression of MAPK3 mRNA

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

MDM2 proto-oncogene

decreases expression

Corn Oil results in decreased expression of MDM2 mRNA

NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544

G

O-6-methylguanine-DNA methyltransferase

increases expression

Corn Oil results in increased expression of MGMT mRNA

NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983

G

microsomal glutathione S-transferase 2

increases expression

Corn Oil results in increased expression of MGST2 mRNA

NCBI chr 4:139,665,819...139,754,618
Ensembl chr 4:139,665,768...139,740,745

G

malonyl-CoA decarboxylase

decreases expression

Corn Oil results in decreased expression of MLYCD mRNA

NCBI chr16:83,899,115...83,927,031
Ensembl chr16:83,899,115...83,951,445

G

methylsterol monooxygenase 1

affects expression

Corn Oil affects the expression of MSMO1 mRNA

NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of MTR mRNA

NCBI chr 1:236,795,281...236,903,981
Ensembl chr 1:236,795,260...236,921,278

G

MX dynamin like GTPase 2

affects expression

Corn Oil affects the expression of MX2 mRNA

NCBI chr21:41,362,027...41,409,393
Ensembl chr21:41,361,999...41,409,393

G

MYD88 innate immune signal transduction adaptor

increases expression

Corn Oil results in increased expression of MYD88 mRNA

NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024

G

NFE2 like bZIP transcription factor 2

decreases activity

Corn Oil results in decreased activity of NFE2L2 protein

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NFKB inhibitor alpha

increases expression

Corn Oil results in increased expression of NFKBIA mRNA

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NLR family CARD domain containing 4

increases expression

Corn Oil results in increased expression of NLRC4 mRNA

NCBI chr 2:32,224,449...32,265,743
Ensembl chr 2:32,224,453...32,265,732

G

nuclear receptor subfamily 1 group H member 4

affects expression

Corn Oil affects the expression of NR1H4 mRNA

NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414

G

nuclear receptor subfamily 4 group A member 2

increases expression

Corn Oil results in increased expression of NR4A2 mRNA

NCBI chr 2:156,324,437...156,332,721
Ensembl chr 2:156,324,437...156,342,348

G

NSE3 homolog, SMC5-SMC6 complex component

affects expression

Corn Oil affects the expression of NSMCE3 mRNA

NCBI chr15:29,264,989...29,269,822
Ensembl chr15:29,264,989...29,269,822

G

ornithine aminotransferase

affects expression

Corn Oil affects the expression of OAT mRNA

NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976

G

oxidative stress induced growth inhibitor 1

affects expression

Corn Oil affects the expression of OSGIN1 mRNA

NCBI chr16:83,953,240...83,966,332
Ensembl chr16:83,931,311...83,966,332

G

purinergic receptor P2X 5

affects expression

Corn Oil affects the expression of P2RX5 mRNA

NCBI chr17:3,673,227...3,696,155
Ensembl chr17:3,672,199...3,696,240

G

paired box 8

affects expression

Corn Oil affects the expression of PAX8 mRNA

NCBI chr 2:113,215,997...113,278,921
Ensembl chr 2:113,215,997...113,278,921

G

platelet derived growth factor subunit A

affects expression

Corn Oil affects the expression of PDGFA mRNA

NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296

G

platelet derived growth factor receptor beta

increases expression

Corn Oil results in increased expression of PDGFRB mRNA

NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872

G

PDZ and LIM domain 1

affects expression

Corn Oil affects the expression of PDLIM1 mRNA

NCBI chr10:95,237,572...95,291,003
Ensembl chr10:95,237,572...95,291,012

G

PDZ and LIM domain 2

affects expression

Corn Oil affects the expression of PDLIM2 mRNA

NCBI chr 8:22,578,741...22,598,026
Ensembl chr 8:22,578,279...22,598,025

G

placental growth factor

increases expression

Corn Oil results in increased expression of PGF mRNA

NCBI chr14:74,941,830...74,955,764
Ensembl chr14:74,941,834...74,955,626

G

progesterone receptor membrane component 2

affects expression

Corn Oil affects the expression of PGRMC2 mRNA

NCBI chr 4:128,269,242...128,287,813
Ensembl chr 4:128,269,237...128,288,829

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

increases expression

Corn Oil results in increased expression of PIK3CA mRNA

NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093

G

perilipin 2

affects expression

Corn Oil affects the expression of PLIN2 mRNA

NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290

G

prolactin receptor

affects expression

Corn Oil affects the expression of PRLR mRNA

NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of PTGS2 mRNA

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

protein tyrosine phosphatase receptor type F

affects expression

Corn Oil affects the expression of PTPRF mRNA

NCBI chr 1:43,522,051...43,623,666
Ensembl chr 1:43,525,187...43,623,666

G

PYD and CARD domain containing

increases expression

Corn Oil results in increased expression of PYCARD mRNA

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

Rac family small GTPase 1

increases expression

Corn Oil results in increased expression of RAC1 mRNA

NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967

G

receptor interacting serine/threonine kinase 1

increases expression

Corn Oil results in increased expression of RIPK1 mRNA

NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187

G

receptor interacting serine/threonine kinase 2

increases expression

Corn Oil results in increased expression of RIPK2 mRNA

NCBI chr 8:89,757,816...89,791,064
Ensembl chr 8:89,757,806...89,791,064

G

S100 calcium binding protein A8

increases expression

Corn Oil results in increased expression of S100A8 mRNA

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

increases expression

Corn Oil results in increased expression of S100A9 mRNA

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

stearoyl-CoA desaturase

affects expression

Corn Oil affects the expression of SCD1 mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

sodium voltage-gated channel beta subunit 1

affects expression

Corn Oil affects the expression of SCN1B mRNA

NCBI chr19:35,030,470...35,040,449
Ensembl chr19:35,030,470...35,040,449

G

serine dehydratase

affects expression

Corn Oil affects the expression of SDS mRNA

NCBI chr12:113,392,445...113,403,887
Ensembl chr12:113,392,445...113,426,301

G

secreted frizzled related protein 2

decreases expression

Corn Oil results in decreased expression of SFRP2 mRNA

NCBI chr 4:153,780,591...153,789,083
Ensembl chr 4:153,780,591...153,789,083

G

solute carrier family 25 member 20

multiple interactions

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of SLC25A20 mRNA

NCBI chr 3:48,856,926...48,898,882
Ensembl chr 3:48,856,926...48,898,904

G

solute carrier family 25 member 25

affects expression

Corn Oil affects the expression of SLC25A25 mRNA

NCBI chr 9:128,068,232...128,109,245
Ensembl chr 9:128,068,201...128,109,245

G

superoxide dismutase 1

multiple interactions
decreases activity

[Corn Oil co-treated with Iron, Dietary] results in decreased activity of SOD1 protein; [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]; Iron, Dietary promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

secreted protein acidic and cysteine rich

increases expression

Corn Oil results in increased expression of SPARC mRNA

NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975

G

squalene epoxidase

affects expression

Corn Oil affects the expression of SQLE mRNA

NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283

G

sterol regulatory element binding transcription factor 1

affects expression

Corn Oil affects the expression of SREBF1 mRNA

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

somatostatin receptor 3

decreases expression

Corn Oil results in decreased expression of SSTR3 mRNA

NCBI chr22:37,204,237...37,220,548
Ensembl chr22:37,204,237...37,212,477

G

SGT1 homolog, MIS12 kinetochore complex assembly cochaperone

increases expression

Corn Oil results in increased expression of SUGT1 mRNA

NCBI chr13:52,652,836...52,700,909
Ensembl chr13:52,652,709...52,700,909

G

spleen associated tyrosine kinase

increases expression

Corn Oil results in increased expression of SYK mRNA

NCBI chr 9:90,801,600...90,898,549
Ensembl chr 9:90,801,787...90,898,549

G

tachykinin precursor 1

decreases expression

Corn Oil results in decreased expression of TAC1 mRNA

NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472

G

tyrosine aminotransferase

affects expression

Corn Oil affects the expression of TAT mRNA

NCBI chr16:71,565,660...71,577,092
Ensembl chr16:71,565,660...71,577,092

G

TBC1 domain family member 14

affects expression

Corn Oil affects the expression of TBC1D14 mRNA

NCBI chr 4:6,909,466...7,033,114
Ensembl chr 4:6,909,242...7,033,118

G

transforming growth factor alpha

decreases expression

Corn Oil results in decreased expression of TGFA mRNA

NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193

G

TIR domain containing adaptor molecule 1

increases expression

Corn Oil results in increased expression of TICAM1 mRNA

NCBI chr19:4,815,932...4,831,712
Ensembl chr19:4,815,932...4,831,712

G

tight junction protein 2

increases expression

Corn Oil results in increased expression of TJP2 mRNA

NCBI chr 9:69,121,264...69,255,208
Ensembl chr 9:69,121,264...69,274,615

G

tight junction protein 3

increases expression

Corn Oil results in increased expression of TJP3 mRNA

NCBI chr19:3,708,384...3,750,813
Ensembl chr19:3,708,362...3,750,813

G

TNF receptor superfamily member 1A

increases expression

Corn Oil results in increased expression of TNFRSF1A mRNA

NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114

G

toll interacting protein

increases expression

Corn Oil results in increased expression of TOLLIP mRNA

NCBI chr11:1,274,371...1,309,632
Ensembl chr11:1,274,371...1,309,654

G

two pore segment channel 2

affects expression

Corn Oil affects the expression of TPCN2 mRNA

NCBI chr11:69,048,932...69,090,597
Ensembl chr11:69,048,932...69,136,316

G

tumor protein, translationally-controlled 1

increases expression

Corn Oil results in increased expression of TPT1 mRNA

NCBI chr13:45,333,471...45,341,183
Ensembl chr13:45,333,471...45,341,284

G

vascular endothelial growth factor B

decreases expression

Corn Oil results in decreased expression of VEGFB mRNA

NCBI chr11:64,234,584...64,239,264
Ensembl chr11:64,234,584...64,239,264

G

vanin 1

affects expression

Corn Oil affects the expression of VNN1 mRNA

NCBI chr 6:132,680,849...132,714,055
Ensembl chr 6:132,680,849...132,714,055

G

X-linked inhibitor of apoptosis

decreases expression

Corn Oil results in decreased expression of XIAP mRNA

NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972

G

X-prolyl aminopeptidase 2

affects expression

Corn Oil affects the expression of XPNPEP2 mRNA

NCBI chr X:129,738,979...129,769,536
Ensembl chr X:129,738,949...129,769,536

G

zinc finger DHHC-type palmitoyltransferase 23

affects expression

Corn Oil affects the expression of ZDHHC23 mRNA

NCBI chr 3:113,947,901...113,979,508
Ensembl chr 3:113,947,901...113,965,401

linoleamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisome proliferator activated receptor gamma

increases activity

linoleamide analog results in increased activity of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

linoleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
decreases expression
increases expression
increases phosphorylation
increases degradation

1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein]
Linoleic Acid analog results in decreased expression of ABCA1 mRNA
Linoleic Acid results in increased expression of ABCA1 mRNA
Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
Linoleic Acid results in increased phosphorylation of ABCA1 protein

PMID:16118212 PMID:18356535 PMID:27939595

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily G member 1

decreases expression

Linoleic Acid results in decreased expression of ABCG1 mRNA; Linoleic Acid results in decreased expression of ABCG1 protein

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

acetyl-CoA carboxylase alpha

decreases expression

Linoleic Acid results in decreased expression of ACACA mRNA

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

acyl-CoA dehydrogenase medium chain

increases expression

Linoleic Acid results in increased expression of ACADM mRNA

NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575

G

ATP citrate lyase

decreases expression

Linoleic Acid results in decreased expression of ACLY mRNA

NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542

G

aminocarboxymuconate semialdehyde decarboxylase

decreases expression

Linoleic Acid results in decreased expression of ACMSD mRNA

NCBI chr 2:134,838,616...134,902,034
Ensembl chr 2:134,838,616...134,902,034

G

acyl-CoA oxidase 1

increases expression

Linoleic Acid results in increased expression of ACOX1 mRNA

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

adiponectin, C1Q and collagen domain containing

decreases expression

Linoleic Acid results in decreased expression of ADIPOQ mRNA

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

adiponectin receptor 1

increases expression

Linoleic Acid analog results in increased expression of ADIPOR1 mRNA

NCBI chr 1:202,940,825...202,958,572
Ensembl chr 1:202,940,826...202,958,572

G

advanced glycosylation end-product specific receptor

multiple interactions

AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]

NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322

G

aryl hydrocarbon receptor

multiple interactions

Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

arachidonate 15-lipoxygenase

increases oxidation

ALOX15 protein results in increased oxidation of Linoleic Acid

NCBI chr17:4,630,919...4,641,678
Ensembl chr17:4,630,919...4,642,294

G

apolipoprotein A1

multiple interactions

Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

achaete-scute family bHLH transcription factor 2

decreases expression

Linoleic Acid results in decreased expression of ASCL2 mRNA

NCBI chr11:2,268,498...2,270,588
Ensembl chr11:2,268,498...2,270,588

G

butyrylcholinesterase

increases expression

Linoleic Acid results in increased expression of BCHE mRNA

NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462

G

BCL2 apoptosis regulator

multiple interactions

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

catalase

increases expression
multiple interactions

Linoleic Acid results in increased expression of CAT protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased activity of CAT protein]

PMID:10946007 PMID:34111468

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

increases expression

Linoleic Acid results in increased expression of CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

CD36 molecule (CD36 blood group)

multiple interactions

[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

chorionic gonadotropin subunit beta 3

decreases secretion

Linoleic Acid results in decreased secretion of CGB3 protein

NCBI chr19:49,022,869...49,024,333
Ensembl chr19:49,022,869...49,024,333

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of CHRNA7 mRNA]

NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018

G

cannabinoid receptor 1

affects response to substance
multiple interactions

CNR1 protein affects the susceptibility to Linoleic Acid
CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein]

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

collagen type I alpha 1 chain

increases expression

Linoleic Acid results in increased expression of COL1A1 mRNA

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type III alpha 1 chain

decreases expression

Linoleic Acid results in decreased expression of COL3A1 mRNA

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

carnitine palmitoyltransferase 1A

increases expression

Linoleic Acid results in increased expression of CPT1A mRNA

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

CREB binding protein

multiple interactions

Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]

NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713

G

cytochrome c, somatic

multiple interactions

[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein

NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

decreases activity

Linoleic Acid results in decreased activity of CYP1A2 protein

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 2 subfamily A member 6

multiple interactions
increases expression

NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]
Linoleic Acid results in increased expression of CYP2A6 mRNA; Linoleic Acid results in increased expression of CYP2A6 protein

NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions
decreases activity

CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]
Linoleic Acid results in decreased activity of CYP2C19 protein

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions
decreases activity

CYP2C9 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]
Linoleic Acid results in decreased activity of CYP2C9 protein

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

decreases activity

Linoleic Acid results in decreased activity of CYP2E1 protein

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 3 subfamily A member 4

decreases activity

Linoleic Acid results in decreased activity of CYP3A4 protein

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

DNA damage inducible transcript 3

increases expression

Linoleic Acid analog results in increased expression of DDIT3 protein

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

iodothyronine deiodinase 1

decreases activity

Linoleic Acid results in decreased activity of DIO1 protein

NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086

G

iodothyronine deiodinase 2

decreases activity

Linoleic Acid results in decreased activity of DIO2 protein

NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757

G

iodothyronine deiodinase 3

decreases activity

Linoleic Acid results in decreased activity of DIO3 protein

NCBI chr14:101,561,495...101,563,452
Ensembl chr14:101,560,139...101,563,452

G

endothelin 1

decreases expression

Linoleic Acid results in decreased expression of EDN1 mRNA; Linoleic Acid results in decreased expression of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

fatty acid binding protein 1

decreases expression

Linoleic Acid results in decreased expression of FABP1 mRNA

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

fatty acid binding protein 3

decreases expression

Linoleic Acid results in decreased expression of FABP3 mRNA

NCBI chr 1:31,359,588...31,373,076
Ensembl chr 1:31,365,253...31,376,850

G

fatty acid binding protein 4

affects localization

Linoleic Acid analog affects the localization of FABP4 protein

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

fatty acid desaturase 2

multiple interactions
increases expression

[Linoleic Acid co-treated with Testosterone] results in increased expression of FADS2 mRNA
FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]
Linoleic Acid results in increased expression of FADS2 mRNA; Linoleic Acid results in increased expression of FADS2 protein

PMID:21457203 PMID:26240151

NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354

G

fatty acid synthase

decreases expression

Linoleic Acid results in decreased expression of FASN mRNA

NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294

G

free fatty acid receptor 3

increases expression

Linoleic Acid analog results in increased expression of FFAR3 mRNA

NCBI chr19:35,358,151...35,360,489
Ensembl chr19:35,358,460...35,360,489

G

forkhead box O1

decreases expression

Linoleic Acid results in decreased expression of FOXO1 protein

NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641

G

glucagon

multiple interactions

CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein]

NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404

G

glutamate-cysteine ligase modifier subunit

increases expression

Linoleic Acid metabolite results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

gap junction protein beta 1

increases abundance

GJB1 protein results in increased abundance of Linoleic Acid

NCBI chr X:71,215,239...71,225,516
Ensembl chr X:71,212,811...71,225,516

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of GRIN2A mRNA]

NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of GRIN2B mRNA]

NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002

G

glutathione S-transferase alpha 1

multiple interactions
increases expression

NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]

NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860

G

hepatitis A virus cellular receptor 1

increases secretion

Linoleic Acid results in increased secretion of HAVCR1 protein

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

heme oxygenase 1

multiple interactions
increases expression

NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]
Linoleic Acid metabolite results in increased expression of HMOX1 mRNA; Linoleic Acid metabolite results in increased expression of HMOX1 protein

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heat shock protein family A (Hsp70) member 5

increases expression

Linoleic Acid analog results in increased expression of HSPA5 protein

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

interferon gamma

increases expression

Linoleic Acid results in increased expression of IFNG protein

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interleukin 10

increases expression

Linoleic Acid results in increased expression of IL10 protein

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

increases expression
multiple interactions

Linoleic Acid results in increased expression of IL1B protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL1B mRNA]

PMID:16305726 PMID:34111468

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 2

decreases expression

Linoleic Acid results in decreased expression of IL2 protein

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 4

decreases expression

Linoleic Acid results in decreased expression of IL4 protein

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 5

decreases expression

Linoleic Acid results in decreased expression of IL5 protein

NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838

G

interleukin 6

affects expression
multiple interactions
increases expression
increases secretion

Linoleic Acid affects the expression of IL6 protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL6 mRNA]
Linoleic Acid results in increased expression of IL6 mRNA
Linoleic Acid results in increased secretion of IL6 protein

PMID:16305726 PMID:17374693 PMID:21457203 PMID:34111468

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

insulin receptor

increases expression

Linoleic Acid analog results in increased expression of INSR mRNA

NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414

G

iodotyrosine deiodinase

multiple interactions

Linoleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969

G

lecithin-cholesterol acyltransferase

increases expression

Linoleic Acid analog results in increased expression of LCAT mRNA

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

G

lysyl oxidase

multiple interactions
increases activity

FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]; TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]

NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413

G

lipin 1

decreases expression

Linoleic Acid analog results in decreased expression of LPIN1 mRNA

NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409

G

lecithin retinol acyltransferase

increases expression

Linoleic Acid results in increased expression of LRAT mRNA

NCBI chr 4:154,740,838...154,753,120
Ensembl chr 4:154,626,945...154,753,120

G

mitogen-activated protein kinase 3

multiple interactions

Linoleic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 9

multiple interactions
decreases expression

Linoleic Acid results in decreased expression of and results in decreased activity of MMP9 protein
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein]
Linoleic Acid results in decreased expression of MMP9 mRNA

PMID:22467055 PMID:23288142

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

neutrophil cytosolic factor 1

multiple interactions

Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]

NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315

G

neutrophil cytosolic factor 2

multiple interactions

Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein]

NCBI chr 1:183,555,562...183,601,849
Ensembl chr 1:183,554,461...183,590,905

G

nuclear receptor coactivator 1

multiple interactions

Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]

NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,254...24,770,702

G

nuclear receptor coactivator 2

multiple interactions

Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein]

NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

Linoleic Acid metabolite results in increased expression of NFE2L2 protein; Linoleic Acid results in increased expression of NFE2L2 mRNA; Linoleic Acid results in increased expression of NFE2L2 protein
NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]

PMID:26879219 PMID:28555106

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor kappa B subunit 1

multiple interactions

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of NFKB1 mRNA]

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

nitric oxide synthase 2

multiple interactions

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

decreases expression

Linoleic Acid results in decreased expression of NOS3 mRNA

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NAD(P)H quinone dehydrogenase 1

increases expression

Linoleic Acid metabolite results in increased expression of NQO1 mRNA

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 5 group A member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Linoleic Acid analog

NCBI chr 1:200,027,710...200,177,415
Ensembl chr 1:200,027,614...200,177,420

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

[Glucose deficiency co-treated with Linoleic Acid] results in increased expression of PCK1 mRNA

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

pyruvate dehydrogenase kinase 4

increases expression

Linoleic Acid results in increased expression of PDK4 mRNA

NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516

G

phospholipase D2

multiple interactions

PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr17:4,807,152...4,823,430
Ensembl chr17:4,807,152...4,823,434

G

perilipin 1

increases expression

Linoleic Acid analog results in increased expression of PLIN1 mRNA

NCBI chr15:89,664,367...89,679,367
Ensembl chr15:89,664,367...89,679,427

G

paraoxonase 1

multiple interactions
decreases activity

Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]
Linoleic Acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15375178

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression
affects abundance
increases activity
affects binding

[Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased oxidation of Linoleic Acid; Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]; Linoleic Acid binds to and results in increased activity of PPARA protein; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein]
Linoleic Acid results in increased expression of PPARA mRNA
PPARA protein affects the abundance of Linoleic Acid
Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Linoleic Acid]; Linoleic Acid binds to and results in increased activity of PPARA protein
Linoleic Acid results in increased expression of PPARA mRNA; Linoleic Acid results in increased expression of PPARA protein
Linoleic Acid results in increased activity of PPARA protein
Linoleic Acid binds to PPARA protein

PMID:10403814 PMID:11172467 PMID:15491415 PMID:16731579 PMID:18154422 More...

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor delta

multiple interactions
decreases expression
increases expression
increases activity
affects binding

Linoleic Acid binds to and results in increased activity of PPARB protein
Linoleic Acid results in decreased expression of PPARD mRNA
Linoleic Acid results in increased expression of PPARD mRNA
Linoleic Acid results in increased activity of PPARD protein
Linoleic Acid binds to PPARB protein

PMID:11172467 PMID:15708366 PMID:16731579 PMID:23843199 PMID:25786526

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

peroxisome proliferator activated receptor gamma

affects binding
multiple interactions
increases expression
increases activity
decreases expression

Linoleic Acid binds to PPARG protein
Linoleic Acid binds to and results in increased activity of PPARG protein
Linoleic Acid results in increased expression of PPARG mRNA
resveratrol inhibits the reaction [Linoleic Acid results in increased expression of PPARG protein]
Linoleic Acid results in increased activity of PPARG protein
Linoleic Acid results in decreased expression of PPARG mRNA; Linoleic Acid results in decreased expression of PPARG protein

PMID:11172467 PMID:12021203 PMID:15708366 PMID:16731579 PMID:18154422 More...

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

PPARG coactivator 1 alpha

increases expression

Linoleic Acid results in increased expression of PPARGC1A mRNA

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

PPARG coactivator 1 beta

increases expression

Linoleic Acid results in increased expression of PPARGC1B mRNA

NCBI chr 5:149,730,310...149,857,959
Ensembl chr 5:149,730,298...149,855,022

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

Linoleic Acid results in increased expression of PTGS2 mRNA
Linoleic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]

PMID:14563831 PMID:18001219

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

retinoid X receptor alpha

affects binding
multiple interactions

Linoleic Acid binds to RXRA protein
Linoleic Acid binds to and results in increased activity of RXRA protein

PMID:16258897 PMID:16731579

NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585

G

stearoyl-CoA desaturase

multiple interactions
increases expression

[Linoleic Acid co-treated with Testosterone] results in increased expression of SCD mRNA
Linoleic Acid results in increased expression of SCD mRNA; Linoleic Acid results in increased expression of SCD protein

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

serpin family E member 1

increases expression

Linoleic Acid results in increased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

solute carrier family 22 member 6

decreases activity

Linoleic Acid results in decreased activity of SLC22A6 protein

NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967

G

solute carrier family 22 member 8

decreases activity

Linoleic Acid results in decreased activity of SLC22A8 protein

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

SMAD family member 3

decreases abundance

SMAD3 protein results in decreased abundance of Linoleic Acid

NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173

G

sterol regulatory element binding transcription factor 1

decreases expression

Linoleic Acid results in decreased expression of SREBF1 mRNA

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

transforming growth factor beta 1

multiple interactions

TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tumor necrosis factor

decreases response to substance
multiple interactions

Linoleic Acid results in decreased susceptibility to TNF protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TNF mRNA]

PMID:22683933 PMID:34111468

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

transient receptor potential cation channel subfamily V member 1

multiple interactions

TRPV1 results in increased susceptibility to [Linoleic Acid co-treated with Freund's Adjuvant]

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

uncoupling protein 2

increases expression

Linoleic Acid results in increased expression of UCP2 mRNA

NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843

G

vascular endothelial growth factor A

multiple interactions

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

Wnt family member 10B

decreases expression

Linoleic Acid results in decreased expression of WNT10B mRNA

NCBI chr12:48,965,340...48,971,735
Ensembl chr12:48,965,340...48,971,735

linoleic acid hydroperoxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions
increases lipidation

Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

cytoglobin

increases metabolic processing

CYGB protein results in increased metabolism of linoleic acid hydroperoxide

NCBI chr17:76,527,356...76,551,193
Ensembl chr17:76,527,356...76,551,175

G

glutathione peroxidase 1

increases reduction

GPX1 protein results in increased reduction of linoleic acid hydroperoxide

NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605

G

glutathione peroxidase 2

increases reduction

GPX2 protein results in increased reduction of linoleic acid hydroperoxide

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

lipoxin A4

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

angiotensinogen

multiple interactions

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

aryl hydrocarbon receptor

multiple interactions

AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

arachidonate 5-lipoxygenase

multiple interactions
affects abundance

zileuton inhibits the reaction [ALOX5 protein affects the abundance of lipoxin A4]

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

BCL2 associated X, apoptosis regulator

multiple interactions

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

increases expression
multiple interactions

lipoxin A4 results in increased expression of CASP3 protein
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

collagen type I alpha 1 chain

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of COL1A1 mRNA]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type I alpha 2 chain

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of COL1A2 protein]

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

C-X-C motif chemokine ligand 2

multiple interactions

lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 8

multiple interactions
decreases expression

lipoxin A4 analog inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; lipoxin A4 analog inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; lipoxin A4 inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased secretion of CXCL8 protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]
lipoxin A4 analog results in decreased expression of CXCL8 protein

PMID:12235371 PMID:21659618 PMID:23063943 PMID:27663891

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

formyl peptide receptor 2

multiple interactions
increases activity

[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein
lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA]
lipoxin A4 results in increased activity of FPR2

PMID:12594298 PMID:19597002 PMID:21765620

NCBI chr19:51,761,180...51,770,531
Ensembl chr19:51,752,026...51,770,531

G

heme oxygenase 1

increases expression
multiple interactions

lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein
lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

intercellular adhesion molecule 1

affects response to substance
multiple interactions
increases expression

ICAM1 protein affects the susceptibility to lipoxin A4
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of ICAM1 protein]

PMID:7602232 PMID:36057361

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 10

multiple interactions

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 13

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL13 protein]

NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110

G

interleukin 1 beta

decreases expression
decreases secretion
multiple interactions

lipoxin A4 analog results in decreased expression of IL1B protein
lipoxin A4 analog results in decreased secretion of IL1B protein
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]

PMID:10377187 PMID:21659618

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 4

increases secretion
multiple interactions

lipoxin A4 analog results in increased secretion of IL4 protein
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]

PMID:10377187 PMID:34537180

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 5

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL5 protein]

NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838

G

interleukin 6

multiple interactions

lipoxin A4 inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased secretion of IL6 protein]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

mitogen-activated protein kinase 1

multiple interactions

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

Gentamicins inhibits the reaction [lipoxin A4 results in increased phosphorylation of MAPK9 protein]

NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]

NCBI chr 6:159,888,787...159,917,447
Ensembl chr 6:159,890,988...159,917,447

G

myeloperoxidase

multiple interactions

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

NFE2 like bZIP transcription factor 2

affects localization
multiple interactions

lipoxin A4 affects the localization of NFE2L2 protein
lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NFKB inhibitor alpha

multiple interactions

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]

PMID:21831303 PMID:29969931

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

nitric oxide synthase 2

multiple interactions

butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

platelet derived growth factor subunit B

multiple interactions

lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]

PMID:12223454 PMID:20709806

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

platelet derived growth factor receptor beta

multiple interactions
decreases phosphorylation

lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]

PMID:12223454 PMID:20709806

NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872

G

peroxisome proliferator activated receptor gamma

multiple interactions

lipoxin A4 binds to and results in increased activity of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

platelet activating factor receptor

multiple interactions

[WEB 2086 binds to and results in decreased activity of PTAFR protein] which results in decreased susceptibility to lipoxin A4

NCBI chr 1:28,147,166...28,193,856
Ensembl chr 1:28,147,166...28,193,936

G

prostaglandin-endoperoxide synthase 2

multiple interactions
affects abundance

[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

PMID:15326064 PMID:21765620

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]

PMID:21831303 PMID:23063943 PMID:29969931

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

selectin P

affects response to substance

SELP protein affects the susceptibility to lipoxin A4

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

suppressor of cytokine signaling 2

multiple interactions
increases expression

AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]
lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein

NCBI chr12:93,569,969...93,626,236
Ensembl chr12:93,569,814...93,583,487

G

signal transducer and activator of transcription 3

multiple interactions

lipoxin A4 inhibits the reaction [Ovalbumin results in increased phosphorylation of STAT3 protein]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transforming growth factor beta 1

increases expression
multiple interactions

lipoxin A4 results in increased expression of TGFB1 protein
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TGFB1 protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tumor necrosis factor

multiple interactions

lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TNF protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

PMID:10377187 PMID:21575454 PMID:21831303 PMID:23063943 PMID:29969931 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

methyl linoleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

multiple interactions

methyl linoleate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969

methyl oleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

methyl oleate binds to and results in increased activity of AHR protein

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

estrogen receptor 1

multiple interactions

methyl oleate binds to and results in increased activity of ESR1 protein

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

peroxisome proliferator activated receptor gamma

multiple interactions

methyl oleate binds to and results in increased activity of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

N-oleoyldopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cannabinoid receptor 1

multiple interactions

N-oleoyldopamine binds to and results in increased activity of CNR1 protein

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

collagen type I alpha 1 chain

multiple interactions

N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

transforming growth factor beta 1

multiple interactions

N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transient receptor potential cation channel subfamily V member 1

multiple interactions
increases activity

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]
N-oleoyldopamine results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein]

PMID:12569099 PMID:15615864

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

oleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression
increases phosphorylation
increases degradation

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ABCA1 mRNA; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Oleic Acid results in increased expression of ABCA1 mRNA
Oleic Acid results in increased phosphorylation of ABCA1 protein
Oleic Acid results in increased degradation of ABCA1 protein
Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]

PMID:16118212 PMID:18356535 PMID:30547786

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 11

increases expression

Oleic Acid results in increased expression of ABCB11 mRNA

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily D member 3

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in increased expression of ABCD3 mRNA]

NCBI chr 1:94,385,131...94,518,663
Ensembl chr 1:94,418,389...94,518,666

G

ATP binding cassette subfamily G member 1

decreases expression

Oleic Acid results in decreased expression of ABCG1 mRNA; Oleic Acid results in decreased expression of ABCG1 protein

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

ATP binding cassette subfamily G member 2 (JR blood group)

increases expression

Oleic Acid results in increased expression of ABCG2 mRNA

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

acetyl-CoA acyltransferase 1

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA

NCBI chr 3:38,122,715...38,137,127
Ensembl chr 3:38,103,129...38,137,242

G

acetyl-CoA acyltransferase 2

increases expression
multiple interactions

Oleic Acid results in increased expression of ACAA2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAA2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA

NCBI chr18:49,782,164...49,813,533
Ensembl chr18:49,782,164...49,813,953

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA; cyhalothrin promotes the reaction [Oleic Acid results in increased expression of ACACA protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA]

PMID:30611723 PMID:36529352 PMID:36905866

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

acetyl-CoA carboxylase beta

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACB mRNA

NCBI chr12:109,111,189...109,268,226
Ensembl chr12:109,116,587...109,268,226

G

acyl-CoA dehydrogenase family member 9

multiple interactions
increases expression

[Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of ACAD9 mRNA]

NCBI chr 3:128,879,620...128,913,114
Ensembl chr 3:128,879,596...128,924,003

G

acyl-CoA dehydrogenase long chain

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA

NCBI chr 2:210,187,923...210,225,447
Ensembl chr 2:210,187,126...210,225,447

G

acyl-CoA dehydrogenase medium chain

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADM mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADM mRNA

PMID:26190035 PMID:30611723

NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575

G

acyl-CoA dehydrogenase short chain

multiple interactions
increases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADS mRNA
Oleic Acid results in increased expression of ACADS mRNA

NCBI chr12:120,725,826...120,740,008
Ensembl chr12:120,725,774...120,740,008

G

acyl-CoA dehydrogenase very long chain

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADVL mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADVL mRNA

NCBI chr17:7,217,125...7,225,266
Ensembl chr17:7,217,125...7,225,266

G

acetyl-CoA acetyltransferase 1

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT1 mRNA

NCBI chr11:108,116,705...108,147,603
Ensembl chr11:108,116,695...108,147,603

G

acetyl-CoA acetyltransferase 2

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT2 mRNA

NCBI chr 6:159,762,045...159,779,112
Ensembl chr 6:159,762,045...159,779,112

G

ATP citrate lyase

multiple interactions
decreases expression

[[Vehicle Emissions results in increased abundance of Particulate Matter] which co-treated with Oleic Acid] results in decreased expression of ACLY mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACLY mRNA
Oleic Acid results in decreased expression of ACLY mRNA

PMID:30611723 PMID:31340670

NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542

G

acyl-CoA thioesterase 1

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT1 mRNA

NCBI chr14:73,490,933...73,543,796
Ensembl chr14:73,537,143...73,543,796

G

acyl-CoA thioesterase 12

multiple interactions
increases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT12 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA
Oleic Acid results in increased expression of ACOT12 mRNA

NCBI chr 5:81,308,609...81,394,134
Ensembl chr 5:81,329,996...81,394,179

G

acyl-CoA thioesterase 4

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA

NCBI chr14:73,591,873...73,595,766
Ensembl chr14:73,591,873...73,595,766

G

acyl-CoA thioesterase 6

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA

NCBI chr14:73,610,945...73,619,888
Ensembl chr14:73,610,945...73,619,888

G

acyl-CoA thioesterase 7

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT7 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT7 mRNA

NCBI chr 1:6,264,272...6,393,767
Ensembl chr 1:6,264,269...6,393,767

G

acyl-CoA thioesterase 8

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA

NCBI chr20:45,841,721...45,857,392
Ensembl chr20:45,841,721...45,857,405

G

acyl-CoA oxidase 1

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Fenofibrate co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [tesaglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA]

PMID:24534255 PMID:30611723 PMID:36905866

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

acyl-CoA oxidase 2

decreases expression
multiple interactions

Oleic Acid results in decreased expression of ACOX2 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA

NCBI chr 3:58,505,136...58,537,190
Ensembl chr 3:58,505,136...58,537,283

G

acyl-CoA synthetase long chain family member 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ACSL1 mRNA

NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818

G

acyl-CoA synthetase long chain family member 3

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACSL3 mRNA

NCBI chr 2:222,861,036...222,944,639
Ensembl chr 2:222,860,942...222,944,639

G

acyl-CoA synthetase long chain family member 4

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACSL4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA

PMID:30547786 PMID:30611723

NCBI chr X:109,641,335...109,733,257
Ensembl chr X:109,624,244...109,733,403

G

acyl-CoA synthetase long chain family member 5

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA

NCBI chr10:112,374,116...112,428,376
Ensembl chr10:112,374,116...112,428,379

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of ACTA2 mRNA
Oleic Acid results in increased expression of ACTA2 mRNA

PMID:26187275 PMID:32918399

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

adiponectin, C1Q and collagen domain containing

decreases expression
multiple interactions

Oleic Acid results in decreased expression of ADIPOQ mRNA
sophocarpine inhibits the reaction [Oleic Acid results in decreased expression of ADIPOQ mRNA]

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

adiponectin receptor 2

decreases expression

oleic acid cotreated with ethanol decreases expression of adipor2 mRNA in rat primary hepatocytes

RGD

NCBI chr12:1,691,070...1,788,674
Ensembl chr12:1,688,574...1,788,674

G

1-acylglycerol-3-phosphate O-acyltransferase 1

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA

NCBI chr 6:32,168,212...32,178,108
Ensembl chr 6:32,168,212...32,178,096

G

1-acylglycerol-3-phosphate O-acyltransferase 2

increases expression
multiple interactions

Oleic Acid results in increased expression of AGPAT2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AGPAT2 mRNA

PMID:30547786 PMID:30611723

NCBI chr 9:136,673,143...136,687,457
Ensembl chr 9:136,673,143...136,687,457

G

1-acylglycerol-3-phosphate O-acyltransferase 5

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT5 mRNA

NCBI chr 8:6,708,642...6,761,503
Ensembl chr 8:6,708,642...6,761,503

G

aryl hydrocarbon receptor

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AHR mRNA

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

aldo-keto reductase family 7 like (gene/pseudogene)

decreases expression

Oleic Acid results in decreased expression of AKR7L protein

NCBI chr 1:19,265,982...19,274,122
Ensembl chr 1:19,265,982...19,274,194

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein]
[Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of AKT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]

PMID:14604813 PMID:25536389 PMID:26847930

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

albumin

multiple interactions
affects binding
decreases secretion

[ALB protein binds to Oleic Acid] promotes the reaction [ALB protein results in increased reduction of Dithionitrobenzoic Acid]; [ALB protein binds to Oleic Acid] promotes the reaction [Pyruvaldehyde results in increased oxidation of ALB protein]; [ALB protein modified form binds to Oleic Acid] which results in decreased reduction of Dithionitrobenzoic Acid; [Oleic Acid co-treated with muraglitazar] results in increased expression of ALB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ALB mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ALB mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein]; Quercetin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]

PMID:23348005 PMID:24534255 PMID:25451573 PMID:38103844

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

aldehyde dehydrogenase 1 family member A1

decreases expression

Oleic Acid results in decreased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

angiopoietin like 4

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ANGPTL4 mRNA

NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370

G

annexin A2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ANXA2 mRNA

NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883

G

apolipoprotein A1

multiple interactions

Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein A4

increases expression

Oleic Acid results in increased expression of APOA4 mRNA

NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304

G

apolipoprotein A5

increases expression
multiple interactions

Oleic Acid results in increased expression of APOA5 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA

NCBI chr11:116,789,367...116,792,420
Ensembl chr11:116,789,367...116,792,420

G

apolipoprotein B

multiple interactions
decreases expression
increases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of APOB protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of APOB protein]; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein]; Oleic Acid results in increased expression of and results in increased secretion of APOB protein
Oleic Acid results in decreased expression of APOB mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA]; Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein]

PMID:12048068 PMID:15618547 PMID:17237316 PMID:19383982 PMID:26854922 More...

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

apolipoprotein C3

multiple interactions

[Oleic Acid co-treated with muraglitazar] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of APOC3 mRNA

NCBI chr11:116,829,907...116,833,072
Ensembl chr11:116,829,706...116,833,072

G

apolipoprotein C4

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA

NCBI chr19:44,942,237...44,945,496
Ensembl chr19:44,942,237...44,945,496

G

apolipoprotein E

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of APOE mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOE mRNA

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

arginase 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ARG1 mRNA

NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332

G

activating transcription factor 6

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of ATF6 mRNA]

PMID:32369900 PMID:32976987

NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574

G

autophagy related 5

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein]

NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791

G

autophagy related 7

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein]

NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665

G

beta-1,4-galactosyltransferase 5

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of B4GALT5 mRNA

NCBI chr20:49,632,945...49,713,878
Ensembl chr20:49,632,945...49,713,878

G

beta-secretase 1

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]

NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259

G

BCL2 associated X, apoptosis regulator

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

multiple interactions
increases cleavage

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA
Oleic Acid results in increased cleavage of CASP3 protein
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased cleavage of CASP3 protein]

PMID:32369900 PMID:32976987 PMID:36273635

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions
increases cleavage

IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA

PMID:14604813 PMID:32369900

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catalase

multiple interactions
increases activity
decreases activity

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; Quercetin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]
Oleic Acid results in increased activity of CAT protein
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased activity of CAT protein; [Oleic Acid co-treated with Palmitic Acid] results in increased activity of CAT protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased activity of CAT protein]; gossypin inhibits the reaction [Oleic Acid results in increased activity of CAT protein]

PMID:23348005 PMID:26854922 PMID:30547786 PMID:37696682

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolin 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of CAV2 mRNA

NCBI chr 7:116,499,738...116,508,541
Ensembl chr 7:116,287,380...116,508,541

G

CD36 molecule (CD36 blood group)

multiple interactions
increases expression

GW 4064 inhibits the reaction [Oleic Acid results in increased expression of CD36 protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA]
Oleic Acid results in increased expression of CD36 mRNA
[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA

PMID:23371517 PMID:28552552 PMID:30611723 PMID:36347319 PMID:38092172 More...

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

cyclin dependent kinase inhibitor 1A

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

cell death inducing DFFA like effector c

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CIDEC mRNA

NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255

G

collagen type I alpha 1 chain

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of COL1A1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of COL1A1 mRNA]

PMID:26187275 PMID:32918399

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

cytochrome c oxidase assembly factor heme A:farnesyltransferase COX10

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of COX10 mRNA

NCBI chr17:14,069,504...14,208,677
Ensembl chr17:14,069,490...14,231,736

G

carnitine palmitoyltransferase 1A

increases expression
decreases expression
multiple interactions

Oleic Acid results in increased expression of CPT1A mRNA
Oleic Acid results in decreased expression of CPT1A mRNA
[Starch co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Sucrose co-treated with Oleic Acid] results in increased expression of CPT1A mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT1A mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; isosilybin promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of CPT1A mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]

PMID:11171094 PMID:24534255 PMID:25048947 PMID:26190035 PMID:26854922 More...

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

carnitine palmitoyltransferase 2

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of CPT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA]

PMID:24534255 PMID:30611723 PMID:36905866

NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197

G

CREB binding protein

decreases expression

Oleic Acid results in decreased expression of CREBBP mRNA

NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713

G

C-reactive protein

multiple interactions

[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of CRP protein

NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589

G

C-X-C motif chemokine ligand 10

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL10 mRNA

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL2 mRNA

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 3

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL3 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL3 mRNA

NCBI chr 4:74,036,589...74,038,689
Ensembl chr 4:74,036,589...74,038,807

G

C-X-C motif chemokine ligand 8

multiple interactions
increases expression

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CXCL8 mRNA; Quercetin inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]

PMID:23348005 PMID:30547786

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome c, somatic

multiple interactions

[Oleic Acid co-treated with anastrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with letrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein

PMID:24161488 PMID:27016407

NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
increases expression

[Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 mRNA]; [Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 protein]
Oleic Acid results in increased expression of CYP1A1 mRNA; Oleic Acid results in increased expression of CYP1A1 protein

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions
decreases expression

Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP1A2 mRNA]

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 24 subfamily A member 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP24A1 mRNA

NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986

G

cytochrome P450 family 26 subfamily A member 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP26A1 mRNA

NCBI chr10:93,073,475...93,077,885
Ensembl chr10:93,073,475...93,077,885

G

cytochrome P450 family 26 subfamily B member 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP26B1 mRNA

NCBI chr 2:72,129,238...72,147,862
Ensembl chr 2:72,129,238...72,147,862

G

cytochrome P450 family 2 subfamily A member 6

increases expression

Oleic Acid results in increased expression of CYP2A6 mRNA; Oleic Acid results in increased expression of CYP2A6 protein

NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447

G

cytochrome P450 family 2 subfamily B member 6

multiple interactions
decreases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of CYP2B6 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP2B6 mRNA]

PMID:24534255 PMID:30611723

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP2C65 mRNA]

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of CYP2E1 mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2E1 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in increased expression of CYP2E1 mRNA]

PMID:26854922 PMID:30611723

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 3 subfamily A member 4

decreases expression
multiple interactions

Oleic Acid results in decreased expression of CYP3A4 mRNA; Oleic Acid results in decreased expression of CYP3A4 protein
Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP3A4 mRNA]

PMID:26739624 PMID:30611723

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 4 subfamily A member 11

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP4A11 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CYP4A11 mRNA

NCBI chr 1:46,929,188...46,941,476
Ensembl chr 1:46,929,177...46,941,484

G

cytochrome P450 family 4 subfamily A member 22

multiple interactions

[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in decreased expression of CYP4A1 mRNA

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

cytochrome P450 family 4 subfamily F member 8

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP4F16 mRNA]

NCBI chr19:15,615,218...15,630,639
Ensembl chr19:15,615,218...15,630,639

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

Oleic Acid results in decreased expression of CYP7A1 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA]

PMID:32738331 PMID:38103844

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

DNA damage inducible transcript 3

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 mRNA]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]

PMID:32369900 PMID:32976987 PMID:37009739

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

2,4-dienoyl-CoA reductase 1

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of DECR1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA

NCBI chr 8:90,001,477...90,053,633
Ensembl chr 8:90,001,405...90,053,633

G

derlin 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of DERL1 mRNA

NCBI chr 8:123,013,170...123,042,302
Ensembl chr 8:123,013,170...123,042,302

G

diacylglycerol O-acyltransferase 1

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of DGAT1 mRNA

NCBI chr 8:144,314,584...144,326,852
Ensembl chr 8:144,314,584...144,326,910

G

diacylglycerol O-acyltransferase 2

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of DGAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of DGAT2 mRNA

PMID:30611723 PMID:38092172

NCBI chr11:75,768,778...75,801,534
Ensembl chr11:75,759,512...75,801,535

G

dehydrodolichyl diphosphate synthase subunit

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of DHDDS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of DHDDS mRNA

NCBI chr 1:26,432,321...26,471,306
Ensembl chr 1:26,432,282...26,471,306

G

dynamin 1 like

affects phosphorylation

Oleic Acid affects the phosphorylation of DNM1L protein

NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650

G

dystonin

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DST mRNA

NCBI chr 6:56,457,996...56,954,830
Ensembl chr 6:56,457,987...56,954,830

G

dynein cytoplasmic 1 heavy chain 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1H1 mRNA

NCBI chr14:101,964,573...102,056,443
Ensembl chr14:101,964,573...102,056,443

G

dynein cytoplasmic 1 intermediate chain 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1I1 mRNA

NCBI chr 7:95,772,554...96,110,322
Ensembl chr 7:95,772,506...96,110,322

G

E2F transcription factor 1

decreases expression

Oleic Acid results in decreased expression of E2F1 protein

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

enoyl-CoA hydratase 1

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ECH1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of ECH1 mRNA

PMID:24534255 PMID:30611723

NCBI chr19:38,815,422...38,831,794
Ensembl chr19:38,815,422...38,831,841

G

enoyl-CoA hydratase, short chain 1

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ECHS1 mRNA

NCBI chr10:133,362,485...133,373,354
Ensembl chr10:133,362,485...133,373,354

G

endothelin 1

decreases expression

Oleic Acid results in decreased expression of EDN1 mRNA; Oleic Acid results in decreased expression of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EGFR mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein]
Oleic Acid results in increased phosphorylation of EGFR protein

PMID:27447558 PMID:30547786 PMID:38103844

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of EHHADH mRNA

NCBI chr 3:185,190,624...185,254,049
Ensembl chr 3:185,190,624...185,281,990

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EIF2AK3 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA

PMID:30547786 PMID:32369900

NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518

G

ELOVL fatty acid elongase 5

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ELOVL5 mRNA

NCBI chr 6:53,267,404...53,348,950
Ensembl chr 6:53,267,398...53,349,179

G

ELOVL fatty acid elongase 6

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ELOVL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Fenofibrate] affects the expression of ELOVL6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ELOVL6 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ELOVL6 mRNA

PMID:24534255 PMID:30547786 PMID:30611723

NCBI chr 4:110,045,846...110,199,202
Ensembl chr 4:110,045,846...110,199,199

G

enolase 3

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ENO3 mRNA

NCBI chr17:4,948,710...4,957,129
Ensembl chr17:4,948,092...4,957,131

G

ER lipid raft associated 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ERLIN1 mRNA

NCBI chr10:100,150,094...100,186,029
Ensembl chr10:100,150,094...100,186,033

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA

NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819

G

fatty acid binding protein 1

affects binding
decreases expression
multiple interactions

Oleic Acid binds to FABP1 protein
Oleic acid binds to Fabp1 protein
Oleic Acid results in decreased expression of FABP1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FABP1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FABP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of FABP1 mRNA; Dibutyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Diethylhexyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Oleic Acid inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein]
Bezafibrate inhibits the reaction [Oleic Acid binds to FABP1 protein]

CTD
RGD

PMID:2328261 PMID:30547786 PMID:30611723 PMID:31110286 PMID:38092172 More...

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

fatty acid binding protein 2

affects binding

FABP2 protein modified form binds to Oleic Acid

NCBI chr 4:119,317,250...119,322,138
Ensembl chr 4:119,317,250...119,322,138

G

fatty acid binding protein 4

multiple interactions
affects localization
increases expression

[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of FABP4 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of FABP4 mRNA
Oleic Acid analog affects the localization of FABP4 protein
Oleic Acid results in increased expression of FABP4 mRNA

PMID:8536680 PMID:26739624 PMID:27939595

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

Fas cell surface death receptor

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FAS mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein]
Oleic Acid results in increased expression of FAS mRNA

PMID:26190035 PMID:32918399 PMID:36347319 PMID:36905866

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

fatty acid synthase

multiple interactions

[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of FASN mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FASN mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein; [Oleic Acid co-treated with Fenofibrate] affects the expression of FASN mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein]
[Sucrose co-treated with Oleic Acid] results in increased expression of FASN mRNA
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of FASN mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FASN mRNA

PMID:24534255 PMID:26854922 PMID:26895660 PMID:30611723 PMID:33508418 More...

NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294

G

farnesyl-diphosphate farnesyltransferase 1

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FDFT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FDFT1 mRNA

NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395

G

farnesyl diphosphate synthase

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of FDPS mRNA

NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666

G

free fatty acid receptor 1

decreases expression

Oleic Acid results in decreased expression of FFAR1 mRNA

NCBI chr19:35,347,902...35,353,864
Ensembl chr19:35,347,902...35,353,864

G

fibroblast growth factor 21

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FGF21 mRNA

NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333

G

fission, mitochondrial 1

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA

NCBI chr 7:101,239,472...101,245,081
Ensembl chr 7:101,239,458...101,252,316

G

flotillin 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FLOT1 mRNA

NCBI chr 6:30,727,709...30,742,687
Ensembl chr 6:30,727,709...30,742,732

G

farnesyltransferase, CAAX box, subunit alpha

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of FNTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FNTA mRNA

NCBI chr 8:43,056,323...43,085,785
Ensembl chr 8:43,034,194...43,085,788

G

farnesyltransferase, CAAX box, subunit beta

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of FNTB mRNA

NCBI chr14:64,986,895...65,062,650
Ensembl chr14:64,986,895...65,062,652

G

forkhead box A1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FOXA1 mRNA

NCBI chr14:37,589,552...37,595,249
Ensembl chr14:37,589,552...37,596,059

G

forkhead box O1

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of FOXO1 protein; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]

NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641

G

ferritin heavy chain 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein]

NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

glucagon

multiple interactions
increases secretion

GNAT3 protein promotes the reaction [Oleic Acid results in increased secretion of GCG protein]

NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein]

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein]

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

geranylgeranyl diphosphate synthase 1

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of GGPS1 mRNA

NCBI chr 1:235,327,216...235,344,532
Ensembl chr 1:235,327,350...235,344,532

G

gamma-glutamyltransferase 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of GGT1 mRNA

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

glucagon like peptide 1 receptor

multiple interactions
affects localization

[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein; Acetylcysteine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; Chloroquine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; exenatide inhibits the reaction [[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein]; Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein; wortmannin inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]
Oleic Acid affects the localization of GLP1R protein

NCBI chr 6:39,048,781...39,091,303
Ensembl chr 6:39,048,781...39,091,303

G

glutamate dehydrogenase 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD1 mRNA

NCBI chr10:87,050,202...87,094,843
Ensembl chr10:87,050,202...87,094,843

G

glutamate dehydrogenase 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of GLUD2 mRNA

NCBI chr X:121,047,610...121,050,094
Ensembl chr X:121,047,610...121,050,094

G

G protein subunit alpha transducin 3

multiple interactions

GNAT3 protein promotes the reaction [Oleic Acid results in increased secretion of GCG protein]

NCBI chr 7:80,458,635...80,512,064
Ensembl chr 7:80,458,635...80,512,064

G

glycerol-3-phosphate acyltransferase, mitochondrial

multiple interactions

[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein; acadesine inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]

NCBI chr10:112,149,865...112,227,677
Ensembl chr10:112,149,865...112,215,377

G

glycerol-3-phosphate acyltransferase 3

increases expression
multiple interactions

Oleic Acid results in increased expression of GPAT3 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT3 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of GPAT3 mRNA

NCBI chr 4:83,535,587...83,605,875
Ensembl chr 4:83,535,914...83,605,875

G

glycerol-3-phosphate acyltransferase 4

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of GPAT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT4 mRNA

NCBI chr 8:41,578,200...41,625,001
Ensembl chr 8:41,577,187...41,625,001

G

glutamic--pyruvic transaminase

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

glutathione peroxidase 4

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]

NCBI chr19:1,103,994...1,106,779
Ensembl chr19:1,103,982...1,106,791

G

glycogen synthase kinase 3 beta

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

glutathione S-transferase alpha 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of GSTA1 mRNA

NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADH mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADH mRNA

NCBI chr 4:107,989,889...108,035,171
Ensembl chr 4:107,989,714...108,035,241

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions
increases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADHA mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHA mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHA mRNA]

NCBI chr 2:26,190,635...26,244,632
Ensembl chr 2:26,190,635...26,244,672

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

increases expression
multiple interactions

Oleic Acid results in increased expression of HADHB mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHB mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHB mRNA]; Oleic Acid promotes the reaction [GW 7647 results in increased expression of HADHB mRNA]

NCBI chr 2:26,244,939...26,290,465
Ensembl chr 2:26,243,170...26,290,465

G

hepatitis A virus cellular receptor 1

increases secretion

Oleic Acid results in increased secretion of HAVCR1 protein

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HIF1A protein

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

hypoxia inducible lipid droplet associated

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HILPDA protein

NCBI chr 7:128,455,878...128,458,418
Ensembl chr 7:128,455,849...128,458,418

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HMGCR mRNA
[[Palmitic Acid co-treated with Oleic Acid] co-treated with IFNA2 protein alternative form] results in decreased expression of HMGCR protein

PMID:30611723 PMID:31299271

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

[perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of HMGCS1 mRNA

NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512

G

heme oxygenase 1

multiple interactions

[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]

PMID:26634892 PMID:32976958 PMID:36905866

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

hepatocyte nuclear factor 4 alpha

multiple interactions
increases expression

sophocarpine inhibits the reaction [Oleic Acid results in increased expression of HNF4A protein]
[Palmitic Acid co-treated with Oleic Acid] affects the expression of HNF4A mRNA

PMID:23395669 PMID:30547786

NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845

G

hydroxysteroid dehydrogenase like 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HSDL2 mRNA

NCBI chr 9:112,380,108...112,472,405
Ensembl chr 9:112,380,080...112,472,405

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

Oleic Acid results in increased expression of HSPA5 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of HSPA5 mRNA]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]
[Palmitic Acid co-treated with Oleic Acid] affects the expression of HSPA5 mRNA

PMID:24349266 PMID:30547786 PMID:32976987 PMID:37009739

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

interleukin 18

multiple interactions

[perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL18 mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL18 protein

NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096

G

interleukin 1 alpha

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of IL1A mRNA

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 1 beta

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL1B protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA]

PMID:26190035 PMID:36423729 PMID:37009739 PMID:37696682 PMID:38103844

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions
increases expression
decreases expression

3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; [Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein; Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]
Oleic Acid results in decreased expression of IL6 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of IL6 protein]
Oleic Acid results in increased expression of IL6 mRNA; Oleic Acid results in increased expression of IL6 protein

PMID:25348860 PMID:26634892 PMID:30611723 PMID:32918399 PMID:37009739 More...

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

insulin

multiple interactions

[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]
[[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with alitretinoin] results in increased uptake of Oleic Acid

PMID:10777552 PMID:11292061

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

INS-IGF2 readthrough

multiple interactions
increases secretion

Oleic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]
Oleic Acid results in increased secretion of INS1 protein
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

PMID:24349266 PMID:26847930

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

insulin receptor

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]

NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414

G

insulin receptor substrate 2

multiple interactions

IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein]; Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein]

NCBI chr13:109,752,695...109,786,583
Ensembl chr13:109,752,695...109,786,583

G

iodotyrosine deiodinase

multiple interactions

Oleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969

G

Janus kinase 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of JAK1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of JAK1 protein

NCBI chr 1:64,833,229...65,067,746
Ensembl chr 1:64,833,223...65,067,754

G

Janus kinase 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of JAK2 mRNA

NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948

G

kelch like ECH associated protein 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein]

NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558

G

laminin subunit beta 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of LAMB1 mRNA

NCBI chr 7:107,923,799...108,003,161
Ensembl chr 7:107,923,799...108,003,213

G

low density lipoprotein receptor

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of LDLR mRNA

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

leptin

decreases expression
increases expression
multiple interactions

Oleic Acid results in decreased expression of LEP mRNA
Oleic Acid results in increased expression of LEP mRNA
sophocarpine inhibits the reaction [Oleic Acid results in increased expression of LEP mRNA]

PMID:9002984 PMID:23395669

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

lipase C, hepatic type

multiple interactions
decreases expression

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid
Oleic Acid results in decreased expression of LIPC mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of LIPC mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LIPC mRNA; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of LIPC mRNA]

PMID:24777581 PMID:30611723 PMID:32918399

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lipase G, endothelial type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid

NCBI chr18:49,561,479...49,599,185
Ensembl chr18:49,560,699...49,599,185

G

lysyl oxidase

increases activity

Oleic Acid results in increased activity of LOX protein

NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413

G

lipin 1

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in increased expression of LPIN1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN1 mRNA

NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409

G

lipin 2

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA

NCBI chr18:2,916,994...3,013,144
Ensembl chr18:2,885,296...3,013,144

G

lipin 3

decreases expression
multiple interactions

Oleic Acid results in decreased expression of LPIN3 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA

NCBI chr20:41,340,821...41,360,582
Ensembl chr20:41,340,821...41,360,582

G

microtubule associated protein 1 light chain 3 beta

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of MAP1LC3B mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased lipidation of MAP1LC3B protein

PMID:30547786 PMID:36905866

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mitogen-activated protein kinase kinase kinase 8

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP3K8 mRNA

NCBI chr10:30,434,021...30,461,833
Ensembl chr10:30,434,021...30,461,833

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA

NCBI chr 2:101,697,707...101,894,690
Ensembl chr 2:101,696,850...101,894,690

G

malonyl-CoA-acyl carrier protein transacylase

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MCAT mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MCAT mRNA

NCBI chr22:43,132,206...43,143,398
Ensembl chr22:43,132,209...43,143,398

G

mitochondrial trans-2-enoyl-CoA reductase

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of MECR mRNA

NCBI chr 1:29,167,696...29,230,934
Ensembl chr 1:29,192,657...29,230,942

G

mitochondrial fission factor

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA

NCBI chr 2:227,325,251...227,357,836
Ensembl chr 2:227,325,151...227,357,833

G

mitofusin 1

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA

NCBI chr 3:179,347,709...179,394,936
Ensembl chr 3:179,347,709...179,394,936

G

monoglyceride lipase

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] affects the reaction [Chlorpyrifos results in decreased activity of MGLL protein]

NCBI chr 3:127,689,066...127,823,185
Ensembl chr 3:127,689,062...128,052,190

G

microRNA 497

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA]

NCBI chr17:7,017,911...7,018,022
Ensembl chr17:7,017,911...7,018,022

G

mixed lineage kinase domain like pseudokinase

multiple interactions
increases phosphorylation

necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]

NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960

G

MLX interacting protein like

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA

NCBI chr 7:73,593,202...73,647,907
Ensembl chr 7:73,593,194...73,624,543

G

matrix metallopeptidase 2

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MMP2 mRNA

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 9

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

metallothionein 2A

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MT2A mRNA

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

microsomal triglyceride transfer protein

decreases expression
multiple interactions

Oleic Acid results in decreased expression of MTTP mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MTTP mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of MTTP mRNA]

PMID:30547786 PMID:30611723 PMID:32918399 PMID:36347319 PMID:38092172

NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA]
Oleic Acid results in increased expression of NFE2L2 mRNA; Oleic Acid results in increased expression of NFE2L2 protein

PMID:26634892 PMID:26847930 PMID:28555106 PMID:32976958 PMID:36905866

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nitric oxide synthase 3

decreases expression

Oleic Acid results in decreased expression of NOS3 mRNA

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein]

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 0 group B member 2

decreases expression
increases expression
multiple interactions

Oleic Acid results in decreased expression of NR0B2 mRNA
Oleic Acid results in increased expression of NR0B2 mRNA
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of NR0B2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA

PMID:30611723 PMID:32738331

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

nuclear receptor subfamily 1 group H member 3

multiple interactions

[Oleic Acid co-treated with Fenofibrate] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with rosiglitazone] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with tesaglitazar] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with troglitazone] affects the expression of NR1H3 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of NR1H3 mRNA

PMID:24534255 PMID:26190035

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

nuclear receptor subfamily 1 group H member 4

multiple interactions
decreases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of NR1H4 mRNA; [Oleic Acid co-treated with Fenofibrate] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of NR1H4 mRNA
Oleic Acid results in decreased expression of NR1H4 mRNA

PMID:24534255 PMID:30547786 PMID:30611723

NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414

G

nuclear receptor subfamily 1 group I member 3

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Troglitazone] affects the expression of NR1I3 mRNA

PMID:24534255 PMID:30611723

NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244

G

nuclear respiratory factor 1

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]

NCBI chr 7:129,611,720...129,757,076
Ensembl chr 7:129,611,720...129,757,082

G

purinergic receptor P2X 7

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein; resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA]; resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein]

NCBI chr12:121,132,876...121,188,032
Ensembl chr12:121,132,819...121,188,032

G

poly(ADP-ribose) polymerase 1

increases cleavage
increases activity
multiple interactions

Oleic Acid results in increased cleavage of PARP1 protein
Oleic Acid results in increased activity of PARP1 protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in increased activity of PARP1 protein]
[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]

PMID:21132278 PMID:25536389 PMID:30165350

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

pyruvate carboxylase

decreases expression

Oleic Acid results in decreased expression of PC mRNA

NCBI chr11:66,848,420...66,958,383
Ensembl chr11:66,848,417...66,958,386

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of PCK1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PCK1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PCK1 mRNA

PMID:8536680 PMID:9518257 PMID:26847930 PMID:30611723

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

platelet derived growth factor subunit B

increases expression
multiple interactions

Oleic Acid results in increased expression of PDGFB mRNA
Sorafenib inhibits the reaction [Oleic Acid results in increased expression of PDGFB mRNA]

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

pyruvate dehydrogenase kinase 4

increases expression
multiple interactions

Oleic Acid results in increased expression of PDK4 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 protein

PMID:26739624 PMID:30547786

NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516

G

decaprenyl diphosphate synthase subunit 1

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PDSS1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PDSS1 mRNA

NCBI chr10:26,697,701...26,746,798
Ensembl chr10:26,697,701...26,746,798

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PEBP1 mRNA

NCBI chr12:118,136,124...118,145,584
Ensembl chr12:118,136,124...118,145,584

G

peroxisomal trans-2-enoyl-CoA reductase

decreases expression
multiple interactions

Oleic Acid results in decreased expression of PECR mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of PECR mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PECR mRNA

NCBI chr 2:216,029,088...216,081,809
Ensembl chr 2:215,996,329...216,082,955

G

PGAM family member 5, mitochondrial serine/threonine protein phosphatase

multiple interactions

PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]

NCBI chr12:132,710,842...132,722,734
Ensembl chr12:132,710,819...132,722,734

G

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of PIK3C2A mRNA

NCBI chr11:17,086,575...17,207,986
Ensembl chr11:17,077,730...17,207,986

G

PTEN induced kinase 1

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA

NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511

G

pyruvate kinase L/R

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PKLR mRNA

NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438

G

phospholipase D1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PLD1 mRNA

NCBI chr 3:171,600,404...171,810,483
Ensembl chr 3:171,600,404...171,810,950

G

pleckstrin

multiple interactions

Oleic Acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]

NCBI chr 2:68,365,282...68,397,453
Ensembl chr 2:68,365,282...68,397,453

G

perilipin 1

increases expression

Oleic Acid results in increased expression of PLIN1 mRNA

NCBI chr15:89,664,367...89,679,367
Ensembl chr15:89,664,367...89,679,427

G

perilipin 2

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN2 mRNA; Oleic Acid promotes the reaction [LG 100268 results in increased expression of PLIN2 protein]; Oleic Acid promotes the reaction [pirinixic acid results in increased expression of PLIN2 protein]
Rimonabant inhibits the reaction [Oleic Acid results in increased expression of PLIN2 protein]
Oleic Acid results in increased expression of PLIN2 mRNA; Oleic Acid results in increased expression of PLIN2 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 protein; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Dichlorodiphenyl Dichloroethylene promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]

PMID:16489205 PMID:24534255 PMID:25048947 PMID:26739624 PMID:30547786 More...

NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290

G

perilipin 3

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN3 mRNA

NCBI chr19:4,838,341...4,867,667
Ensembl chr19:4,838,341...4,867,694

G

perilipin 4

multiple interactions
increases expression

Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; Troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]

NCBI chr19:4,502,192...4,518,486
Ensembl chr19:4,502,192...4,518,486

G

perilipin 5

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA]

NCBI chr19:4,522,531...4,535,224
Ensembl chr19:4,522,531...4,535,224

G

phospholipid phosphatase 6

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA

NCBI chr 9:4,662,294...4,665,258
Ensembl chr 9:4,662,294...4,665,258

G

patatin like phospholipase domain containing 3

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PNPLA3 mRNA

NCBI chr22:43,923,805...43,947,582
Ensembl chr22:43,923,792...43,964,488

G

paraoxonase 1

multiple interactions
decreases activity

[Calcium co-treated with Oleic Acid] results in increased stability of PON1 protein; Calcium promotes the reaction [Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [Hydrogen Peroxide results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]
Oleic Acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15104111 PMID:15375178

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

peroxisome proliferator activated receptor alpha

multiple interactions
affects binding
increases expression
affects abundance
decreases expression
increases activity

Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Oleic Acid]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid inhibits the reaction [troglitazone results in decreased expression of PPARA mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC13A1 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of ABCD3 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP2C65 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP4F16 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC27A4 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC6A3 mRNA]
Oleic Acid binds to PPARA protein
Oleic Acid results in increased expression of PPARA mRNA; Oleic Acid results in increased expression of PPARA protein
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARA mRNA; [tetrabromobisphenol A co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]
Oleic Acid results in decreased expression of PPAR mRNA; Oleic Acid results in decreased expression of PPARA mRNA; Oleic Acid results in decreased expression of PPARA protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PPARA mRNA; [Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of PPARA mRNA]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased activity of and results in increased localization of PPARA protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PPARA protein]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid results in increased activity of and results in increased localization of PPARA protein; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]
Oleic Acid results in increased activity of PPARA protein

PMID:9688458 PMID:10403814 PMID:11056218 PMID:15491415 PMID:15949695 More...

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor delta

increases expression
multiple interactions
decreases expression

Oleic Acid results in increased expression of PPARD mRNA
Oleic Acid binds to and results in increased activity of PPARB protein
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of PPARD mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA]; Oleic Acid binds to and results in increased activity of PPARB protein; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA]
Oleic Acid results in decreased expression of PPARD mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PPARD mRNA; Oleic Acid binds to and results in increased activity of PPARB protein

PMID:11172467 PMID:16731579 PMID:24349266 PMID:25048947 PMID:26190035 More...

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

peroxisome proliferator activated receptor gamma

increases expression
affects binding
multiple interactions

Oleic Acid results in increased expression of PPARG mRNA
Oleic Acid binds to PPARG protein
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of PPARG mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]
[cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARG mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARG mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein]; Oleic Acid binds to and results in increased activity of PPARG protein
Oleic Acid results in increased expression of PPARG mRNA; Oleic Acid results in increased expression of PPARG protein

PMID:11172467 PMID:18154422 PMID:24534255 PMID:24998974 PMID:25048947 More...

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

PPARG coactivator 1 alpha

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PRKAA1 mRNA

NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374

G

protein kinase AMP-activated catalytic subunit alpha 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of PRKAA2 mRNA

NCBI chr 1:56,645,314...56,715,335
Ensembl chr 1:56,645,314...56,715,335

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RAB18, member RAS oncogene family

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RAB18 mRNA

NCBI chr10:27,504,304...27,542,239
Ensembl chr10:27,504,174...27,543,207

G

Rab geranylgeranyltransferase subunit alpha

multiple interactions

[Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA

NCBI chr14:24,265,538...24,271,627
Ensembl chr14:24,265,538...24,271,611

G

Rab geranylgeranyltransferase subunit beta

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of RABGGTB mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA

NCBI chr 1:75,786,194...75,795,090
Ensembl chr 1:75,786,197...75,795,086

G

RB transcriptional corepressor 1

decreases phosphorylation

Oleic Acid results in decreased phosphorylation of RB1 protein

NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436

G

Ras homolog, mTORC1 binding

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHEB mRNA

NCBI chr 7:151,466,012...151,519,895
Ensembl chr 7:151,466,012...151,520,120

G

ras homolog family member B

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of RHOB mRNA

NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440

G

receptor interacting serine/threonine kinase 1

increases phosphorylation
multiple interactions

Oleic Acid results in increased phosphorylation of RIPK1 protein
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]

NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187

G

receptor interacting serine/threonine kinase 3

increases phosphorylation
multiple interactions

Oleic Acid results in increased phosphorylation of RIPK3 protein
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]

NCBI chr14:24,336,025...24,339,991
Ensembl chr14:24,336,025...24,340,022

G

Rho associated coiled-coil containing protein kinase 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ROCK2 protein

NCBI chr 2:11,179,759...11,345,437
Ensembl chr 2:11,179,759...11,348,330

G

retinoid X receptor alpha

multiple interactions

Oleic Acid binds to and results in increased activity of RXRA protein

PMID:16731579 PMID:27131391

NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585

G

stearoyl-CoA desaturase

multiple interactions
decreases expression

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of SCD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA]
Oleic Acid results in decreased expression of SCD mRNA

PMID:24534255 PMID:30547786 PMID:30611723 PMID:36423729 PMID:38092172 More...

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

stearoyl-CoA desaturase 5

multiple interactions
decreases expression

[Farnesol analog co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA
Oleic Acid results in decreased expression of SCD5 mRNA

NCBI chr 4:82,629,539...82,798,796
Ensembl chr 4:82,629,539...82,798,796

G

sterol carrier protein 2

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of SCP2 mRNA

NCBI chr 1:52,927,276...53,051,698
Ensembl chr 1:52,927,276...53,051,698

G

serpin family E member 1

multiple interactions

[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]

PMID:11292061 PMID:30547786

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

sirtuin 1

increases expression
decreases activity
multiple interactions

Oleic Acid results in increased expression of SIRT1 protein
Oleic Acid results in decreased activity of SIRT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased activity of SIRT1 protein]; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
[Ethanol co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SIRT1 protein

PMID:24349266 PMID:25536389 PMID:26854922

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

sirtuin 4

decreases expression

Oleic Acid results in decreased expression of SIRT4 mRNA

NCBI chr12:120,291,780...120,313,249
Ensembl chr12:120,302,316...120,313,249

G

solute carrier family 13 member 1

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC13A1 mRNA]

NCBI chr 7:123,113,531...123,199,971
Ensembl chr 7:123,113,531...123,199,972

G

solute carrier family 16 member 9

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA]

NCBI chr10:59,650,764...59,710,079
Ensembl chr10:59,650,764...59,736,002

G

solute carrier family 25 member 11

decreases expression

Oleic Acid results in decreased expression of SLC25A11 mRNA

NCBI chr17:4,937,130...4,940,046
Ensembl chr17:4,937,130...4,940,053

G

solute carrier family 25 member 20

increases expression
multiple interactions

Oleic Acid results in increased expression of SLC25A20 protein
[Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC25A20 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA

PMID:24349266 PMID:30611723

NCBI chr 3:48,856,926...48,898,882
Ensembl chr 3:48,856,926...48,898,904

G

solute carrier family 25 member 22

decreases expression

Oleic Acid results in decreased expression of SLC25A22 mRNA

NCBI chr11:790,475...798,281
Ensembl chr11:790,475...798,281

G

solute carrier family 27 member 1

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC27A1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA

NCBI chr19:17,468,767...17,506,168
Ensembl chr19:17,468,769...17,506,168

G

solute carrier family 27 member 2

multiple interactions

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SLC27A2 mRNA

PMID:30611723 PMID:38092172

NCBI chr15:50,182,196...50,236,385
Ensembl chr15:50,182,196...50,236,385

G

solute carrier family 27 member 4

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC27A4 mRNA]

NCBI chr 9:128,340,527...128,361,470
Ensembl chr 9:128,340,527...128,361,470

G

solute carrier family 2 member 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SLC2A1 mRNA

NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893

G

solute carrier family 2 member 2

increases expression
multiple interactions

Oleic Acid results in increased expression of SLC2A2 mRNA
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of SLC2A2 mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of SLC2A2 mRNA]

PMID:12048068 PMID:30547786

NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743

G

solute carrier family 6 member 3

multiple interactions

PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC6A3 mRNA]

NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440

G

small integral membrane protein 20

increases expression

Oleic Acid results in increased expression of SMIM20 mRNA

NCBI chr 4:25,914,220...25,929,812
Ensembl chr 4:25,861,830...25,929,813

G

synaptosome associated protein 23

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SNAP23 mRNA

NCBI chr15:42,491,129...42,533,058
Ensembl chr15:42,491,233...42,545,356

G

small nucleolar RNA host gene 14

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SNHG14 mRNA; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]

NCBI chr15:24,823,608...25,419,462
Ensembl chr15:24,978,583...25,420,336

G

suppressor of cytokine signaling 1

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOCS1 mRNA

NCBI chr16:11,254,417...11,256,204
Ensembl chr16:11,254,417...11,256,204

G

suppressor of cytokine signaling 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SOCS2 mRNA

NCBI chr12:93,569,969...93,626,236
Ensembl chr12:93,569,814...93,583,487

G

suppressor of cytokine signaling 3

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS3 mRNA

NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077

G

superoxide dismutase 1

multiple interactions
decreases secretion
decreases expression

Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in decreased secretion of SOD1 protein]; gastrodin inhibits the reaction [Oleic Acid results in decreased expression of SOD1 mRNA]

PMID:26634892 PMID:27996362

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

superoxide dismutase 2

increases expression
multiple interactions

Oleic Acid results in increased expression of SOD2 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA

PMID:24349266 PMID:30547786

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

sequestosome 1

multiple interactions
increases expression

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein]; necrostatin-1 inhibits the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]

PMID:36273635 PMID:36905866

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions
decreases expression

Oleic Acid results in increased expression of SREBF1 mRNA
Oleic Acid results in increased expression of SREBF1 mRNA; Oleic Acid results in increased expression of SREBF1 protein
[N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; sophocarpine inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Dibutyl Phthalate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of SREBF1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 protein]
Oleic Acid results in decreased expression of SREBF1 mRNA; Oleic Acid results in decreased expression of SREBF1 protein

PMID:15949695 PMID:23395669 PMID:23603006 PMID:26190035 PMID:26854922 More...

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

thromboxane A2 receptor

multiple interactions

Phenolsulfonphthalein inhibits the reaction [Oleic Acid results in increased expression of TBXA2R mRNA]

NCBI chr19:3,594,507...3,606,875
Ensembl chr19:3,594,507...3,606,875

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[GW 4064 co-treated with Oleic Acid] results in decreased expression of TECR mRNA

NCBI chr19:14,527,726...14,565,980
Ensembl chr19:14,517,085...14,565,980

G

transcription factor A, mitochondrial

multiple interactions

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]

NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220

G

transferrin receptor

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein]

NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153

G

transforming growth factor beta 1

multiple interactions
increases expression

Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TGFB1 protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transforming growth factor beta 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA

NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619

G

thyroid hormone responsive

multiple interactions
decreases expression

Bezafibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]

NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TIMP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of TIMP1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TIMP1 mRNA]

PMID:26187275 PMID:30547786 PMID:32918399

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

tumor necrosis factor

decreases response to substance
increases expression
multiple interactions

Oleic Acid results in decreased susceptibility to TNF protein
Oleic Acid results in increased expression of TNF mRNA; Oleic Acid results in increased expression of TNF protein
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ENO3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ERLIN1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PLD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PRKAA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RAB18 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHEB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SLC2A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOCS1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TNFAIP2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TUBB2A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CXCL8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FLOT1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of LDLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP3K8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS3 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF protein]

PMID:22683933 PMID:23348005 PMID:26190035 PMID:26634892 PMID:30547786 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF alpha induced protein 2

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TNFAIP2 mRNA

NCBI chr14:103,121,469...103,137,439
Ensembl chr14:103,121,476...103,137,439

G

tumor protein p53

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

tubulin beta 2A class IIa

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TUBB2A mRNA

NCBI chr 6:3,153,666...3,157,544
Ensembl chr 6:3,153,497...3,157,544

G

Tu translation elongation factor, mitochondrial

multiple interactions

[Palmitic Acid co-treated with Oleic Acid] affects the expression of TUFM mRNA

NCBI chr16:28,842,411...28,846,348
Ensembl chr16:28,842,411...28,846,348

G

uncoupling protein 2

increases expression
multiple interactions
decreases expression

Oleic Acid results in increased expression of UCP2 mRNA
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in decreased expression of UCP2 protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]
Oleic Acid results in decreased expression of UCP2 mRNA

PMID:11341955 PMID:12588052 PMID:24349266 PMID:25048947 PMID:26854922

NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843

G

uncoupling protein 3

increases expression
multiple interactions

Oleic Acid results in increased expression of UCP3 mRNA
Oleic Acid inhibits the reaction [troglitazone results in decreased expression of UCP3 mRNA]

PMID:11056218 PMID:12630940

NCBI chr11:74,000,277...74,009,085
Ensembl chr11:74,000,277...74,009,085

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of UGCG mRNA

NCBI chr 9:111,896,814...111,935,369
Ensembl chr 9:111,896,814...111,935,369

G

vesicle associated membrane protein 4

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VAMP4 mRNA

NCBI chr 1:171,700,160...171,742,065
Ensembl chr 1:171,700,160...171,742,074

G

versican

multiple interactions

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VCAN mRNA

NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303

G

vanin 1

multiple interactions

Oleic Acid promotes the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of VNN1 mRNA]

NCBI chr 6:132,680,849...132,714,055
Ensembl chr 6:132,680,849...132,714,055

G

X-box binding protein 1

multiple interactions

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased splicing of XBP1 mRNA]

PMID:32369900 PMID:32976987

NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597

G

Yes1 associated transcriptional regulator

affects localization

Oleic Acid affects the localization of YAP1 protein

NCBI chr11:102,110,447...102,233,424
Ensembl chr11:102,110,447...102,233,424

oleoyl ethanolamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1

increases export

ABCB1 protein results in increased export of N-oleoylethanolamine

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

peroxisome proliferator activated receptor alpha

increases response to substance
multiple interactions

PPARA results in increased susceptibility to N-oleoylethanolamine
N-oleoylethanolamine binds to and results in increased activity of PPARA protein

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

prostaglandin-endoperoxide synthase 2

decreases expression

N-oleoylethanolamine results in decreased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

palmitoleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases degradation
multiple interactions
increases phosphorylation

palmitoleic acid results in increased degradation of ABCA1 protein
palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
palmitoleic acid results in increased phosphorylation of ABCA1 protein

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

apolipoprotein A1

multiple interactions

palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

interleukin 6

increases expression

palmitoleic acid results in increased expression of IL6 mRNA

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

insulin

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of palmitoleic acid analog

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

[Glucose deficiency co-treated with palmitoleic acid] results in increased expression of PCK1 mRNA

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

paraoxonase 1

multiple interactions
decreases activity

palmitoleic acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; palmitoleic acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]
palmitoleic acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15375178

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

ricinoleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cannabinoid receptor 1

affects binding

ricinoleic acid analog binds to CNR1 protein

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

cannabinoid receptor 2

multiple interactions

ricinoleic acid analog binds to and affects the activity of CNR2 protein

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

interleukin 4

multiple interactions

ricinoleic acid inhibits the reaction [IL4 protein results in increased expression of VCAM1 protein]

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

prostaglandin D2 synthase

affects binding

ricinoleic acid binds to PTGDS protein

NCBI chr 9:136,977,504...136,981,742
Ensembl chr 9:136,975,092...136,981,742

G

transient receptor potential cation channel subfamily V member 1

multiple interactions

ricinoleic acid analog binds to and affects the activity of TRPV1 protein

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

vascular cell adhesion molecule 1

multiple interactions

ricinoleic acid inhibits the reaction [IL4 protein results in increased expression of VCAM1 protein]

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

soybean oil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

affects expression

Soybean Oil affects the expression of ABCB11 mRNA

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily B member 4

affects expression

Soybean Oil affects the expression of ABCB4 mRNA

NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

affects expression

Soybean Oil affects the expression of ABCC1 mRNA

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily C member 2

affects expression

Soybean Oil affects the expression of ABCC2 mRNA

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 5

affects expression

Soybean Oil affects the expression of ABCC5 mRNA

NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939

G

ATP binding cassette subfamily C member 6

affects expression

Soybean Oil affects the expression of ABCC6 mRNA

NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522

G

acetyl-CoA acetyltransferase 1

decreases activity

Soybean Oil results in decreased activity of ACAT1 protein

NCBI chr11:108,116,705...108,147,603
Ensembl chr11:108,116,695...108,147,603

G

BCL2 apoptosis regulator

increases expression

Soybean Oil results in increased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

catalase

increases activity

Soybean Oil results in increased activity of CAT protein

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cyclin D1

increases expression

Soybean Oil results in increased expression of CCND1 mRNA

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cytochrome P450 family 4 subfamily A member 22

affects expression

Soybean Oil affects the expression of CYP4A1 mRNA

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

cytochrome P450 family 7 subfamily A member 1

increases activity

Soybean Oil results in increased activity of CYP7A1 protein

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

glutathione S-transferase pi 1

multiple interactions

Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]

NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases activity

Soybean Oil results in increased activity of HMGCR protein

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

interleukin 12B

decreases expression

Soybean Oil results in decreased expression of IL12B mRNA

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

solute carrier family 22 member 1

affects expression

Soybean Oil affects the expression of SLC22A1 mRNA

NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718

G

solute carrier family 22 member 7

affects expression

Soybean Oil affects the expression of SLC22A7 mRNA

NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538

triolein

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

decreases expression

Triolein results in decreased expression of ABCA1 mRNA

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily G member 5

decreases expression

Triolein results in decreased expression of ABCG5 mRNA

NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865

G

ATP binding cassette subfamily G member 8

decreases expression

Triolein results in decreased expression of ABCG8 mRNA

NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988

G

acetyl-CoA carboxylase alpha

multiple interactions

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of ACACA mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of ACACA mRNA]

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

apolipoprotein A4

multiple interactions

[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein

NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304

G

apolipoprotein E

multiple interactions

[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

catalase

multiple interactions

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of CAT mRNA]

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cytochrome P450 family 27 subfamily A member 1

decreases expression

Triolein results in decreased expression of CYP27A1 mRNA

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

fatty acid synthase

multiple interactions

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of FASN mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of FASN mRNA]

NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294

G

glutathione peroxidase 1

multiple interactions

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA]

NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Triolein results in increased expression of HMGCR mRNA

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

microsomal triglyceride transfer protein

increases expression

Triolein results in increased expression of MTTP mRNA

NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

Triolein results in decreased expression of NPC1L1 mRNA

NCBI chr 7:44,512,535...44,541,330
Ensembl chr 7:44,512,535...44,541,330

G

superoxide dismutase 1

multiple interactions

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD1 mRNA]

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

superoxide dismutase 2

multiple interactions

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD2 mRNA]

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

sterol regulatory element binding transcription factor 1

multiple interactions

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 protein]]

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26034
role	25961
biological role	25929
biochemical role	25162
metabolite	25092
eukaryotic metabolite	24514
animal metabolite	24055
crustacean metabolite	18199
Daphnia metabolite	18182
Daphnia galeata metabolite	870
(2Z,5Z,8Z,11Z,14Z,17Z)-icosa-2,5,8,11,14,17-hexaenoic acid	0
(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoic acid	0
all-cis-5,8,11,14,17-icosapentaenoic acid +	0
all-cis-octadeca-6,9,12,15-tetraenoic acid +	0
arachidonic acid +	324
cholesterol +	354
linoleic acid +	276
oleic acid +	440
palmitoleic acid +	6

paths to the root